Sheet 1 of 1

	ATTY. DOCKET NO. 10177-211-999	APPLICATION NO. 09/910,388
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Kunz et al.	
	FILING DATE July 20, 2001	ART UNIT

xaminer nitials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document
408	A01	5.405.919	04/11/1995	Keefer et al.
1	A02	5,464,650	11/07/1995	Berg et al.
<u> </u>	A03	5,516.781	05/14/1996	Morris et al.
	Λ04	5,525,357	06/11/1996	Keefer et al.
	A05	5.632,981	05/27/1997	Saavedra et al.
	A06	5.650.447	07/22/1997	Keefer et al.
	A07	6.200,558	03/13/2001	Saavedra et al.
	A08	6,379,660	04/30/2001	Saavedra et al.
· 1/	A09	2002/0119115	08/29/2002	Keefer et al.

	FOREIGN PATENT DOCUMENTS											
*Examiner Foreign Patent Document Country Code, Number, Date Name of Patentee or Applicant Initials Kind Code (if known) mm/dd/yy of Cited Document												
CAM		301	WO 91/12779	09/05/1991	Medtronic, Inc.							
	, E	302	WO 94/13268	06/23/1994	Kaplan							
V	E	303	WO 94/21308	09/29/1994	Cedars-Sinai Medical Center							

	NON PATENT LITERATURE DOCUMENTS										
*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т								
	C01										
	C02										
	C03										
	C04										

NYI-3944007v1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

REVISED LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY, DOCKET NO	APPLICATION NO.
10177-211-999	09/910,388
APPLICANT	١
Kunz et al.	
FILING DATE	GROUP
FILING DATE	GROOT
July 20, 2001	1652

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	6,783,543	08/31/04	Jang	. /		
	A02	6,764,507	07/20/04	Shanley, et al.			
	A03	6,689,159	02/10/04	Lau, et al.			
	A04	6,663,881	12/16/03	Kunz, et al.			
	A05	6,656,216	12/02/03	Nossainy, et al.			7
	A06	6,656,162	12/02/03	Santini Jr., et al.			7
	A07	6,616,765	09/09/03	Castro, et al.			
	A08	6,616,690	09/09/03	Rolando, et al.			
	A09	6,599,928	07/29/03	Kunz, et al.			
	A10	6,596,022	07/22/03	Lau, et al.			
	All	6,575,993	07/10/03	Yock			
	A12	6,562,065	05/13/03	Shanley			
	A13	6,555,138	04/29/03	Karlsson			
	A14	6,544,790	04/08/03	Sabatini			
	A15	-6,544,544	04/08/03	Hunter, et al.			7
	A16	6,527,789	03/04/03	Lau, et al.			
	A17	6,515,009	02/04/03	Kunz, et al.		1	1
/	A18	6,497,647	12/24/02	Tucker			1
	A19	6,492,106	12/10/02	Sabatini et al.		\	
	A20	6,491,617	12/10/02	Ogle, et al.		1	
	A21	6,488,694	12/03/02	Lau, et al.		1/	
	A22	6,485,511	11/26/02	Lau, et al.		ΧI	· , , , ,
.	A23	6,476,200	11/05/02	Sabatini, et al.			
	A24	6,461,381	10/08/02	Israel, et al.		/	
	A25	6,443,982	09/03/02	Israel, et al.		_/\	
	A26	6,432,133	08/13/02	Lau, et al.		_/	
	A27	6,429,232	08/06/02	Kinsella, et al.		_/	
	A28	6,395,326	05/28/02	Castro, et al.		/ 1	
	Λ29	6,309,414	10/30/01	Rolando, et al.		/	
	A30	6,309,412	10/30/01	Lau, et al.		/	
	A31	6,306,421	10/23/01	Kunz, et al.	/		
	A32	6,251,920	06/26/01	Grainger, et al.			
	A33	6,241,762	06/05/01	Shanley			1
	Λ34	6,210,393	04/03/01	Brisken, et al.			
	A35	6,203,536	03/20/01	Berg, et al.	/		

1						or Application	n No. 09/910.388
10	A36	6,198,016	03/06/01	Lucast, et al.			
	A37	6,187,370	02/13/01	Dinh, et al.			
	A38	6,168,619	01/02/01	Dinh, et al.			
	A39	6,152,869	11/28/00	Park, et al.			
	A40	6,146,358	11/14/00	Rowe			
	A41	6,133,242	10/17/00	Zalewski, et al.			
	A42	6,129,757	10/10/00	Weadock			
	A43	6,120,536	09/19/00	Ding, et al.			
	A44	6,110,483	08/29/00	Whitbourne, et al.			
	A45	6,106,454	08/22/00	Berg, et al.			
	A46	6,099,562	08/08/00	Ding, et al.			
	A47	6,099,499	08/08/00	Ciamacco, et al.			
	A48	6,096,070	08/01/00	Ragheb, et al.	······		
	A49	6,093,142	07/25/00	Kunz, et al.			
	A50	6,086,910	07/11/00	Howard, et al.	•		
	A51	6,074,659	06/13/00	Kunz, et al.			
	A52	6,074,337	06/13/00	Tucker et al.			
	A53	6,066,167	05/23/00	Lau, et al.			
	A54	6,042,875	03/28/00	Ding, et al.			
	A55	6,036,715	03/14/00	Yock			
	A56	6,033,866	02/08/00	Falk, et al.			
	A57	6,013,099	01/11/00	Dinh, et al.			
	A58	6,001,622	12/14/99	Dedhar, et al.		•	
	A59	5,990,095	11/23/99	Falk, et al.			
	A60	5,981,568	11/09/99	Kunz, et al.			
	A61	5,980,972	11/09/99	Ding		-	
1.	A62	5,972,018	10/26/99	Israel, et al.			
- 	A63	5,948,639	09/07/99	Ginemo, et al.			
	A64	5,902,332	05/11/99	Schatz			<u> </u>
	A65	5,900,246	05/04/99	Lambert			
	A66	5,877,224	03/02/99	Brocchini, et al.			
	A67	5,873,904	02/23/99	Ragheb, et al.			,
	Λ68	5,863,285	01/26/99	Coletti			·
1 1	A69	5,849,034	12/15/98	Schwartz			
	A70	5,847,007	12/08/98	Grainger, et al.			
	A71 .	5,843,120	12/01/98	Israel, et al.			
	A72	5,837,313	11/17/98	Ding, et al.			
	A73	5,837,008	11/17/98	Berg, et al.			
-	A74	5,824,647	10/20/98	Postlethwaite, et al.			
	A75	5,824,054	10/20/98	Khosravi, et al.			
- 	A76	5,824,049	10/20/98	Ragheb, et al.			
	A77	5,821,234	10/13/98	Dzau.			
	A78	5,811,447	09/22/98	Kunz, et al.			
	A79	5,800,507	09/01/98	Schwartz			
\/ +	A80	5,797,898	08/25/98	Santini Jr., et al.			

ملد						of Application	on No. 09/910,388
1	A81	5,779,732	07/14/98	Amundson			
	A82	5,773,479	06/30/98	Grainger, et al.			
	A83	5,770,609	06/23/98	Grainger, et al.			
	A84	5,767,079	06/16/98	Glaser, et al.			
	A85	5,749,915	05/12/98	Slepian			
	A86	5,749,888	05/12/98	Yock			
	A87	5,747,510	05/05/98	Draper			
	A88	5,735,897	04/07/98	Buirge			
	A89	5,733,303	03/31/98	Israel, et al.		1	
	A90	5,731,424	03/24/98	Toothman, et al.			
	A91	5,731,200	03/24/98	Ichijo, et al.			1
	A92	5,731,144	03/24/98	Toothman, et al.			
	A93	5,726,186	03/10/98	Grese			
	A94	5,722,984	03/03/98	Fischell, et al.			
	A95	5,705,609	01/06/98	Ruoslahti, et al.			
	A96	5,705,477	01/06/98	Sporn, et al.		<u> </u>	
	A97	5,700,559	12/23/97	Sheu, et al.		1.	
	A98	5,697,967	12/16/97	Dinh, et al.		1	-
	Λ99	5,693,607	12/02/97	Segrini, et al.		 	<u> </u>
	A100	5,688,855	11/18/97	Stoy, et al.		 	
	A101	5,688,813	11/18/97	Sall, et al.			
	A102	5,686,476	11/11/97	May			
	A103	5,686,467	11/11/97	Bumol, et al.	<u> </u>		
	A104	5,681,835	10/28/97	Willson		 	
	A105	5,679,400	10/21/97	Tuch	+	 	
	A106	5,667,764	09/16/97	Kopia, et al.		 	<u> </u>
	A107	5,662,712	09/02/97	Pathak, et al.	- 		†· · · · · · · · · · · · · · · · · · ·
	A108	5,660,873	08/26/97	Nikolaychik, et al.			
	A109	5,658,951	08/19/97	Magarian, et al.		1	
	A110		08/19/97	Magarian, et al.			
		5,658,883	08/19/97	Ogawa, et al.			
1	1	5,656,587	08/12/97 -	Sporn, et al.		<u> </u>	
1		5,656,450	08/12/97	Boyan, et al.		 	
	A114	5,652,259	07/29/97	May			
	AII5	5,651,627	07/29/97	Dowzall, et al.			
	A116	5,643,580	07/01/97	Subramanian	+	-	
	A117	5,641,790	06/24/97	Draper	 	 	
	A118	5,639,738	06/17/97	Falk, et al.		 	
	A119	5,639,274	06/17/97	Fischell, et al.			
		5,637,113	06/10/97	Tartaglia, et al.	+		
	12	5,635,489	06/03/97	Haley	 	<u> </u>	
	1	5,632,840	05/27/97	Campbell	- 		
		5,629,077	05/13/97	Turnlund, et al.			<u>.</u>
· .	A124	5,626,600	05/06/97	Horzewski, et al.		 	
7/2		5,622,975	04/22/97	Singh, et al.		 	

	,				of Application	No. 09/910,388
HX.	A126		03/11/97	Draper		
	A127	5,610,166	03/11/97	Singh		
	A128	5,609,629	03/11/97	Fearnot, et al.		
	A129	5,607,463	03/04/97	Schwartz, et al.		
	A130	5,605,700	02/25/97	DeGregorio, et al.		
	A131	5,605,696	02/25/97	Eury, et al.		
	A132	5,599,844	02/04/97	Grainger, et al.		
	A133	5,597,578	01/28/97	Brown, et al.		
	A134	5,595,722	11/21/97	Grainger, et al.		
	A135	5,591,224	01/07/97	Schwartz, et al.		
	A136	5,583,153	12/10/96	Brahn		
	A137	5,580,898	12/03/96	Trojanowski, et al.		
	A138	5,578,703	11/16/96	Ichijo, et al.		
	A139	 	11/26/96	Dayton		····
	A140	 	11/19/96	Mansson, et al.		
	A141	5,574,047	11/12/96	Bumol, et al.		· · · · · · · · · · · · · · · · · · ·
	A142	5,571,808	11/05/96	Leeds		
	A143	5,571,714	11/05/96	Dasch, et al.		V - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
	A144	5,571,166	11/05/96	Dinh, et al.		
	A145	5,569,463	10/29/96	Helmus, et al.		
	A146	5,567,713	10/22/96	Cullinan, et al.		
	A147	5,563,054	10/08/96	Briggs, et al.		
	A148	5,562,922	10/08/96	Lambert		
	A149	5,556,876	09/17/96	Bryant, et al.		· · · · · · · · · · · · · · · · · · ·
	A150	5,554,182	09/10/96	Dinh, et al.		
	A151	5,552,433	09/03/96	Bryant, et al.		
	A152	5,552,415	09/03/96	May		
·	A153	5,551,954	09/03/96	Buscemi, et al.		
	A154		08/13/96	Grainger, et al.		
	A155	5,545,409	08/13/96	Laurencin, et al.		
	A156	5,545,208	08/13/96	Wolff, et al.		
	A157	5,543,155	08/06/96	Fekete, et al.		
	A158	5,541,174	07/30/96	Sorenson		
	A159	5,538,892	06/23/96	Donahoe, et al.		
	A160	5,534,527	07/09/96	Black, et al.		
	A161	5,525,624	06/11/96	Gitter, et al.		
	A162	5,523,092	06/04/96	Hanson, et al.		**************************************
	A163	5,521,198	05/28/96	Zuckerman		
	A164	5,521,191	05/28/96	Greenwald		
	A165	5,521,172	05/28/96	Bryant, et al.		
		5,521,171	05/28/96	Sorenson		
		5,516,807	05/14/96	Hupe, et al.		
		5,514,154	05/07/96	Lau, et al.		
	1	5,510,370	04/23/96	Hock, et al.		
71/	A170	5,510,077	04/23/96	Dinh, et al.		

r la					of Applicati	on No. 09/910,38
41	A171	5,508,292	04/16/96	Sall, et al.		
)	A172	5,500,013	03/19/96	Buschemi, et al.		
	A173	5,498,775	03/12/96	Novak, et al.		
	A174	5,496,851	03/05/96	Grinnell		
	A175	5,496,828	03/05/96	Cullinan		
	A176	5,496,557	03/05/96	Feijen, et al.		
	A177	5,496,346	03/05/96	Horzewski, et al.		
	A178	5,492,927	02/20/96	Gitter, et al.		
	A179	5,492,926	02/20/96	Cullinan, et al.		
	A180	5,492,922	02/20/96	Palkowitz		
	A181	5,492,921	02/20/96	Bryant, et al.		
	A182	5,492,895	02/20/96	Vlasuk, et al.		
	A183	5,491,173	02/13/96	Toivola, et al.		
	A184	5,491,159	02/13/96	Malamas		
	A185	5,489,587	02/06/96	Fontana		
	A186	5,486,357	01/23/96	Narayanan		
	A187	5,484,808	01/16/96	Grinell		
	A188	5,484,798	01/16/96	Bryant, et al.		
	A189	5,484,797	01/16/96	Bryant, et al.		
	A190	5,484,796	0,1/16/96	Bryant, et al.		
	A191	5,484,795	01/16/96	Bryant, et al.		
	A192	5,482,950	01/09/96	Bryant, et al.		
	A193		01/09/96	Black, et al.		
	A194	5,482,851	01/09/96	Derynck, et al.		
	A195	5,480,904	01/02/96	Bryant, et al.		-
	A196	5,480,903	01/02/96	Piggott, et al.		—
	A197	5,480,888	01/02/96	Kodama, et al.		
	A198	5,478,847	12/26/95	Draper		
		5,472,985	12/05/95	Grainger, et al.		
		5,470,883	11/28/95	Stromberg		<u> </u>
		5,470,876	11/28/95	Proctor		
	A202		11/14/95	Godfrey		<u> </u>
-	A203		11/07/95	Buscemi, et al.		
+++	A204	5,462,950	10/31/95	Fontana		
	A205		10/31/95	Jones, et al.		
	A206		10/31/95	Cullinan, et al.		
	A207		10/24/95	Black, et al.		
	A208	5,461.064	10/24/95	Cullinan, G.J.		
		5,457,117	10/10/95	Black, et al.		
		5,457,116	10/10/95	Black, et al.		
_		5,457,113	10/10/95	Cullinan, et al.		
	A212	5,455,275	10/03/95	Fontana		
		5,453,492	09/26/95	Butzow, et al.		
1, 1	Λ214	5,453,442	09/26/95	Bryant, et al.		
\forall		5,451,603	09/19/95	Piggott		

						of Applicatio	n No. 09/910,388
HK		A216	5,451,590	09/19/95	Dodge		
	T	A217	5,451,589	09/19/95	Dodge		
		A218	5,451,414	09/19/95	Steward		
	Τ	A219	5,451,233	09/19/95	Yock		
	╁	A220	5,449,382	09/12/95	Dayton		
	†	Λ221	5,447,941	09/05/95	Zuckerman		
	╁	A222	5,447,724	09/05/95	Helmus, et al.		
	\top	A223	5,446,070	08/29/95	Mantelle		
	T	A224	5,446,053	08/29/95	Keohane		
	1	A225	5,445,941	08/29/95	Yang		
	1	A226	5,443,458	08/22/95	Eury		
	1	A227	5,441,986	08/15/95	Thompson		
		A228	5,441,966	08/15/95	Dodge		
	 	A229	5,441,965	08/15/95	Sall, et al.		***
	T	A230	5,441,964	08/15/95	Bryant, et al.		
		A231	5,441,734	08/15/95	Reichert, et al.		
	T	A232	5,439,931	08/08/95	Sales		
	\dagger	A233	5,439,923	08/08/95	Cullinan		
		A234	5,439,689	08/08/95	Hendrickson, et al.		
	†	A235	5,436,243	07/25/95	Sachs, et al.		
	\dagger	A236	5,434,166	07/18/95	Glasebrook		
	•	A237	5,429,634	07/04/95	Narcisco, et al.		
	T	A238	5,429,618	07/04/95	Keogh		
	\dagger	A239	5,426,123	06/20/95	Fontana		
	╁	A240	5,424,331	06/13/95	Shlyankevich		
		A241	5,421,955	06/06/95	Lau, et al.		
	1	A242	5,420,243	05/30/95	Ogawa, et al.	··· ·-	
	1	A243	5,419,760	05/30/95	Narciso, Jr.		
		A244	5,418,252	05/23/95	Williams		
	1	A245	5,415,619	05/16/95	Lee, et al.		
		A246	5,411,988	05/02/95	Bockow, et al.		· · · · · · · · · · · · · · · · · · ·
		A247	5,407,658	04/18/95	Hattner		
		A248	5,407,609	04/18/95	Tice, et al.		
	П	A249	5,401,730	03/28/95	Sauvage, et al.		• • • • • • • • • • • • • • • • • • • •
		A250	5,399,352	03/21/95	Hanson		
		A251	5,395,842	03/07/95	Labrie, et al.		
	П	A252	5,393,785	02/28/95	Labrie, et al.		······
	П			02/21/95	Cullinan, et al.		
		A254	5,391,378	02/21/95	Sanderson		
	П			02/14/95	Fontana		····
	П	A256	5,384,332	01/24/95	Fontana		
			5,383,928	01/24/95	Scott, et al.		
		A258	5,380,299	01/10/95	Fearnot, et al.		
1,		A259	5,378,475	01/03/95	Smith, et al.		
1		A260	5,356,433	10/18/94	Rowland, et al.		·

Sheet 7 of 33 of List of References of Application No. 09/910,388

					2	1101 077710,500
1	A261	5,354,801	10/11/94	O'toole, et al.		
1	A262	5,344,926	09/13/94	Murakata, et al.		
	A263	5,342,926	08/30/94	Hattner		
•	A264	5,342,348	08/30/94	Kaplan		
	A265	5,338,770	08/16/94	Winters, et al.		
	A266		07/26/94	Mantelle		
		5,324,739	06/28/94	Germick, et al.		
	A268	5,318,779	06/07/94	Hakamatsuka, et al.		
	A269	5,308,889	05/03/94	Rhee, et al.		
	A270	5,304,121	04/19/94	Sahatjian		
	A271	5,302,584	04/12/94	Kao, et al.		
	A272	5,292,802	03/08/94	Rhee, et al.		
	A273	5,290,271	03/01/94	Jernberg		
	A274	5,282,823	02/01/94	Schwartz, et al.		
	A275	5,280,040	01/18/94	Labroo, et al.		
	A276	5,262,451	11/16/93	Winters, et al.		
	A277		11/16/93	Iwata, et al.		
	_1	5,258,020	11/02/93	Froix		
	A279	5,234,957	08/10/93	Mantelle		
1	A280	5,234,456	08/10/93	Silverstrini		
	A281	5,226,913	07/13/93	Pinchuk		
		5,222,971	06/29/93	Willard, et al.		
		5,216,021	06/01/93	Sorenson		
		5,211,940	05/18/93	Ishiguro, et al.		
	A285	5,199,951	04/06/93	Spears		
	A286	5,195,984	03/23/93	Schatz		
		5,185,408	02/09/93	Tang, et al.		
	1	5,182,317	01/26/93	Winters, et al.		
		5,180,376	01/19/93	Fischell		
	A290	5,167,960	12/01/92	Ito, et al.		
		5,166,191	11/24/92	Cronin, et al.		
		5,163,952	11/17/92	Froix		
		5,145,838	09/08/92	Pickart		
		5,145,684	09/08/92	Liversidge, et al.		
		5,126,348	06/30/92	МсМитау.		
		5,118,791	06/02/92	Burnier, et al.		
		5,114,847	05/19/92	Jungfer, et al.		
		5.108,989	05/28/32	Amento, et al.		
		5,102,417	04/07/92	Palmaz		
	A300	5,100,885	03/31/92	Abrams, et al.		
	1 , , , , ,	5,099,504	03/24/92	Pettit		
		5,092,877	03/03/92	Pinchuk		
		5,082.834	01/21/92	Sorenson		
	1	5,075,321	12/24/91	Schreiber		
/	A305	5,064,435	11/12/91	Porter		

10					,	of Applicatio	n No. 09/910,388
4	A306	5,061,275	10/29/91	Wallsten, et al.			
	A307	5,061,273	10/29/91	Yock			
	A308	5,053,048	10/01/91	Pinchuk, et al.			
	A309	5,040,548	08/20/91	Yock			
	A310	5,037,641	08/06/91	Juhos, et al.			
	A311	5,034,265	07/23/91	Hoffman, et al.			
	A312	5,030,637	07/09/91	Einzig, et al.			
	A313	5,023,237	06/11/91	Pickart, et al.			
	A314	5,019,504	05/28/91	Christen, et al.			
	A315	5,008,279	04/16/91	Franckowiak, et al.			
	A316	5,002,531	03/26/91	Bonzel			
	A317	4,999,347	03/12/91	Sorenson			
	A318	4,996,225	02/26/91	Toivola, et al.			
	A319	4,994,384	02/19/91	Prather, et al.			
	A320	4,994,071	02/19/91	McGregor			
	A321	4,990,158	02/05/91	Kaplan, et al.			
	A322	4,984,594	01/15/91	Vinegar, et al.			
	A323	4,973,755	11/27/90	Gafe, et al.			
	A324	4,973,601	11/27/90	Dowd, et al.			
	A325	4,959,355	09/25/90	Fischbarg, et al.			
	A326	4,956,188	09/11/90	Anderson			
	A327	4,954,126	09/04/90	Wallsten			
	A328	4,952,607	08/28/90	Sorenson			
	A329	4,922,905	05/08/90	Strecker			
	A330	4,916,193	04/10/90	Tang, et al.			
	A331	4,900,561	02/13/90	Abdel-Monem, et al.			
	A332	4,886,062	12/12/89	Wiktor			
	A333	4,872,867	10/10/89	Joh, et al.			
	A334	4,853,377	08/01/89	Pollack,			
	A335	4,840,939	06/20/89	Leveen, et al.			·
	A336	4,824,661	04/25/89	Wagner			
	A337	4,793,348	12/27/88	Palmaz			
	A338	4,786,500	11/22/88	Wong			
	A339	4,776,337	10/11/88	Palmaz			
	Λ340	4,767,758	08/30/88	Breccia, et al.	[
	A341	4,762,129	08/09/88	Bonzel			
	A342	4,760,051	07/26/88	Pickart			
	A343	4,758,555	07/19/88	Sorenson			
	A344	4.758,554	07/19/88	Sorenson, et al.			
	A345	4,757,059	07/12/88	Sorenson			
	A346	4,753,652	06/28/88	Langer, et al.			
	A347	4,748,982	06/07/88	Horzewski, et al.			
	A348	4,739,762	04/26/88	Palmaz			
	A349	4,733,665	03/29/88	Palmaz			
<u> </u>	A350	4,705,647	11/10/87	Yamaguchi, et al.	;		
				·		····	

				.,		Application	1110, 07/710,000
HR	A351	4,696,949	08/29/87	Toivola, et al.			
	A352	4,689,046	08/25/87	Bokros			
	A353	4,687,482	08/18/87	Hanson			
	A354	4,678,466	07/07/87	Rosenwald			
	A355	4,670,428	06/02/87	Sorenson			
	A356	4,664,097	05/12/87	McGrath, et al.			
	A357	4,657,928	04/14/87	Sorenson			
	A358	4,656,083	04/07/87	Hoffman, et al.			
	A359	4,655,771	04/07/87	Wallsten		,	
	A360	4,629,694	12/16/86	Harpel			
	A361	4,613,665	09/23/86	Larm			
	A362	4,605,644	08/12/86	Foker			
	A363	4,536,516	08/20/85	Harper, et al.			
	A364	4,491,574	01/01/85	Seifter, et al.			
	A365	4,487,780	12/11/84	Scheinberg			
	A366	4,440,754	04/03/84	Sorenson			
	A367	4,428,963	01/31/84	Confalone, et al.			
	A368	4,418,068	11/29/83	Jones			
	. A369	4,382,143	05/03/83	Shepherd			
	A370	4,380,635	04/19/83	Peters			
	A371	4,339,429	07/13/82	Raaf, et al.			
	A372	4,332,791	06/01/82	Raaf, et al.			
	A373	4,323,707	04/06/82	Suarez, et al.			
	A374	4,317,915	03/02/82	Confalone, et al.			
	A375	4,315,028	02/09/82	Scheinberg			
	A376	4,310,523	01/12/82	Neumann			
	A377	4,307,111	12/22/81	Crawley			
	A378	4,300,244	11/17/81	Bokros			
	A379	4,292,965	10/06/81	Nash, et al.			
	A380	4,287,190	09/01/81	Boettcher, et al.			
	A381	4,282,246	08/04/81	Holland			
	A382	4,239,778	12/16/80	Venton, et al.			
	A383	4,230,862	10/28/80	Suarez, et al.			
	A384	4,221,785	09/09/80	Sorenson	Ī		
	A385	4,219,656	08/26/80	Press, et al.			
	A386	4,219,520	08/26/80	Kline			
	A387	4,205,685	06/03/80	Yoshida, et al.			
	A388		01/09/79	Jones, et al.			
	A389	3,952,334	04/27/76	Bokros, et al.		,	
	A390	3,932,627	01/13/76	Margaf			
	A391	3,879,516	04/22/75	Wolvek			
	A392		06/12/73	Schulte			
	A393		01/11/72	Palopoli, et al.			
	A394	3,526,005	09/01/70	Bokros, et al.			
V	A395	3,445,473	05/20/69	Ruschig, et al.			
_							

Sheet 10 of 33 of List of References of Application No. 09/910,388

T.	M	A396	3,288,806	11/29/66	Dewald, et al.	
· · ·		A397	3,279,996	10/18/66	Long, et al.	
		A398	3,168,565	02/02/65	Palopoli, et al.	
		A399	3,010,965	11/28/61	Elpern	
		A400	2,914,563	11/24/59	Allen, et al.	
-1		A401	2004/0236416	11/25/04	Falotico	
		Λ402	2002/0091433	07/11/02	Ding, et al.	
		A403	2002/0032477	03/14/02	Helmus, et al.	
	/	A404	2002/0013275	01/31/02	Kunz, et al.	

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI	. ^
			·			}	YES	Ţ
la	- B01	31079/93	07/15/93	Australian Patent Application		ļ		1
.	B02	03-297469	12/27/91	Japan (with English abstract)				
	B03	06-121828	06/05/94	Japan (with English abstract)				
	B04	06-205838	07/26/94	Japan (with English abstract)				
	B05	08-33718	02/06/96	Japan (with English abstract)				
T = 1	B06	09-255570	03/21/96	Japan				
	B07	59-042375	03/08/84	Japan				
	B08	60-25288	02/01/94	Japan				
	B09	1 015 787	01/05/96	United Kingdom .				J
	B10	1 587 084	05/25/81	United Kingdom				
	B11	2 273 873	06/07/94	United Kingdom				T
	B12	1 205 743	07/15/96	United Kingdom				T
1	B13	2 153 253	01/25/85	United Kingdom				T
	B14	2,231,727	09/14/04	Canada				†
	B15	2,079,205	03/26/94	Canada				1
	B16	2,086,642	07/10/93	Canada				1
	B17	2,207,659	06/13/96	Canada				t
1	B18	2255063	07/18/75	France			-	t
	B19	4320896	01/05/95	Germany				Ť
 	B20	4320898	01/05/95	Germany				Ť
1	B21	4401554	08/18/94	Germany				t
+	B22	DE A 3 918 736	12/13/90	Germany (with English abstract)				t
	B23	DE A 40 22 956	02/06/92	Germany (with English abstract)		<u> </u>		T
+	B24	1247527	04/24/91	Italy				T
-	B25	EP 0 095 875 A2	12/07/83	Europe				t
1	B26	EP 0 002 341	06/13/79	Europe				T
	B27	EP 0 024 096	02/25/81	Europe				T
	B28	EP 0 054 168 A1	06/23/82	Europe				T
	B29	EP 0 524 093	01/20/93	Europe				-
	B30	EP 0 566 245 A1	10/20/93	Europe				+
	* B31	EP 0 578 998	01/1994	Europe				-
	B32	EP 0 604 022 A1	06/29/94	Europe				 -

								of Application	No. 09/910	0,388
100	/		B34	EP 0 621 015 A1	04/23/04	Europe				
7	[B35	EP 0 623 345 A1	05/03/94	Europe				
	1	<u> </u>	B36	EP 0 639 577	02/22/95	Europe				1
			B37	EP 0 673 936	09/27/95	Europe				†
	1		B38	EP 0 701 802 A1	03/20/93	Europe				1
	 		B39	EP 0 706 376 B1	06/25/97	Europe				†
	†		B40	EP 0 716 836 A1	12/11/95	Europe			 	1
ļ	<u> </u>	*	B41	EP 0 717 041 B1	06/19/96	Europe ·		1		
		Г	B42	EP 0 734 721 A2	10/02/96	Europe	******		1	
	†	*	B43	EP 0 747 069	12/11/96	Europe				
			B44	EP 0 975 340	10/08/98	Europe				<u> </u>
			B45	EP 1 360 967 A1	11/12/03	Europe				-
			B46	EP A 0 430 542	11/20/90	Europe				
-			B47	EP A 0 435 518	12/13/90	Europe		}	1	
			B48	EP 0 290 012	11/09/88	Europe				
			B49	EP 0 302 034	02/01/89	Europe				1
			B50	EP 0 635 270	01/25/95	Europe				
			B51	EP 0 377 526B1	07/11/90	Europe				
			B52	EP 0 524 093	01/20/93	Europe			<u> </u>	
			B53	EP 0 542 679	05/19/93	Europe				
			B54	EP 0 551 182	07/14/93	Europe				
		*	B55	EP 0 623 354	11/09/94	Europe				
			B56	EP 0 629 697	12/21/94	Europe				
			B57	EP 0 639 577	02/22/95	Europe	······································			<u> </u>
			B58	EP 0 659 413 A2	06/28/95	Europe .				ļ .
			B59	EP 0 659 415 A2	06/28/95	Europe			 	
			B60	EP 0 659 418	06/28/95	Europe				
			B61	EP 0 659 419 A1	06/28/95	Europe				
			B62	EP 0 659 429 A1	06/28/95	Europe				
			B63	EP 0 664 121	07/26/95	Europe				
			В64	EP 0 664 122	07/26/95	Europe				
			B65	EP 0 664 123	07/26/95	Europe	-			
			B66	EP 0 664 124 A1	07/26/95	Europe				
			B67	EP 0 664 125	07/26/95	Europe				
			B68	EP 0 664 198	07/26/95	Europe				
			B69	EP 0 665 015 A2	08/02/95	Europe				
			B70	EP 0 668 075 A2	08/23/95	Еигоре		· · · · · · · · · · · · · · · · · · ·		
			B71	EP 0 670 162	09/06/95	Europe				
			B72	EP 0 673 936	09/27/95	Europe				
			B73	EP 0 674 903	10/04/95	Europe				
			B74	EP 0 675 121	10/04/95	Europe				***********
			B75	EP 0 684 259 A1	11/29/95	Europe				
				EP 0 699 673	03/06/96	Europe				
				EP 0 734 721 A2	02/10/96	Europe				
			B78	WO 00/00238	01/06/00	PCT				
\mathcal{J}	2 T		B79	WO 0047197	08/17/00	PCT				

Sheet 12 of 33 of List of References of Application No. 09/910,388

				·		,	of Application	110. 07/7/0	7,366
4180		B80	WO 89/03232	04/20/89	PCT				
)		B81	WO 90/07328	07/12/90	PCT				
		B82	WO 91/08291	06/13/91	PCT				
		B83	WO 91/17789 A1	11/28/91	PCT				
		B84	WO 91/18940 A1	12/12/91	PCT				
		B85	WO 92/00330	01/09/92	PCT				
		B86	WO 92/06068	04/16/92	PCT				
		B87	WO 92/13867	08/20/92	PCT				
		B88	WO 92/19612	11/12/92	PCT				
		B89	WO 93/02065	02/04/93	PCT				
		B90	WO 93/04191	03/04/93	РСТ				
		B91	WO 93/09228	05/13/93	PCT	<u> </u>			
	<u> </u>	B92	WO 93/09790	05/27/93	PCT				
		B93	WO 93/09800	05/27/93	PCT	<u> </u>			· · · · · · · · · · · · · · · · · · ·
		B94	WO 93/09802	05/27/93	PCT				
		B95	WO 93/10808	06/10/93	PCT				<u> </u>
		B96	WO 93/11757	06/24/93	PCT		 		
		B97	WO 93/16724	09/02/93	PCT				
		B98	WO 93/19746	10/14/93	PCT				
	-	B99	WO 93/19769	10/14/93	РСТ			-	
		B100	WO 94/01056	01/20/94	PCT				
		B101	WO 94/02595	02/03/94	PCT				
		B102	WO 94/07529	04/14/94	PCT				
		B103	WO 94/09010	04/28/94	PCT				
		B104	WO 94/09764	05/11/94	PCT .				
		B105	WO 94/09812	05/11/94	PCT				
		B106	WO 94/10187	05/11/94	PCT				
	*	B107	WO 94/13706	06/23/94	PCT				
 		B108	WO 94/15589	07/21/94	PCT				
		B109	WO 94/16706	08/04/94	PCT				
		B110	WO 94/20098	09/15/94	PCT				
	_	B111	WO 94/20099	09/15/94	PCT				
	_	B112	WO 94/20116	09/15/94	PCT				
	-	B113	WO 94/20117	09/15/94	PCT				
	_	B114	WO 94/20126	09/15/94	PCT				
	\neg	B115	WO 94/20127	09/15/94	PCT				
}		B116	WO 94/21309	09/29/94	РСТ				
		B117	WO 94/23068	10/13/94	PCT				
		B118		10/27/94	PCT				
<u> </u>	-	B119		11/10/94	РСТ				
 		B120	WO 94/25053	11/10/94	РСТ				
		B121	WO 94/25588	11/10/94	PCT				
	•	B122	WO 94/26291	11/24/94	PCT				
		B123	WO 94/26303	11/24/94	PCT				
		B124	WO 94/26888	10/06/95	PCT				
7	1	B125	WO 94/27612	12/08/94	РСТ		****		

- A' A 11 41	N/	00/010 100
of Application	NO.	09/910,388

						or Approaction	1100 07777	.,,,,,,,,,
+ M	1	B126	WO 95/04544	02/16/95	PCT			
	1	B127	WO 95/05191	02/23/95	PCT		1	
	11,	B128	WO 95/10611	04/20/95	PCT			
		B129	WO 95/17095	06/29/95	PCT			
		B130	WO 95/19987	07/27/95	PCT		1	
		B131	WO 95/20582	08/03/95	PCT			
	1	B132	WO 95/30900	11/16/95	PCT			
	1	B133	WO 95/33736	12/14/95	PCT			
	1	B134	WO 96/01102	01/18/96	PCT			
	• 1	B135	WO 96/03092	02/08/96	PCT			
	1 1	B136	WO 96/07402	03/14/96	PCT			
	1	B137	WO 96/15224	05/23/96	PCT			
	T i	B138	WO 96/20698	07/11/96	PCT			
	1	B139	WO 96/21442	07/18/96	PCT			
	ı	B140	WO 96/21443	07/18/96	PCT			
	E	B141	WO 96/24356	08/15/96	PCT			1
	* 6	B142	WO 96/25176	08/22/96	PCT			
	E	B143	WO 96/32907	10/24/96	PCT .			
	I	B144	WO 96/36349	11/21/96	PCT			
	F	B145	WO 96/40098	12/19/96	PCT			
1	E	B146	WO 97/10011	03/20/97	PCT			
	F	B147	WO 97/10334	03/20/97	PCT			
T	E	B148	WO 97/15319	05/01/97	PCT ·			
	E	B149	WO 97/21455	06/19/97	PCT			
	1	B150	WO 97/22697	06/26/97	PCT			
	E	B151	WO 97/33552	09/18/97	РСГ			
	E	B152	WO 97/45105	12/04/97	PCT			

		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
the	C01	"Breast Cancer Prevention Trial Should Resume, ODAC Says", <i>The Breast Cancer Letter. 20</i> , 4-5, (June 17, 1994)
	C02	"Churchill's Medical Dictionary", definition of "cytostatic". 473, (1989)
	C03	"Coronary Artery Disease: Restenosis and Reocclusion After Surgical and Nonsurgical Interventions, Part 1", Durg and Market Development, 5, 121-129 (Sept. 26, 1994)
	C04	"Glaxo Wellcome Preclinical Data: Preclinical studies conducted with GW 5638, a selective estrogen receptor modulator developed by Glaxo Wellcome, indicate that the compound acts both as an agonist and antagonist at estrogen receptor within specific", R & D Focus Drug News, (September 8, 1997)
	C05	"Growth Factor Via Gene Therapy Abates Sore Rheumatoid Joints", BioWorld Today: The Daily Biotechnology Newspaper, 9(115), Leff, David N., Editor, I, (June 17, 1998)
	C06	"Health Report The Good News", Time, 23, (Apr. 1, 1996)
	C07	"Heparin", In: Modern Pharmacology, Craig, C.R., et al., (eds.), Little, Brown and Company, Boston, MA, p. 399, (1982)
	C08	"ICI United States, Inc., Tamoxifen citrate, Summary For Basis of Approval", (December 30, 1977)
	C09	"Johnson & Johnson receives FDA approval to market Palmaz Balloon-expandable Stent for iliac arteries," Business Wire, Oct. 2, 1991.
	C10	"Micellar and Lyotropic Liquid Crystalline Phases Containing Nonionic Active Substances", In: Lyotropic Liquid Crystals and the Structure of Biomembranes, S. Fribert, (ed.), Advances in Chemistry Series, No. 152, American Chemical Society, 28-42, (1976)
	CH	"Muscle-Binding Gene Sees Two-Track Payoff: Human Therapies, Animal Meat", BioWorld Today: The Daily Biotechnology Newspaper, 8(85), Leff, David N., Editor, 1-3, (May 2, 1997)
	C12	"Prevention of Coronary Heart Disease", In: Avery's Drug Treatment — Principles and Practice of Clinical Pharmocology and Therapeutics, Speight, T. M., (ed.), Williams and Wilkins, Baltimore, 594-595, (1987)
(,)	C13	"Quantikine Human TGF-betal Immunoassay", Product Brochure, Catalog No. DB100, R&D Systems, Inc., pp. 1-
NYI-3900293v7		

		of Application No. 09/910,388
ill		19 (3/1996)
1	C14	"Schering/Orion Fareston Anti-Estrogen for Treatment of Metastatic Breast Cancer 'Similar' to Tamoxifen, FDA Oncologic Committee Says in Approval Vote", F-D-C Reports, 15-16, (Oct. 23, 1995)
	CI5	"Shiga Medical Center for Adult Diseases, "The Impact of Tranilast on Restenosis Following Coronary Angioplasty: The Tranilast Restenosis Following Angioplasty Trial (TREAT)", Circulation, 90, 1-82, Abstract No. 0, (October 1988)
	C16	"Tamoxifen therapy found safe for survivors of breast cancer", Fred Hutchinson Cancer Research Center Newsletter, 1(21), (October 1995)
	C17	"Toprol XLTM Tablets", In: Physician's Desk Reference., 658-660, (Probably 1992)
	C18	Agarwal, A.K., et al., "Estrogen Receptor-Binding Affinity of Tamoxifen Analogs with Various Side Chains and their Biologic Profile in Immature Rat Uterus", Steroids, 56, 486-489, (1991)
	C19	AinMelk, Y., et al., "Tamoxifen Citrate Therapy in Male Fertility", Fertility and Sterility, 48, 113-117, (July 1987)
	C20	Alberts, B. et al., "Molecular Biology of the Cell" 2 nd edition 1989, p653
	C21	Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of the Cell, Garland Publishing, London, 571, (1983)
	C22	Alderson, T. 1990 "New targets for cancer chemotherapy – poly(ADP-ribosylation) processing and polyisoprenc metabolism," Biol. Rev. 65:623-641
	C23	Aldridge, D.C., et al., "The Structures of Cytochalasins A and B", J. Chem. Soc., 17, 1667-1676, (1967)
	C24	Alich, A.A., et al., "Comparison of Aspirin and Copper Aspirinate with Respect to Gastric Mucosal Damage in the Rat", Journal of Pharmaceutical Sciences, 72, 1457-1461, (Dec. 1983)
	C25	Alich, A.A., et al., "Gastric Mucosal Damage Due to Aspirin and Copper Aspirinate Assessed by Gastric Mucosal Potential Difference Changes", Journal of Pharmacological and Toxicological Methods, 27, 245-250, (Jul. 1992)
	C26	Alich, A.A., et al., "Response to: 'The Ulcerogenic Potential of Copper Aspirinate Seems to be More Imaginary than Real'", Journal of Pharmaceutical Sciences, 73, Open Forum, 1876-1877, (Dec. 1984)
	C27	Allemann, et al., "Distribution, Kinetics, and Elimination of Radioactivity after Intravenous and Intramuscular Injection of 14C-Savoxepoine Loaded Poly (D,L-lactic acid) Nanospheres to Rats", J. Controlled Release, 29, 97-104, (1994)
	C28	Allen, K.E., et al., "Evidence For The Metabolic Activation of Non-Steroidal Antioestrogens: A Study of Structure-Activity Relationships", Br.J. Pharmac., 71, 83-91, (1980)
	C29	Allen, R.E. & Boxhor, L.K. "Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta," J Cell. Physiol. 133:567-572.(1987)
	C30	Allgemeine und spezielle Pharmakologie und Toxikolgie, by W. Forth et al. 1984, pages 524-531 and 627-633
	C31	Alvarado, et al. "Evaluation of Polymer-Coated Balloon Expandable Stents in Bile Ducts," Radiology 165 (suppl.):33 1 (1987)
	C32	Anderson et al., "Restenosis after coronary angioplasty," J. Interv. Cardiol., 6(3)187-202 (1993)
	C33	Ando et al., "Chimeric DNA-RNA hammerhead ribozyme targeting transforming growth factor-beta 1 mRNA inhibits neointima formation in rat carotid artery after balloon injury", Eur. J. Phamacol., 438:207-14 (2004)
	C34	Anker, et al., "Plasma Levels of the Atherogenic Amino Acid Homocysteine in Post-Menopausal Women with Breast Cancer Treated with Tamoxifen", Int. J. Cancer, 60, 365-368, (1995)
	C35	Arao, Y., et al., "A synthetic oestrogen antagonist, tamoxifen, inhibits oestrogen-induced transcriptional, but not post-transcriptional, regulation of gene expression", Biochem, J., 313, 269-274, (1996)
	C36	Askelband et al., "Rapamycin Inhibits Spontaneous and Fibroblast Growth Factor Beta-Stimulated Prolifereation of Endothelial Cells and Fibroblasts," Transplantantion Proceedings, 23 2833-2836 (1991)
	C37	Assoian et al., "Transforming growth factor-beta in human platelets: identification of a major storage site, purification, and characterization", J. Biol. Chem. 258:7155-7160 (t983)
	C38	Assoian, R.K., et al., "Cellular Transformation by Coordinated Action of Three Peptide Growth Factors from Human Platelets", Nature, 309, 804-806, (June 28, 1984)
	C39	Babaev, et al., "Heterogeneity of smooth muscle cells in atheromatous plaques of human aorta," Am J. Pathol. 136:1031- 1042. (1990)
	C40	Bailey et al., "Polymer Coating of Palmaz-Schatz Stent Attenuates Vascular Spasm after stent placement." Circulation 82:III-541 (1990)
	C41	Baim, D.S., et al., "Nonatherosclerotic Coronary Heart Disease", In: The Heart: Arteries and Veins, Sixth Edition, Logue, R.B., et al., (eds.), McGraw-Hill Book Company, New York, 1016-1025, (1986)
	C42	Bang, H.O., et al., "The Composition of the Eskimo Food in North Western Greenland", Am. J. Clin. Nutr., 33, 2657-2661, (1980)
	C43	Baquial, J.G., et al., "Down-Regulation of NADPH-Diaphorase (Nitric Oxide Synthase) May Account for the Pharmacological Activities of Cu(II)sub2(3,5-Diisopropylsalicylate)sub4., J. Inorganic Biochem., 60, 133-148, (1995)
<u>.</u>	C44	Baral, E., et al., "Modulation of Lymphokine-Activated Killer Cell-Mediated Cytotoxicity By Estradiol and Tamoxifen", Int. J. Cancer, 66, 214-218, (1996)
	C45	Barbucci, et al., Coating of Commercially available materials with a new heparinizable material, 1991, pp. 1259-

+1		of Application No. 09/910,388
4100		1274
	C46	Baringa, "Gene Therapy for Clogged Arteries Passes Test in Pigs", Science, 265, 738 (Aug. 5, 1994)
	C47	Barnard, et al., "Regulation of intestinal epithelial cell growth by transforming growth factor-beta." Proc. Natl Acad. Sci. USA 86:1518-1582.(1989)
	C48	Bassing et al., "FKBP12 is not required for the modulation of transforming growth factor beta receptor I signaling activity in embryonic fibroblasts and thymocytes", Cell Growth Differ., 9(3):223-8 (1998)
	C49	Battegay et al., "TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop", Cell, 63:5t5-524 (1990)
	C50	"Duraflo Biocompatible Treatment", Baxter Healthcare Corp., 1995
	C51	Beck, L., et al., "Vascular Development: Cellular and Molecular Regulation", The FASEB Journal, 11, 365-373, (1997)
	C52	Benita et al., "Submicron Emulsions as Colloidal Drug Carries for Intravenous Administration: Comprehensive Physicochemical Characterization", Journal of Pharmaceutical Sciences, 82, (November 1993)
	C53	Bergstrom, Reduction of fibrinogen adsorption on PEG-coated polystyrene surfaces, 1992, p. 779-790, Baxter Healthccare Corp. Duraflo Biocompatible Treatment
	C54	Bernhardt et al., "Acetylsalicylic acid, at high concentrations, inhibits vascular smooth muscle cell proliferation". J. Cardiovasc. Pharmacol., 21(6):973-6 (1993)
	C55	Berven, L.A., et al., "Cellular Function of p70S6K: A Role in Regulating Cell Motility", Immunology and Cell Biology, 78, 447-451, (2000)
	C56	Bier et al., "Arterial Remodeling: Importance in Primary Versus Restenoic Lesions", JACC, p. 139A, Abstract N 875-96 (February 1994)
	C57	Billmeyer, F., Textbook of Polymer Science (2d ed.) John Wiley & Sons, Inc. (1971)
	C58	Binmoeller, et al., "Silicone-Covered Expandable Metallic Stents in the Esophagus: An Experimental Study" Endoscopy 1992; 24:416-20.
	C59	Bittiner, S.B., et al., "A Double-Blind, Randomised, Placebo-Controlled Trial of Fish Oil in Psoriasis", The Lancet, 1, 378-380, (Feb. 20, 1988)
	C60	Bjorkerud, "Effects of transforming growth factor-betal on human arterial smooth muscle cells in vitro", Arterioscler. Thromb., 11(4):892-902 (1991)
	C61	Block, P.C. "Coronary-artery stents and other endoluminal devices," New Engl.J.Med. 1991; 324-52-3
	C62	Bluming, "Hormone Replacement Therapy: Benefits and Risks for the General Postmenopausal Female Population and for Women with a History of Previously Treated Breast Cancer", Seminars in Oncology, 20, 662-
	C63	674, (December 1993) Bohmova et al., "Effect of sirolimus on ischemia/reperfusion injury in transgenic hypertensive rat", Transplant Proc., 34(8):3051-3052 (2002)
	C64	Border, W.A., et al., "Targeting TGF-Beta for Treatment of Disease", Nature Medicine, 1(10), 1000-1001, (October 1995)
	C65	Boscoboinik et al., "Alpha-tocopherol (vitamin E) regulates vascular smooth muscle cell proliferation and protein kinase C activity", Arch. Biochem. Biophys., 286(1):264-9 (1991)
	C66	Boyle, "Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture", Curr. Vasc Pharmacol., 3(1):63-8 (2005)
	C67	Brand, C., et al., "Transforming Growth Factor Betal Decreases Cholesterol Supply to Mitochondria via Repression of Steroidogenic Acute Regulatory Protein Expression", The Journal of Biochemistry, 273(11), 6410-6416, (1998)
	C68	Braun-Dullaeus et al., "Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin", Arterioscler Thromb Vasc Biol. 21(7):1152-58 (2001)
	C69	Brem et al., "Polymers as Controlled Drug Delivery Devices for the Treatment of Malignant Brain Tumours." European Journal of Pharmaceuticals and Biopharmaceutics, 1993, Vol. 39, No. 1, pp 2-7
	C70	Brody, J.E., "Study Finds New Estrogen Offers Benefit Without Risk", The New York Times, A32, (December 4 1997)
	C71	Brott et al., "Vessel Remodeling After Angioplasty: Comparative Anatomic Studies", JACC, p. 138A, Abstract No. 875-43 (February 1994)
	C72	Burr, M.L., et al., "Effects of Changes in Fat, Fish and ibre Intakes on Death and Myocardial Reinfarction: Diat and Reinfarction Trial (DART)", The Lancet, 757-761, (Sep. 30, 1989)
	C73	Burton, T.M., "Lilly Osteoporosis Treatment Shows Promise", The Wall Street Journal, p. A3, A6, (June 6, 1997)
	C74	C. Chamsangavej et al., A New Expandable Mctallic Stent for Dilation of Stenotic Tubular Structures: Experimental and Clinical Evaluation, Houston Medical Journal 1987;2:41-51
	C'75	C. T. Dotter, "Transluminally Placed Coil Spring Endarterial Tube Grafts Long Term Patency in Canine Poplitea Arteries," Investigative Radiology 1969;4:329-332.
	C76	Calver et al. "Intracoronary Multi-link stents: experience in 218 patients using aspirin alone," Heart 1998;80:49 504
d	C77	Camenzind, et al., "Use of Locally Delivered Conventional Drug Therapies", Semin. Intervent. Cardiol., 1, 67-76

1.1.40		(1996)
	(370	Cannon, M., et al., "Competition Between Trichodermin and Several Other Sesquiterpene Antibiotics for Binding
	C78	to their Receptor Site(s) on Eukaryotic Ribosomes", Biochem. J., 160, 137-145, (1976)
	C79	Castellot et al., "Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth", J. Cell Biol., 90:372-379 (1981)
	C80	Castellot et al., "Effect of heparin on vascular smooth muscle cells. I. Cell metabolism", J. Cell. Physiol., 124:21-28 (1985)
	C81	Castellot et al., Heparin selectively inhibits a protein kinase c-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells, J Cell Biol., 109:3147-3155 (1989)
	C82	Chamberlain, 'Transforming growth factor-beta: a promising target for anti-stenosis therapy", Cardiovasc. Drug Rev, 19(4):329-344 (2001)
	C83	Chamley-Campbell and Campbell, "What controls smooth muscle phenotype?", Atherosclerosis, 40:347-357 (1981)
	C84	Chamsangavej et al., "Endovascular Stent for Vena Caval Stenosis: Laboratory Experiment and Potential Clinical Applications," Radiology 1985 Nov;157(P):66 Abs. 129.
	C85	Chandrasekar, B., et al., "Dietary Omega-3 Lipids Delay the Onset and Progression of Autoimmune Lupus Nephritis by Inhibiting Transforming Growth Factor Beta mRNA and Protein Expression", Journal of Autoimmunity, 8, 381-393, (1995)
	C86	Chandy, T., et al., "Chitosan Matrix for Oral Sustained Delivery of Ampicillin", Biomaterials, 14, 939-944, (1993)
	C87	Chang, M.P., et al., "Comparison of the Intoxication Pathways of Tumor Necrosis Factor and Diphtheria Toxin", Infection and Immunity, 58, 2644-2650, (Aug., 1990)
	C88	Charles Dotter et al., "Transluminal Treatment of Arteriosclerotic Obstruction Description of a New Technique and a Preliminary Report of its Application," Circulation 1964;30:654-669
	C89	Charlier, C., et al., "Tamoxifen and Its Active Metabolite Inhibit Growth of Estrogen Receptor-Negative MDA-MB-435 cells", Biochemical Pharmacology, 49(3), 351-358, (January 1995)
	C90	Charlier, et al., "Tamoxifen in the Treatment of Breast Cancer", J. Gynecol. Obstet Biol. Reprod., 23, 751-756, (1994)
	C91	Charnsangavej, et al., "Stenosis of the Vena Cava: Preliminary Assessment of Treatment with Expandable Metallic Stents," Radiology 1986 Nov;161:295.
	C92	Chauhan et al., "Activation of Transforming Growth Factor-B is Inversely Correlated with Three Major Risk Factors for Coronary Artery Disease: Lipoprotein(a), LDL-Cholesterol and Plasminogen Activator Inhibitor-1", Circulation, 90 I-623, Abstract No. 3354 (October 1994)
	C93	Cheitlin, M.D., et al., "Myocardial Infarction without Atherosclerosis", JAMA, 231, 951-959, (1975)
\neg	C94	Chen et al., "Transforming growth factor type beta specifically stimulates synthesis of proteoglycan in human adult arterial smooth muscle cells", Proc. Natl. Acad. Sci., 84:5287-5291 (1987)
	C95	Clark, D.A., et al., "Coronary Artery Spasm: Medical Management, Surgical Denegration, and Autotransplantation", The Journal of Thoracic and Cardiovascular Surgery, 73, 332-339, (1977)
	C96	Clarke, S.C., et al., "Tolerance and Responses To Tamoxifen and Toremifene in Male Patients with Coronary Artery Disease.", Abstract for ACC Meeting, March 1999
	C97	Clinton, S.K., et al., "Induction in vivo of Interleukin-1 (IL-1) Gene Expression in Rabbit Aortic Tissue", Abstracts of the 61st Scientific Sessions of the American Heart Association, Washington, D.C., November 14-17, 1988. Circulation, 78 (4 Part 2): p 1165 (1988)
	C98	Clowes and Kamowsky, "Suppression by heparin of smooth muscle cell proliferation in injured arteries", Nature, 265:625-626 (1977)
	C99	Clowes et al., "Heparin and cilazapril together inhibit injury-induced intimal hyperplasia", Hypertension, 18:11-65-11-69 (1991)
	C100	Colletta, A.A. et al., "Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts", Br. J. Cancer, 62, 405-409, (1990)
	C101	Columbo et al., "A Novel Strategy for Stent Deployment in the Treatment of Acute or Threatened Closure Complicating Balloon Coronary Angioplasty," JACC 1993 Dec;22(7):1887-91,
	C102	Comezoglu, F.T. et al., "Serum Stability and Cytotoxicity of the Macrocyclic Trichothecenes Roridin A, Verrucarin A and Their Monoclonal Antibody Conjugates", Proceedings of the American Association for Cancer Research, 31, Abstract No. 1723, p. 291, (Mar., 1990)
	C103	Coombes, R.C., et al., "Idoxifene: Report of a Phase I Study in Patients with Metastatic Breast Cancer", Cancer Research, 55, 1070-1074, (Mar. 1, 1995)
	C104	Corcos, et al., "Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty", Am. Heart J., 109(5):926-931 (1985)
	C105	Cotton, P., "Restenosis Trials Suggest Role for Remodeling", JAMA, 271, 1302-1305, (May 4, 1994)
	C106	Craig et al., "Anticoagulant Drugs" in Modern Pharmacology; Little, Brown & Co.: Boston; p. 399 (1982)
	C107	Csernok, E., et al., "Transforming Growth Factor-beta (TGF-beta) Expression and Interaction with Proteinase 3 (PR3) in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis", Clin. Exp. Immunol., 105, 104-111, (1996)
	C108	Cunningham, A., et al., "A Study of the Structural Basis of the Carcinogenicity of Tamoxifen, Toremifene and their Metabolites", Mutation Research, 349, 85-94, (1996)

		of Application No. 09/910,388
ile	C109	Currier et al., "Low molecular weight heparin (enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbit", J. Am. Coll. Cardiol., 17(6):118B-125B (1991)
	C110	Currier, "Restenosis After Percutaneous Transluminal Coronary Angioplasty: Have We Been Aiming at the Wrong Target?", JACC, 25 516-520 (February 1995)
	CHI	Dangas, G., et al., "Management of Restenosis after Coronary Intervention", American Heart Journal, 132, 428-436, (1996)
	C112	Davies, A.M., et al., "Peroxidase Activation of Tamoxifen and Toremifene Resulting in DNA Damage and Covalently Bound Protein Adducts", Carcinogenesis, 16, 539-545, (1995)
	C113	deAlvare, L.R., et al., "Mechanism of Superoxlde Anion Scavenging Reaction by Bis-(Salicylato)-Copper(II) Complex", Biochemical and Biophysical Research Communications, 69, 687-694, (1976)
	C114	Dehmer, G.J., et al., "Reduction in the Rate of Early Restenosis After Coronary Angioplasty by a Diet Supplemented with n-3 Fatty Acids", N. Engl. J. Med., 319, 733-740, (1988)
	C115	Del Vecchio et al., "Inhibition of human scleral fibroblast proliferation with heparin, Invest" Ophthalmol. Vis. Sci., 29:1272-1276 (1988)
	C116	Delmas, P.D., "Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women", The New England Journal of Medicine, 337(23), (1997)
	C117	Chenoweth, D. E., "Complement Activation in Extracorporeal Circuits" Annals of the New York Academy of Sciences Vol. 516 pp. 306-313 (1987)
	C118	DiGiacomo, R.A., et al., "Fish-Oil Dietary Supplementation in Patients with Raynaud's Phenomenon: A Double-Blind, Controlled, Prospective Study", Am. J. Med., 86, 158-164, (Feb. 1989)
	C119	DiLuccio, R.C., et al., "Sustained-Release Oral Delivery of Theophylline by Use of Polyvinyl Alcohol and Polyvinyl Alcohol-Methyl Acrylate Polymers", Journal of Pharmaceutical Sciences, 83, 104-106, (January 1994)
	C120	DiMario, "Is the Mechanism of Restenosis Device-Independent? Serial Assessment with Intracoronary Ultrasound", Circulation, 90, 1-24, Abstract 115 (October 1994)
	C121	Donnelly, J., et al., "Protective Efficacy of Intramuscular Immunization with Naked DNA; DNA Vaccines: A New Era in Vaccinology, Margaret A. Liu et al., eds.", Annals of the New York Academy of Sciences, 772, 40-44, (1995)
	C122	Dotter, "Intraventional Radiology - Review of an Emerging Field," Seminars In Roentgenology 1982;16(1):7-8,
	C123	Dove, C.R., et al., "Effect of Vitamin E and Copper on the Vitamin E Status and Performance of Growing Pigs", Anim. Sci., 69, 2516-2523, (1991)
	C124	Dowsett, M., "New Developments in the Hormonal Treatment of Breast Cancer", In: The Treatment of Cancer: Beyond Chemotherapy, Conference Documentation, The Glouster Hotel, London, 7 p., (Mar. 13-14, 1995)
	C125	Dragan, Y.P., et al., "Comparison of the Effects of Tamoxifen and Toremifene on Liver and Kidney Tumor Promotion in Female Rats", Carcinogenesis, 16, 2733-2741, (1995)
	C126	Draper, M.W., et al., "Antiestrogenic Properties of Raloxifene", Pharmacology, 50, 209-217, (April 1995)
	C127	Dyerberg, J., "PlateletVessel Wall Interaction: Influence of Diet", Phil. Trans. R. Soc. Lond., B 294, 372-381, (1981)
	C128	Dyerberg, J., et al., "The Effect of Arachidonic- and Eicosapentaenoic Acid on the Synthesis of Prostacyclin-like Material in Human Umbilical Vasculature", Artery, 8, 12-17, (1980)
	C129	Edelman, E.R., et al., "Effect of Controlled Adventitial Heparin Delivery on Smooth Muscle Cell Proliferation Following Endothelial Injury", Proc. Natl. Acad. Sci. USA, 87, 3773-3777, (May, 1990)
	C130	Ellis et al., "Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty", Am, Heart J., 117(4):777-782 (1989)
	C131	Ellis, S.G., et al., "In-Hospital Cost of Percutaneous Coronary Revascularization: Critical Determinants and Implications", Circulation, 92, 741-747, (1995)
	C132	Endres, S., et al., "The Effect of Dietary Supplementation with n-3 polyunsaturated Fatty Acids on the Synthesis of Interleukin-1 and Tumor Necrosis Factor by Mononuclear Cells", N. Engl. J. Med., 320, 265-271, 1989)
	C133	Esnouf, M.P., et al., "The Inhibition of the Vitamin K-Dependent Carboxylation of Glutamyl Residues in Prothombin by Some Copper Complexes", FEBS Letters, 107, 146-150, (1979)
	C134	Espinosa, E., et al., "17-Estradiol and Smooth Muscle Cell Proliferation in Aortic Cells of Male and Female Rats" Biochemical and Biophysical Research Communication, 221, 8-14, (1996)
	C135	Evans, G.L., et al., "Tissue-Selective Actions of Estrogen Analogs", Bone, 17, 181S-190S, (October 1995)
	C136	Faxon et al., "Enozaprain, a low molecular weight heparin, in the prevention of restenosis after angioplasty: result of a double blind randomized trial", JACC 19:258A, Abstract 783-3 (1992)
	C137	Ferrari, R.P., et al., "Changes of Serum Iron Transferrin and Copper Ceruloplasmin in Rats Given Cu(11) sub2 (Acetylsalicyate) sub4 During Acute Inflammation", Anticancer Res., 9, 771-774, (1989)
	C138	Fett-Neto, A.G., et al., "Effect of White Light on Taxol and Baccatin III Accumulation in Cell Cultures of Taxus Cuspidata Sieb and Zucc.", J. Plant Physiol., 146, 584-590, (1995)
	C139	Fischell, et al., "Low-Dose, beta-Particle Emission From 'Stent' Wire Results in Complete, Localize Inhibition of Smooth Muscle Cell Proliferation", Circulation, 90 2956-2963 (December, 1994)
	C140	Fischman, et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease:, The New England Journal of Medicine, 331, 496-501 (August, 1994)
		Fisher, M., et al., "Dietary n-3 Fatty Acid Supplementation Reduces Superoxide Production and

		of Application No. 09/910,368
AR	C142	Flanders, K.C., et al., "Altered Expression of Transforming Growth Factor-B in Alzheimer's Disease", Neurology, 45, 1561-1569, (August 1995)
	C143	Flanders, K.C., et al., "Transforming Growth Factor-B1: Histochemical Localization With Antibodies to Different
		Epitopes", Journal of Cell Biology, 108, 653-660, (Feb. 1989) Foekens, J.A., et al., "Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor
	C144	Response to Tamoxifen Therapy in Recurrent Breast Cancer", Journal of the National Cancer Institute, 87(10),
		751-756. (May 1995)
	C145	Forney-Prescott et al., "Angiotensin-converting enzyme inhibito' versus angiotensin II, ATI receptor antagonist:
	(143	effects on smooth muscle cell migration and proliferation after balloon catheter injury", Am J Pathol, 139:1291-
		1296 (1991)
	C146	Fox and DiCorleto, "Fish oils inhibit endothelial cell production of platelet-derived growth factor-like protein",
		Science, 241 (4864):453-456 (1988) Frautschy, S.A., et al., "Rodent Models of Alzheimer's Disease: Rat A Infusion Approaches to Amyloid
	C147	Deposits", Neurobiology of Aging, 17, 311-321, (1996)
	C148	Frazier-Jessen, et al., "Estrogen Modulation of JE/Monocytte Chemoattractant Protein-1 mRNA Expression in
		Murine Macrophages", J. Immunol., 1828-1845
	C149	Frye, L.L., et al., "Oxolanosterol Oximes: Dual-Action Inhibitors of Cholesterol Biosynthesis", Journal of Lipid Research, 35, 11333-1344, (1994)
	C150	Fukaura, H., et al., "Induction of Circulating Myelin Basic Protein and Proteolipid Protein-Specific Transforming
	(.130	Growth Factor- B1-secreting Th3 T Cells by Oral Administration of Myelin in Multiple Sclerosis Patients", J.
		Clin, Invest., 98, 70-77, (1996)
	C151	Fukuda, et al., "Distinct Expression of Transforming Growth Factor-B Receptor Subtypes on Vascular Smooth
		Muscle Cells from Spontaneously Hypertensive Rats and Wistar-Kyoto Rats", Clin. Exp. Pharmacol. Physiol.
	0:22	Supply., 1, S120, 1995 Furr, B.J., et al., "The Pharmacology and Clinical Uses of Tamoxifen", Pharmac. Ther., 25, 127-205, (1984)
	C152	Gebhardt, R., et al., "Differential Inhibitory Effects of Garlic-Derived Organosulfur Compounds on Cholesterol
	C153	Biosynthesis in Primary Rat Hepatocyte Cultures", Lipids, 31, 1269-1276, (1996)
	C154	Gebhardt, R., et al., "Inhibition of Cholesterol Biosynthesis by Allicin and Ajoene in Rat Hepatocytes and HepG2 Cells", Biochimica et Biophysica Acta, 1213, 57-62, (1994)
	C155	Gertz et al., "Geometric Remodeling Is Not the Principal Pathogenic Process in Restoenosis After Balloon Angioplasty", Circulation, 90, 3001-3008 (December 1994)
	C156	Giachelli, et al., "Osteopontin is Elevated During Neointima Formation in Rat Arteries and is a Novel Component
	(130	of Human Atherosclerosis Plaques", J. Clin. Invest., 92, 1686-1696, (Oct. 1993)
	C157	Gibbons et al., "The emerging concept of vascular remodeling", New Engl. J. of Medicine, 330 1431-1437 (1994)
	C158	Gibson, D.M., et al., "Initiation and Growth of Cell Lines of Taxus Brevifolia (Pacific Yew)", Plant Cell Reports, 12, 479-482, (1993)
	C159	Glagov, S., "Intimal Hyperplasia, Vascular Modeling, and the Restenosis Problem", Circulation, 89, 2888-2891, (1994)
	C160	Gradishar, W.J., et al., "Clinical Potential of New Antiestrogens", Journal of Clinical Oncology, 15, 840-852, (1997)
	C161	Graham et al., "Dexamethasone Inhibits Grown and Na:H Exchange in Vascular Smooth Muscle Cells" Journal of Endocrinology, 129 (Suppl.) Abstract 180, 10 th Joint Metting of British Endocdrine Societies, Brighton, England, UK, April 15-18, (1991)
	C162	Grainger and Metcalfe, "Transforming growth factor-β and cardiovascular protection, draft" (NeoRx 019151-019213)
	C163	Grainger and Metcalfe, TGF-beta: implications for human vascular disease. J Hum Hypertens., 9(8):679 (1995)
	C164	Grainger and Mosedale, "TGF- β and the cardiovascular system, TGF- β and Related Cytokines in Inflammation," Breit, SN and Wahl, SM (ed.), Birkhauser Verlag, 91-146 (2001) (DJG 006134-006190).
	C165	Grainger et al., "Dictary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions", J. Cell Sci., 113:2355-2361(2000)
	C166	Grainger et al., "Red wine, but not white wine, elevates circulating TGF- β levels -possible role of a salicylate complex"
	C167	Grainger et al., "Transforming growth factor-beta dynamically regulates vascular smooth muscele cell differentiation in vivo", J. Cell Sci., 111:2977-2988 (1998)
	C168	Grainger, D.J., "Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis", Arterioscler. Thromb. Vasc. Biol., 24:399-404 (2004) (DJG 006208-006213)
	C169	Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis?", Biol. Rev., 70, 571-596, (1995)
	C170	Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) in vivo", Circulation, 90, 67th Scientific Session, Abstract No. 3353, p. 1-623, (Oct., 1994)
	C171	Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Mice", Nature, 370 460-462, (Aug. 11, 1994)
	C172	Grainger, D.J., et al., "Active and Acid-Activatable TGF-beta in Human Sera, Platelets and Plasma", Clinica Chemica Acta., 235, 11-31, (Feb., 1995)
(1)	C173	Grainger, D.J., et al., "Active TGF-beta is Depressed Five-fold in Triple Vessel Disease Patients Compared with

		of Application No. 09/910,388
THE		Syndrome X Patients", Journal of Cellular Biochemistry, 18A, Abstract No. E111, p. 267, (1994)
	C174	Grainger, D.J., et al., "Active Transforming Growth Factor-beta is Depressed in Patients with Three Vessel Coronary Artery Disease", Circulation, 90, 67th Scientific Sessions, Abstract No. 2754, p. I-512, (Oct., 1994)
	C175	Grainger, D.J., et al., "Mitogens for Adult Rat Aortic Vascular Smooth Muscle Cells in Serum-Free Primary Culture", Cardiovascular Research, 28, 1238-1242, (1994)
	C176	Grainger, D.J., et al., "Proliferation of Human Smooth Muscle Cells Promoted by Lipoprotein(a)", Science, 260, 1655-1658, (June 11, 1993)
	C177	Grainger, D.J., et al., "Release and Activation of Platelet Latent TFG-Beta in Blood Clots During Dissolution with Plasmin", Nature Medicine, 1, 932-937, (1995)
	C178	Grainger, D.J., et al., "Tamoxifen Elevates Transforming Growth Factor-beta and Suppresses Diet-Induced Formation of Lipid Lesions in Mouse Aorta", Nature Medicine, 1, 1067-1073, (Oct., 1995)
	C179	Grainger, D.J., et al., "Tamoxifen: Teaching an Old Drug New Tricks?", Nature Medicine, 2, 381-385, (Apr., 1996)
	C180	Grainger, D.J., et al., "The Serum Concentration of Active Transforming Growth Factor-beta is Severely Depressed in Advanced Atherosclerosis", Nature Medicine, 1, 74-80, (Jan., 1995)
	C181	Grainger, D.J., et al., "Transforming Growth Factor beta Decreases the Rate of Proliferation of Rat Vascular Smooth Muscle Cells by Extending the G2 Phase of the Cell Cycle and Delays the Rise in Cyclic AMP Before Entry into M Phase", Biochemical Journal, 299, 227-235, (1994)
	C182	Grainger, D.J., et al., "Transforming Growth Factor-beta and Cardiovascular Protection", In: The Ecndothelium in Clinical Practice, Rubanyi, G.M., et al., (eds.), Marcel Dekker, Inc., New York, 203-243, (1997)
	C183	Grainger, D.J., et al., "Transforming Growth Factor-beta is Sequestered into an Inactive Pool by Lipoproteins", Journal of Lipid Research, 38, 117-125, (1997)
	C184	Grainger, D.J., et al., "Transforming Growth Factor-beta: The Key to Understanding Lipoprotein(a)?", Current Opinion In Lipidology, 6, 81-85, (1995)
	C185	Grainger, D.J., University of Cambridge Ph.D. Thesis, Control of the proliferation and differentiation of vascular smooth muscle cells, DJG 005911-006102 (1992) and all references therein
	C186	Gravlee, G.P. MD, Heparin-Coated Cardiopulmonary Bypass Circuits, Journal of Cardiothoracic and Vascular Anesthesia, Vol. 8, No. 2, April 1994, pp. 213-222
	C187	Gref, et al., "Biodegradable Long-Circulating Polymeric Nanoshoeres", Science, 263, 1600-1603, (March 18, 1994)
	C188	Gregory et al., "Rapamycin Inhibits Arterial Intimal Thickening Caused by Both Alloimmune and Mechanical Injury:, Transplantation, 55 1409-1418 (1993)
	C189	Gregory et al., "Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury", Transplant. Proc., 25:120-21 (1993)
	C190	Grese, T.A., et al., "Structure-Activity Relationships of Selective Estrogen Receptor Modulators: Modification to the 2-Arylbenzothiophene Core of Raloxifene", J. Med. Chem., 40, 146-167, (1997)
	C191	Grey, A.B., et al., "The Effect of the Anti-Estrogen Tamoxifen on Cardiovascular Risk Factors in Normal Postmenopausal Women", J. Clinical Endocrinology and Metabolism, 80, 3191-3195, (1995)
	C192	Grigg, L.E., et al., "Determinants of Restenosis and Lack of Effect of Dietary Supplementation with Eicosapentaenoic Acid on the Incidence of Coronary Artery Restenosis After Angioplasty", JACC, 13, 655-672, (1989)
	C193	Gruntzig, et al., "Nonoperative Dilatation of Coronary-Artery Stenosis," New England J. Med 1979 Jul 12;301(2):61-68.
	C194	Guba et al., "Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor", Nat. Med., 8(2):128-35 (2002)
	C195	Guetta, V., et al., "Effects of the Antiestrogen Tamoxifen on Low-Density Lipoprotein Concentrations and Oxidation in Postmenopausal Women", The American Journal of Cardiology, 76, 1072-1073, (November 15, 1995)
	C196	Gulino, A., et al., "Heterogeneity of Binding Sites for Tamoxifen and Tamoxifen Derivatives in Estrogen Target and Nontarget Fetal Organs of Guinea Pig, Cancer Research 42, 1913-1921, (May 1982)
	C197	Guyton et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparin: in vivo studies with anticoagulant and noncoagulant heparin", Circ. Res., 46(5):625-634 (1980)
	C198	Gylling, H., et al., "Tamoxifen and Toremifene Lower Serum Cholesterol by Inhibition of Delta8-Cholesterol Conversion to Lathosterol in Women with Breast Cancer", Journal of Clinical Oncology, 13, 2900-2905, (1995)
	C199	Gylling, H., et al., "Tamoxifen Decreases Serum Cholesterol by Inhibiting Cholesterol Synthesis", Atherosclerosis, 96, 245-247. (1992)
	C200	Hafzi et al., "Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling", Vascul. Pharmacol., 41:167-76 (2004)
	C201	Hahn, L., et al., "The Influence of Acetylsalicylic Acid and Paracetamol on Menstrual Blood Loss in Woman Witl and Without an Intrauterine Contraceptive Device", Am. J. Obstet. Gnecol., 135, 393-396, (1979)
	C202	Hall, I.H., et al., "Hypolipidemic Activity of Tetrakis-mu-(trimethylamine-boranecarboxylato)-bis (trimethylamine-carboxyborane) -dicopper (II) in Rodents and Its Effect on Lipid Metabolism", J. Pharmaceut. Sci., 73, 973-977, (1984)
	C203	Hanson, et al., "In vivo evaluation of artificial surfaces with a nonhuman primate model of arterial thrombosis, "J. Lab. Clin. Med. 95:289-304; 1980
		<u> </u>

		of Application No. 09/910,388
JAK.	C204	Hanson, et al., "Testing of Blood - Materials Interactions," Biomaterials Science (B.D. Ratner, Ed.), Academic Press, 222-238 (1996).
	C205	
	C206	Harpel, et al., "Lp(a) Inhibitor of Plasminogen," Proc. Natl. Acad. Sci. USA, 86, 3847 (1989)
	C207	Harrison, D.C., "Nonatherosclerotic Coronary Artery Disease", In.: Atherosclerosis and Coronary Artery Disease V. Fuster, et al., (eds.), Lippencott-Raven Publishers, pp. 757-772, (1996)
	C208	Hayden, L.J., "Inhibitors of Gastric Lesion in the Rat", J. Pharm. Pharmac., 30, 244-246, (1978)
	C209	Hayes, D.F., et al., "Randomized Comparison of Tamoxifen and Two Separate Doses of Toremifene in Postmenopausal Patients with Metastatic Breast Cancer", Journal of Clinical Oncology, 13, 2556-2566, (Oct. 1995)
	C210	Hehrlein, C., et al., "Low-Dose Radiactive Endovascular Stents Prevent Smooth Muscle Cell Proliferation and Neointimal Hyperplasia in Rabbits", Circulation, 92, 1570-1575, (1995)
	C211	Hehrlein, C., et al., "Pure Beta-particle-emitting Stents Inhibit Neointima Formation in Rabbits", Circulation, 93, 641-645, (1996)
	C212	Hermann and Hirshfeld, Jr., "Clinical Use of the Palmaz-Schatz Intracoronary Stent," Futura Publishing Co. (1993).
	C213	Hoffman, A., "Modification of Material Surfaces to Affect How They Interact with Blood, Blood in Contact with Natural and Artificial Surfaces," Leonard, E. et al., (eds), Annals of the New York Academy of Sciences, 516:96-100 (1987)
	C214	Holmes, et al., "Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis", Circulation, 109:634-640 (2004)
	C215	Holmes, Jr., D.R., "Remodeling Versus Smooth Muscle Cell Hyperpasia", Restenosis Summit VI, The Cleveland Clinic Foundation, 222-223, (1994)
	C216	Hoover, et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparin: II. In vitro studies", Circ. Res., 47(4):578-83 (1980)
	C217	Hopfenberg, H., "Transport Through Polymers, 7 Encyclopedia of Materials Science and Engineering," (Michael B. Bever, (ed.); The MIT Press, 5141-5145 (1986)
	C218	Howell, A., et al., "New Endocrine Therapies for Breast Cancer", European Journal of Cancer, 32A, 576-588, (1996)
	C219	Hsu, Li-Chien "Principles of Heparin-Coating Techniques", Perfusion 6: 209-219 (1991)
	C220	Huang, et al., "Rapamycins: mechanism of action and cellular resistance." Cancer Biol. Ther., 2(3):222-32 (2003)
	C221	Huang, S.S., et al., "Transforming Growth Factor Beta peptide Antagonists and Their Conversion to Partial Agonists", The Journal of Biological Chemistry, 272(43), 27155-57159, 1997
	C222	Huehns, et al., "Adventitia as a Trarget for Intravascular Local Drug Delivery", Heart, 75, 437-438 (1996)
	C223	Hughes, D.E., et al., "Estrogen Promotes Apoptosis of Murine Osteoclasts Mediated by TFG-beta", Nature Medicine, 2, 1132-1136, (1996)
	C224	Ishihara, et al., "Synthesis of phospholipid polymers having a urethane bond in the side chain as coating material on segmented polyurethane and their platelet adhesion-resistant properties," Biomaterials, 1995 16(11): 873-879
	C225	Isner, "Vascular Remodeling: Honey, I Think I Shrunk the Artery", Circulation, 89 2937-2841 (June 1994).
	C226	Jacinto and Hall, "Tor signalling in bugs, brain and brawn", Nature Rev. Mol. Cell Biol., 4:117-126 (2003)
	C227	Jande et al., "Effects of cytochalasin B and dihydrocytochalasin B on calcium transport by intestinal absorptive cells", Calcif. Tissue Int. 33, 143-151 (1981); Chem. Abs. 94 Abstract No. 189223e (1981)
	C228	Hubbell, J.A., "Pharmacologic Modification of Materials", Cardiovasc Pathol., Vol. 2, No.3 (Suppl.), July-Scpt. 1993, pp. 121S-127S
	C229	Jeng, et al., "Regulation of the levels of three transforming growth factor beta mRNAs by estrogen and their effects on the proliferation of human breast cancer cells", Mol. Cell Endocrinol., 92:115-123 (1993)
	C230	Jenkins et al., "Local Delivery of Taxol Inhibits Neointimal Regrowth Following Balloon Injury of the Rat Carotid Artery: , Circulation, 90, p. I-297, Abrstract No. 1596 (Oct. 1994)
	C231	Johnston, S.R., et al., "Changes in Estrogen Receptor, Progesterone Receptor, and ps2 Expression in Tamoxifen- resistant Human Breast Cancer", Cancer Research, 55, 3331-3338, (August 1995)
	C232	Jones, R.H., et al., "Increased Susceptibility to Metal Catalysed Oxidation of Diabetic Lens beta subL Crystallin: Possible Protection by Dietary Supplementation with Acetylsalicyclic Acid", Exp. Eye Res., 57, 783-790, (1993)
	C233	Jordan, A. et al., "Tubulin as a Target for Anticancer Drugs: Agents which Interact with the Mitotic Spindle", Medicinal Research Reviews, 18, 259-296, (1998)
1	C234	Jordan, V.C., et al., "A Mutant Receptor as a Mechanism of Drug Resistance to Tamoxifen Treatment", Annals New York Academy of Science, 761, 138-147, (1995)
	C235	Jordan, V.C., et al., "Structural Requirements for the Pharmacological Activity of Nonsteroidal Antiestrogens in Vitro", Molecular Pharmacology, 26, 272-278, (1984)
1	C236	Jordan, V.C., et al., "Tamoxifen: Toxicities and Drug Resistance During the Treatment and Prevention of Breast Cancer", Annu. Rev. Pharmacol. Toxicol., 35, 195-211, (1995)
1	C237	Joswig, B.C., et al., "Transmural Myocardial Infarction in the Absence of Coronary Arterial Luminal Narrowing in

of Application No. 09/910,388

			of Application No. 09/910.388
HX			a Young Man with Single Coronary Arterial Anomaly", Catheterization and Cardiovascular Diagnosis, 4, 297-304, (1978)
+11		C238	Kakuta, T., et al., "Differences in Compensatory Vessel Enlargement, Not Intimal Formation, Account for Restenosis After Angioplasty in the Hypercholesterolemic Rabbit Model", Circulation, 89, 2809-2815, (1994)
		C239	Kakuta, T., et al., "The Impact of Arterial Remodeling on the Chronic Lumen Size After Angioplasty in the Atherosclerotic Rabbit", JACC, Abstract No. 875-95, p. 138A, (Feb., 1994)
		C240	Kanzaki, et al., "In vivo effect of TGF-beta1: enhanced intimal thickening by administration of TGF-beta1 in rabbit arteries injured with a balloon catheter", Arterioscler. Thromb. Vasc. Biol., 15(11):1951-57 (1995)
		C241	Kardami et al., "Heparin Inhibits Skeletal Muscle Growth in Vitro", Dev. Biol, 126:19-28 (1988)
J		C242	Kariya et al., "Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells". Atherosclerosis, 80:143-147 (1989)
		C243	Kaski, J.C., et al., "Local Coronary Supersensitivity to Diverse Vasoconstrictive Stimuli in Patients with Variant Angina", Circulation, 74, 1255-1265, (1996)
		C244	Kastrati et al., "Restenosis after coronary placement of various stent types," Am. J. Cardiol., 87:34-49 (2001)
		C245	Ke, H.Z., et al., "Comparative Effects of Droloxifene, Tamoxifen, and Estrogen on Bone, Serum Cholesterol, and Uterine Histology in the Ovariectomized Rat Model", Bone, 20, 31-39, (1997)
		C246	Keen, C.L., et al., "Hypertension Induced Alterations in Copper and Zinc Metabolism: A Link to Vascular Disease?", In: Biology of Copper Complexes, Sorenson, J.R.J., (ed.), Humana Press, Clifton, New Jersey, 141-153, (1987)
		C247	Kellen, J.A., "Tamaoxifen Beyond the Antiestrogen", Birkh∑user, 392 pages, (1996)
		C248	Kellen, J.A., et al., "The Effect of Toremifene on the Expression of Genes in a Rat Mammary Adenocarcinoma", In Vivo, 10, 511-514, (1996)
		C249	Kemp, P.R., et al., "Cloning and Analysis of the Promoter Region of the Rat SM11-Alpha Gene", Biochem. J., 310, 11043, (1995)
		C250	Kemp, P.R., et al., "Inhibition of PDGF BB Stimulated DNA Synthesis in Rat Aortic Vascular Smooth Muscle Cells by the Expression of a Truncated PDGF Receptor", FEBS Letters, 336, 119-123, (Dec., 1993)
		C251	Kemp, P.R., et. al., "ID A Dominant Negative Regulator of Skeletal Muscle Differentiation is Not Involved in Maturation or Differentiation of Vascular Smooth Muscle Cells", FEBS Letters, 368, 81-86, (1995)
		C252	Kim, et al., "Suppression of Vascular Transforming Growth Factor-B1 and Extracellular Matrix Gene Expressions by Cilazapril and Nifedipine in Hypertensive Rats", Clin. Exp. Pharmacaol. Physiol. Suppl., 1, S355, (1995)
		C253	Kim, J. et al., "Production of Taxol and Related Taxanes in Taxus brevifolia Cell Cultures: Effect of Sugar", Biotechnology Letters, 17, 101-106, (Jan., 1995)
		C254	Kingston, D.G., et al., "Synthesis and Structure-Activity Relationships of Taxol Derivatives As Anticancer Agents", In: New Trends in Natural Products Chemistry, Atta-ur-Rahman, et al., (eds.), Studies in Organic Chemistry, Vol. 26, Elsevier Science Publishers B.V., Amsterdam, 219-235, (1986)
·	*	C255	Kirk-Othmer, Encyclopedia of Chemical Technology, 33rd edition, Vol. 17, 1982, John Wiley & Sons, pp. 281-310
		C256	Kirschenlohr, H.L., et al., "Cultures of Proliferating Vascular Smooth Muscle Cells from Adult Human Aorta", In: Human Cell Culture, Jones, G.E., (ED.), Humana Press, Inc., 24 p. (1996)
		C257	Kirschenolohr, H.L., et al., "Proliferation of Human Aortic Vascular Smooth Muscle Cells in Culture is Modulated by Active TGF-Beta", Cardiovascular Research, 29, 848-855, (1995)
		C258	Klebe et al., "Regulation of cell motility, morphology, and growth by sulfated glycosaminoglycans", Cell Motil. Cytoskel., 6:273-281 (1986)
		C259	Klein, H.O. et al., "Experimental Investigations on a Sequential Combination Chemotherapy Protocol" J. Cancer Res. Clin. Oncol vol 96 no.2 Jan, 1980 p 65-78
		C260	Kleinman, N.S., et al., "Prinzmetal's Angina during 5-Fluorouracil Chemotherapy", The American Journal of Medicine, 82, 566-568, (1987)
		C261	Knabbe, C., et al., "Induction of Transforming Grown Factor-B by the Antiestrogens Droloxifene, Tamaoxifen, and Toremifene in MCF-7 Cells", Am. J. Clin. Oncol. 14, S15-S20, (1991)
		C262	Kopp, A., et al., "Transforming Growth Factor Beta2 (TGF-Beta2) Levels in Plasma of Patients with Metastatic Breast Cancer Treated with Tamoxifen", Cancer Research, 55, 4512-4515, (Oct. 15, 1995)
		C263	Kost, J. Langer R, "Controlled Release of Bioactive Agents," Trends in Biotechnology, Vol. 2, No. 2, 1984, pp. 47-51
		C264	Kotoulas, I.G., et al., "Tamoxifen Treatment in Male Infertility. 1. Effect on Spermatozoa", Fertility and Sterility, 61, 911-914, (May 1994)
		C265	Koyama, N., et al., "Regulation of Smooth Muscle Cells Migration by a New Autocrine Migration Factor and TGF-beta", Circulation, 84, Abstract No. 1829, II-459, (1991)
		C266	Kremer, J.M., et al., "Fish-Oil Fatty Acid Supplementation in Active Rheumatoid Arthritis", Annals of Internal Medicine, 106, 497-502, (1987)
		C267	Kunert, et al., "Paclitaxel Inhibits Developpment of Restenosis Following Experimental Balloon Angioplasty in the Rabbit Carotid Artery:, European Heart Journal, 17, Abstract No. P1998, p. 368 (1996)
		C268	Kunz et al., "Defining Coronary Restenosis Newer Clinical and Angiographic Paradigms". Circulation, 88 1310-1323 (September 1993)
1		C269	Kunz et al., "Sustained Dilation and Inhibition of Restenosis in a Pig Femoral Atery Injury Model". Circulation, 90, p I-297, Abstract NO. 1598 (October 1994)

		Т	Kunz et al., "Inhibition of Microfilament Reorganization Following Balloon Angioplasty Decreases Extent of
4		C270	Geometric Remodeling in Restenosis, "J. of Amer. Coll. of Cardiology, AMerican College of Geometric Cardiology 44 th Annual Scientific Session, Abstract No. 122292. (March 19-22, 1995)
		C271	Kunz, L.L., et al., "Efficacy of Cytochalasin B in Inhibiting Coronary Restenosis Caused by Chronic Remodeling After Balloon Trauma in Swine", Journal of the American College of Cardiology, Supplement A., Abstract No. 984-23, p. 302, (Mar. 1995)
		C272	Kuramochi, H., "Conformational Studies and Electronic Structures of Tamoxifen and Toremifene and Their Allylic Carbocations Proposed as Reactive Intermediates Leading to DNA Adduct Formation", J. Med. Chem., 3 2877-2886, (1996)
		C273	Kuzana, S., et al., "Effects of Some Anti-Rheumatic Agents on Copper-Catalyzed Thermal Aggregation of Gamma Globulin", Agents and Actions, 9 375-380, (1979)
		C274	L C Palmaz et. al., Expandable Intraluminal Graft: A Preliminary Study, Radiology 1985;1:73-77.
		C275	Labhsetwar et al., "Nanoparticles for site specific delivery of U-86983 in restenosis on pig coronary arteries," Pro Intern. Symp. Control. Rel. Bioact. Mater. 22, 182-183 (1995).
		C276	Laird, J., et al., "Inhibition of Neointimal Proliferation with Low-dose Irradiation from a Beta-particle-emitting Stent", Circulation, 93, 529-536, (1996)
		C277	Langbein, W., "Too Many Drugs, Too Little Value in CV Conditions", In Vivo, 14-20, (June, 1995)
		C278	Lange, R.A., et al., "Cocaine-Induced Coronary-Artery Vasoconstriction", The New England Journal of Medicin 321, 1557-1562, (1989)
		C279	Lange, R.L., et al., "Nonatheromatous Ischemic Heart Disease following Withdrawal from Chronic Industrial Nitroglycerin Exposure", Circulation, 46, 666-678, (1972)
		C280	Langer, R. et al., "Polymeric Delivery Systems for Macromolecules-Approaches for Studying In Vivo Release Kinetics and Designing Constant Rate Systems", in: <u>Biological Activities of Polymers</u> , Carraher, Jr. and Gebelei (eds), American Chemical Society Symposium Series 186, pp. 95-105 (1982)
		C281	Langer, R. et al., "Polymers for the Sustained Release of Proteins and Other Macromolecules", Nature 263:797-799 (1976)
	*	C282	Langer, R., "New Methods of Drug Delivery". Science, Vol. 249, 28.09 1990, pp. 1527-1533
		C283	Langer, R., "Polymeric Delivery Systems for Controlled Drug Release", Chem. Eng. Communi. 6:1-48 (1980)
		C284	Law et al., "Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells", Mol., Cell. Biol., 22:8184-8198 (2002)
		C285	Lawn, R.M., et al., "Feedback Mechanism of Focal Vascular Lesion Formation in Transgenic Apolipoprotein(a) Mice", The Journal of Biological Chemistry, 271, 31367-31371, (1996)
		C286	Lazier, C.B., et al., "Comparison of the Effects of Tamoxifen and of a Tamoxifen Analogue that Does Not Bind the Estrogen Receptor on Serum Lipid Profiles in the Cockerel", Biochem. Cell Biol., 68, 210-217, (1990)
		C287	LC. Palmaz et al., Expandable Intraluminal Vascular Graft: A Feasibility Study, Surgery 1986 Feb; 199(2): 199-205.
		C288	Lehmann, K. et al., "Effect of cilazapril on the proliferative response after vascular damage", J. of Cardiovascular Pharmacology, 22 (Suppl. 4), S19-24, (1993)
		C289	Lehmann-Bruinsma, et al., "Transforming Growth Factor B2 (TGF-B) Suppression of Smooth Muscle Cell (SM Proliferation After Balloon Angioplasty of Rat Carotid Arteries", Clin. Res. 42, Abstract No. 4A, (February 9-12 1994)
		C290	Leroux, J.C., et al., "Internalization of poly(d L-lactic acid) nanoparticles by isolated human leukocytes and analysis of plasma proteins absorbed onto the particles", J. Biomed. Mater. Res, 28, 471-481, (1994)
		C291	Leroux, et al., "New Approach for the Preparation of Nanoparticles by an Emulsification-Diffusion Method", Eu J. Pharm. Biopharm, 41, 14-18, (1995)
		C292	Levy, et al., "Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants," Chemic Abstracts, 121, 580: Abstract No. 263625g (1994)
		C293	Levy, R.J., et al., "Strategies for Treating Arterial Restonosis Using Polymeric Controlled Release Implants", In: Biotechnology and Bioactive Polymers, Proceedings of an American Chemical Society Symposium, Gebelein, C.G., (ed.), Plenum Press, New York, 259-268, (1994)
		C294	Liau and Chan, "Regulation of extracellular matrix RNA levels in cultured smooth muscle cells: relationship to cellular quiescence", J. Cell Biol., 264:10315-10320 (1989)
		C295	Lichtlen et al., "Retardation of angiographic progression of coronary artery disease by nifedipine", Lancet, 335:1109-1113 (1990)
		C296	Lincoff et al., "Local Drug Delivery for the Prevention of Restenosis" Circulation, 90 2070-2084 (October 1994)
		C297	Lindkaer-Jensen, S., et al., "Inhibition of Salicylate and Lithium Absorption in the Human Intestine by Copper Sulfate", Arch. Toxicol., 35, 175-179, (1976)
		C298	Lindner, "Vascular repair processes mediated by transforming growth factor-beta, Z Kardiol", 90 Suppl 3:17-22 (2001)
	*	C299	Lipold, B.C., "Retardarzneiformen" in E. Numberg, Hagers Handbuch der pharmazeutischen Praxis, Vol. 2, Springer-Verlag Berlin Heidelberg New York, 5 th edition, 1991 pp. 832-840
J		C300	Lippman and Mathews, "Heparins: varying effects on cell proliferation in vitro and lack of correlation with anticoagulant activity", Fed. Proc., 36:55-59 (1977)
•			

	of Application No. 09/910,388
C301	Liu et al., "Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit", Circulation, 81(3): 1089-1093 (1990)
C302	Lopez-Anaya, A., et al., "Pharmacokinetics and Pharmacodynamics in Copper Deficiency I", Biological Trace Element Research, 40, 161-176, (1994)
C303	Lopez-Casillas, et al., "Beta-glycan Presents Ligand to the TGFBeta Signaling Receptor", Cell, 73, 1435-1444,
C304	(July 2, 1993) Loser, R., et al., "In Vivo and in Vitro Antiestrogenic Action of 3-Hydroxytamoxifen, Tamoxifen and 4-
	Hydroxytamoxifen", Eur. J. Cancer Clin. Oncol., 21, 985-990, (1985) Lowe, et al., "Coronary In-Stent Restenosis: Current Status and Future Strategies", Journal of the American
C305	College of Cardiology, 1992, Vol. 39 No. 2, pp. 183-193.
C306	Luan et al., "Rapamycin is an effective inhibitor of human renal cancer metastasis", Kidney Int., 63:917-926 (2003)
C307	Lucas, C., et al., "The Authorrine Production of Transforming Growth Factor-B1 During Lymphocyte Activation", The Journal of Immunology, 145(5), 1415-1422, (1990)
C308	Ludwig K. von Segesser, MD., "Heparin-Bonded Surfaces in Extracorporeal Membrane Oxygenation for Cardiac Support:, The Society of Thoracic Surgeons, (1996)
C309	Luo, H. et al., "Chronic Vessel Constriction is an Important Mechanism of Restenosis After Balloon Angioplasty: An Intravascular Ultrasound Analysis", Circulation, 90, 67 Scientific Sessions, Abstract No. 0318, p. 1-61, (1994)
C310	Luostarinen, R., et al., "Effect of Dietary Fish Oil Supplemented with Different Doses of Vitamin E on Neutrophil Chemotaxis in Healthy Volunteers", Nutrition Research, 12, 1419-1430, (1992)
C311	Lutgens et al., "Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression", Arterioscler. Thromb. Vasc. Biol., 22:975-982 (2002)
C312	Lyons et al., "Mechanism of activation of latent recombinant transforming growth factor beta1 by plasmin", J. Cell. Biol., 110:1361-1367 (1990)
C313	Macander et al., "Balloon Angioplasty for Treatment of In-Stent Restenosis: Feasibility, Safety, and Efficacy", Catheterization and Cardiovascular Diagnosis, 32 125-131 (1994)
C314	Madri et al., "Endothelial cell behavior after denudation injury is modulated by transforming growth factor-betal and fibronectin", Lab. Invest., 60:755-764 (1989)
C315	Magarian, "The Medicinal Chemistry of Nonsteroidal Antiestrogens: A Review", Current Medicinal Chemistry, 1, 61-104, (1994)
C316	Majack, "Beta-type transforming growth factor specifies organizational behavior in vascular smooth muscle cell cultures", J. Cell Biol., 105:465-471 (1987)
C317	Majack, R.A., et al., "Role of PDGF-A Expression in the Control of Vascular Smooth Muscle Cell Growth by Transforming Growth Factor-B", The Journal of Cell Biology, 111, 239-247, (1990)
C318	Majesky, M.W., et al., "Production of Transforming Growth Factor betal During Repair of Arterial Injury", J. Clin. Invest., 88, 904-910, (1991)
C319	Mambetisaeva, E.T., et al. "Effect of New Synthetic Cholesterol Derivatives on Cholesterol Metabolism in Cultured Rabbit Hepatocytes", Biokhimiya (Russia), 58, Translation, Plenum Publishing Corporation, 1126-1132, (1993)
C320	Amiji, M., et al., "Surface Modification of Polymeric Materials with Poly (ethylene oxide), Albumin, and Heparin For Reduced Thrombogenicity," J. Biomater. Sci. Plymer Edn., Vol. 4, No. 3, pp. 217-234 (1993)
C321	Manucci, P.M., et al., "Effect of Tamoxifen on Measurements of Hemostatis in Healthy Women", Arch. Intern. Med., 156, 1806-1810, (1996)
C322	Marx and Marks, "Bench to Bedside: The development of rapamycin and its application to stent restenosis", Circulation 104:852-55 (2001)
C323	Marx, "CMV-p.53 Interaction May Help Explain Clogged Arteries", Science, 265, 320, (Jul 1994).
C324	Marzocchi, A., et al., "Restenosis after Coronary Angioplasty: It's Pathogenesis and Prevention," Cardiologia, 36, 309-320 (December, 1991) English Abstract only, reported in Medline, Accession No. 93046311
C325	Massague and Wotton, "Transcriptional control by the TGF-beta/Smad signaling system", EMBO J., 19(8):1745-54 (2000)
C326	Massague et al., "Type beta transforming growth factor is an inhibitor' of myogenic differentiation", Proc,. Natl. Acad. Sci., 83:8206-8210 (1986)
C327	Massague, "Subunit structure of a high-affinity receptor for' type beta-transforming growth factor: evidence for a disulfide-linked glycosylated receptor complex", J. Biol. Chem., 260(11):7059-7066 (1985)
C328	McAuslan, B.R., et al., "Cellular and Molecular Mechanisms in Angiogenesis", Trans. Ophthal. Soc. U.K., 100, 354-358, (1980)
C329	McCaffrey et al, "Genomic instability in the type II TGF-b1 receptor gene in atherosclerotic and restenotic vascular cells," J Clin Invest, 100:2182-2188 (1997)
C330	McCaffrey et al., "Aging and arteriosclerosis: the increased proliferation of arterial smooth muscle cells isolated from old rats is associated with increased platelet-derived growth factor-like activity," J. Exp. Med., 167:163-174
1 1	(1988)
	C302 C303 C304 C305 C306 C307 C308 C310 C311 C312 C313 C314 C315 C316 C317 C318 C319 C320 C321 C322 C323 C324 C325 C326 C327 C328 C329

·····		of Application No. 09/910,
AR	C3	32 McCaffrey, "TGF-betas and TGF-beta receptors in atherosclerosis," Cytokine and Growth Factor Rev., 11:103 114 (2000)
1	C3	
	C3	
		(4-iodophenyl) -2-phenyl-1-butene)", Organic Preparations and Proc. Int., 26, 343-346, (1994)
	C3	Idoxifene and Axiridinyl 4-Iodotamoxifen.", J. Labelled Compounds and Pharmaceuticals, 34, 297-302, (1994
	C3	McClean, et al., "cDNA sequence of human apolipoprotein (a) is homologous to plasminogen", Nature, 330, I 137 (1987), 132-137, (1987)
	C3	McDonald, C.C., et al., "Cardiac and vascular morbidity in women receiving adjvant tamoxifen for breast cancin a randomised trial", BMJ, 311, 977-980, (October 14, 1995)
	C3	McDonnell, D.P., et al., "Analysis of Estrogen Receptor Function in Vitro Reveals Three Distinct Classes of A estrogens", Molecular Endocrinology, 9, 65-669, (June 1995)
	C3	Animal Health, Pathotox Publishers, Inc., 263-273, (1977)
	C3	the phenotypic modulation, migration and proliferation of aortic smooth muscle cells," Atherosclerosis, 86:227 (1991)
	C3	1298 (1991)
	C3	
1	C3-	Merck Index, (Susan Budavari et al, ed.) 1989, p. 1435
	C3-	synthesis in arterial wall," L Vase. Res. 31:322-329 (1994)
	C34	proteoglycans in balloon catheter-injured neointima of rabbit carotid arteries, 3". Vasc. Res. 37:50-60 (2000)
	C34	
	C34	Metcalfe, et al., "Protein Markers of Lesion Development in the Vessels of Transgenic Apo(a) Mice" Inflammation, Growth Regulatory Molecules & Atherosclerosis, J. Cellular Biochem., Supplement 18A, p 208 Abstract No. E212 (1994)
	C34	
	C34	Meyer, S.C., "Functionalized Cytochalasins for Potential Biotechnology Transfer", Ph. D. Thesis (Selected Pag Syracuse University, New York, 13 p., (May, 1994)
	C35	Bioengineering, Part A: Materials, Vol. 1 (1995)
	C35	Michael N. Helmus, "Materials Selection, Chapter 6, Cardiovsc. Pathol. 2(3)(Suppl.):53s-71s (July-Sept. 1993)
	C35	Michael N. Helmus, "Materials Selecton for Medical Devices," Spectrum, 1-21, (July 30, 1993)
	C35	Michael N. Helmus, "Medical Device DesignA Systems Approach: Central Venous Catheters", (1990)
1	C35	
	C35	
1	C35	
	C35	
	C35	
	C35	Mintz, G.S., et al., "Chronic Compensatory Arterial Dilation Following Coronary Angioplasty: An Intravascula Ultrasound Study", JACC, Abstract No. 875-97, p. 138A, (Feb., 1994)
	C36	 Mintz, G.S., et al., "Geometric Remodeling is the Predominant Mechanism of Clinical Restenosis After Corona Angioplasty", JACC, Abstract No. 875-42, p. 138A, (Feb., 1994)
	C36	Mintz, G.S., et al., "Mechanisms of Late Arterial Response to Transcatheter Therapy: A Serial Quantitative Angiographic and Intravascular Ultrasound Study", Circulation, 90, Abstract No. 117, p. 1-24, (Oct., 1994)
	C36:	
	C36;	Mirjalili, N., et al., "Gas Phase Composition Effects on Suspension Cultures of Taxus cuspidata", Biotechnology and Bioengineering, 48, 123-132, (1995)
	/ C364	Mitchell, L.L., et al., "Copper Deficiency Depresses Rat Aortae Superoxide Dismutase Activity and Prostacyclin Synthesis", Prostaglandins, 35, 977-986, (1988)
	C365	

Chemical Activation of Tamoxifen and 4-Hydroxytamoxifen with DNA Abducts Formed in Vivo". Canc Research, 56, 53-57, (Jan. 1, 1996) Office Research, 56, 53-57, (Jan. 1, 1996) Office Research, 56, 53-57, (Jan. 1, 1996) Office Research, 56, 53-57, (Jan. 1), 1996 Office Research, 56, 53-57, (Jan. 1), 1997 Office Research, 57, 1997 Office Resear			of Application No. 199710,388
Research. 56, 33-37, (Jan. 1, 1996) Chy Morris, R.c., et al., "A targeted anithrombotic conjugate with antiplatelet and fibrinolytic properties which in vivo thrombus formation", Chemical Abstracts, Vol. 120, No. 22, (May 30, 1994) in vivo thrombus formation", Chemical Abstracts, Vol. 120, No. 22, (May 30, 1994) Morris, R.E., "Rapamycins (isofitums) inhibits vascular smooth muscle DNA synthesis in vitro and supprenarowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagoniz factor action on immune and nonimmune cells." Transplant muscle DNA synthesis in Vitro and Synthesis (No. 1995) Chy Morris, R.E., "ct al., "Immunosuppressive Effects of the Morpholinocthyl Ester of Mycophenolic Acid (R. 1984) in Ra and Alonhuman Frimate Recipiens of Heart Allografts," Transplantation Proceedings, 23, 19-25, (1994) Chy Mosedale and Grainger, "An antibody present in normal human serum inhibits the binding of cytokines to receptors in an in vitro system," Biochem J., 343:128-133 (1999) Chy Mosedale, D.E., et al., "Transforming Growth Factor-beta is Correlated with Smooth Muscle Cell Differt in Vivo. (Circulation, 90, 47" Scientific Session, Abstract No. 1950, p. 1-296, (Oct., 1994) Muscler, B.M., et al., "Antibody Conjugates with Morpholinodoxorubicin and Acid-Cleavable Linkers", Bioconjugate Chem. 1, 23-53,01, (1990) Chy Murphy, C.S., et al., "Structura-Activity Relationships of Nonisomerizable Derivatives of Tamoxiffen: in Hydroxy Group and Stde Chain Postioning for Biological Activity", Molecular Pharmacology, 39 4, 16 (1989) Chy Murphy, L.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, 11983 Chy Maphy, C.S., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, 11983 Chy Maphy, C.S., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Prolifer	R	C366	Moorthy, B., et al., "Tamoxifen Metabolic Activation: Comparison of DNA Abducts Formed by Microsomal and
C367 More, R.S., et al., "A targeted antithrombotic conjugate with antiplatelet and fibrinolytic properties which in vivo thrombus formation", Chemical Astracts, Vol. 120, No. 22, (May 30, 1994)	DR.	}	
in vivo thrombus formation", Chemical Astracts, Vol. 120, No. 22, (May 30, 1994) Coal Morris et al., "Rapamycin (isriolimus) inhibits vascular smooth muscle DNA synthesis in vitro and supprenarrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagoniz factor action on immune and nonimmune cells," Transplant Proc., 27:430-1 (1995) Morris, R.E., et al., "Immunosuppressive Effects of the Morpholinochyl Ester of Mycophenolic Acid (R. 1974) Morris, R.E., et al., "Immunosuppressive Effects of the Morpholinochyl Ester of Mycophenolic Acid (R. 1974) Morschale and Grainger, "An antibody present in normal human serum inhibits the binding of cytokines to receptors in an in vitro system," Biochem J., 343:125-136, 1999) Gazz Mosedale, D.E. University of Cambridge Ph.D. Thesis, Differentiated state of smooth muscle and its rela to TGF-Bin vivo. Diz G09552-00599 (1998) and all references therein to TGF-Bin vivo. Diz G09552-00599 (1998) and all references therein a Vivo", Circulation, 96, 67° Scientific Session, Abstract No. 1590, p. 1-296, (Oct., 1994) Gazz Mosedale, D.E., et al., "Tantsforming Growth Factor-beta is Correlated with Smooth Muscle Cell Differs in Vivo", Circulation, 96, 67° Scientific Session, Abstract No. 1590, p. 1-296, (Oct., 1994) Gazz Muscler, B.M., et al., "Antibody Conjugates with Morpholinodoxorubicin and Acid-Cleavable Linkers", Biochem, 34, 1-6, 1993) Gazz Muscler, B.M., et al., "Structure Activity Relationships of Nonisomerizable Derivatives of Tamoxiffen," Biochem, 34, 1-6, 1993) Gazz Muscler, C.S., et al., "Structure Activity Relationships of Nonisomerizable Derivatives of Tamoxiffen, and Acid Copper on Alter the Univariative Activity Relationships of Nonisomerizable Derivatives of Tamoxiffen, and Acid Copper on Alter the Univariative Activity Relationships of Nonisomerizable Derivatives of Tamoxiffen, and Acid Copper on Alter Activity Relationships of Nonisomerizable Derivatives of Tamoxiffen, and Acid Copper on Alter Acid Copper on Alter Acid	10		
Rorris et al., "Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppress from the product arteries evidence that rapamycin antagoniz factor action on immune and nonimmune cells," Transplant Proc. 27:430-31 (1993)	1 1	C367	More, R.S., et al., "A targeted antithrombotic conjugate with antiplatelet and fibrinolytic properties which reduces
narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonize factor action on immune and nonimmune cells," Transplant Proc, 27:43-05; (1995) Gao Morris, R.E., et al., "Immunosuppressive Effects of the Morpholinochtyl Ester of Mycophenolic Acid R. in Rat and Nonhuman Primate Recipients of Heart Allografts", Transplantation Proceedings, 23, 19-23, (1997) Gardina and Nonhuman Primate Recipients of Heart Allografts", Transplantation Proceedings, 23, 19-23, (1997) Gardina and Nonhuman Primate Recipients of Heart Allografts", Transplantation Proceedings, 23, 19-23, (1998) Gardina and Nonhuman Primate Recipients of Heart Allografts", Transplantation Proceedings, 23, 19-23, (1998) Gardina and Nonhuman Prostems (1998) and all references therein to Tor-6-in vivo. Diol Goods-52-005901 (1998) and all references therein in Vivo", Circulation, 96, 95" Scientific Session. Abstract No. 1590, p. 1-296, (Oct., 1994) Gardina Allografts and Allografts and Allografts and Allografts and Acid-Cleavable Linkers", Bioconjugate Chem. 1, 253-330, (1990) Gardina Allografts and Allografts and Allografts and Allografts and Acid-Cleavable Linkers", Bioconjugate Chem. 1, 253-330, (1990) Gardina Allografts and Allografts an			in vivo thrombus formation", Chemical Abstracts, Vol. 120, No. 22, (May 30, 1994)
factor action on immune and nonimmune cells, "Transplant Proc. 27:430-31 (1995) Golf Morris, R.E., "Rapamyris: Antifungal, Antitumor, Antiprofiferative, and Immunosuppressive Macrolid Transplantation Reviews, 6, 39-87, (1992) Golf Morris, R.E., et al., "Immunosuppressive Effects of the Morpholinoethyl Ester of Mycophenolic Acid (R in Rat and Nonhuman Primate Recipients of Heart Allografis", Transplantation Proceedings, 23, 19-25, (1993) Golf Morris, R.E., et al., "Transplantation Freedings", "An antibody present in normal human serum inhibits the binding of cytokines receptors in an in vitro system," Biochem J., 343:125-133 (1999) Golf Morris, "An antibody present in anomal human serum inhibits the binding of cytokines receptors in an in vitro system," Biochem J., 343:125-133 (1999) Golf Morris, "An antibody of Cambridge Ph.D. Thesis, Differentiated state of smooth muscle and its rela to TCF-g in vivor, Circulation, 90, 67° Scientific Session, Abstract No. 1590, p. 1-296, (Oct., 1994) Golf Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen", Bioconiguet Chem. J. 325-330, (1990) Golf Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen", Biochem. 34, 1-6 (1993) Golf Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen", Biochem. 34, 1-6 (1993) Golf Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen", Biochem. 34, 1-6 (1994) Golf Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen", Biochem. 34, 1-6 (1994) Golf Murphy, C.S., et al., "Foreometer Activity Relationships of Nonisomerizable Derivatives of Tamoxifen", Biochem. 34, 1-6 (1994) Golf Murphy, C.S., et al., "Foreometer Activity Relationships of Nonisomerizable Derivatives of Tamoxifen of Hydroxyl Group and Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1983) Golf Murphy, C.S., et	1 1	C368	Morris et al., "Rapamycin (strollmus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses
Google			
Transplantation Reviews, 6, 39-87, (1992) C370 Morsis, R.E., et al., "Immunosuppressive Effects of the Morpholinoethyl Ester of Mycophenolic Acid (R in Rat and Nonhuman Primate Recipients of Heart Allografts", Transplantation Proceedings, 23, 19-25, (1971) C371 Mosedale and Grainger, "An antibody present in normal human serum inhibits the binding of cytokines to receptors in an in vitro system," Biochem J., 343:125-133 (1999) C372 Mosedale, D.E. university of Cambridge Ph.D. Thesis, Differentiated state of smooth muscle and its rela to TGF-β in vivo, DiG 69552-095910 (1998) and all references therein C373 Mosedale, D.E. et al., "Transforming Growth Factor-beta is Correlated with Smooth Muscle Cell Differs in Vivo", Circulation, 90, 67th Scientific Session, Abstract No. 1590, p. 1-296, (20€1, 1994) C374 Mureller, B.M., et al., "Antibody Coningates with Morpholinodoxorubicin and Acid-Cleavable Linkers", Biocenniguate Chem. 1, 325-330, (1990) C375 Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen", Biochem, 34, 1-6 (1994) C376 Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen", Biochem, 34, 1-6 (1994) C377 Murphy, C.S., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985) C378 Myer, R.O., et al., "Porferential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985) C379 Myer, R.O., et al., "Porfermance and Carcass Characteristics of Swine When Fed Diets Containing Canol Added Copper to Alter the Unsaturated-Saturated Ration of Pork Fat", J. Antim. Sci., 70, 1417-1423, (1985) C379 Nabel, E.G., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993) C380 Nagakwa, Y., et al., "Effect of Eicosoppershame in Acid on the Paletel		ļ	factor action on immune and nonimmune cells, transplant rioc, 27/430-31 (1993)
C370 Morris, R.E., et al., "Immunosuppressive Effects of the Morpholinocithy! Ester of Mycophenolic Acid in Rat and Nonhuman Frimate Recipients of Heart Allografts", Transplantation Proceedings, 23, 19-25, (1908). C371 Mosedale and Grainger, "An antibody present in normal human serum inhibits the binding of cytokines to receptors in an in without system," Biochem J., 343:125-133, (1999). C372 Mosedale, D.E., et al., "Transforming Growth Factor-beta is Correlated with Smooth Muscle Cell Different in Vivo", Circulation, 90, 67° Scientific Session, Abstract No. 1590, p. 12-96. (Oct., 1994). C373 Mupler, B.M., et al., "Antibody Conjugates with Morpholinodoxorubicin and Acid-Cleavable Linkers", Bioconjugate Chem. I., 325-330, (1990). C375 Muply, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen: In Of Hydroxyl Group and Side Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 43 (1991). C376 Muply, C.S., et al., "Structural-Activity Relationships of Nonisomerizable Derivatives of Tamoxifen: In Of Hydroxyl Group and Side Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 43 (1991). C377 Muply, L.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Colorate Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 43 (1991). C378 Myer, R.O., et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Candod Copper to Alter the Unsaturated-Staurated Ration of Pork Fat", J. Anim. Sci., 70, 1417-1423, (1985). C380 Myer, R.O., et al., "Direct Transfer of Transforming Growth Factor Beta 1 Group Into Arteries Stimulate Fibrocellular Hyperplasin," Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993). C381 Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Fibroscipal Candod Copper to Alter Mycardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994). C382 Nakano, "Glucocorori	i	C369	
in Rat and Nonhuman Primate Recipients of Heart Allografts", Transplantation Proceedings, 23, 19-25, [1] C371 Mosedale and Grainger, "An antibody present in normal human serum inhibits the binding of cytokines to receptors in an in vitro system," Biochem J., 343;125-133 (1999) C372 Mosedale, D.E. Livisersity of Cambridge Ph.D. Thesis, Differentiated state of smooth muscle and its relation of the Company of			Transplantation Reviews, 0, 39-67, (1992)
C371 Mosedale and Grainger, "An antibody present in normal human serum inhibits the binding of cytokines to receptors in an in vitro system," Biochem J., 343:125-133 (1999) C372 Mosedale, D. E. University of Cambridge Ph.D. Thesis, Differentiated state of smooth muscle and its rela to Topic file in vivo." (Circulation, 90, 67th Scientific Session, Abstract No. 1590, p. 1-296, (Oct., 1994) C373 Mosedale, D. E., et al., "Transforming Growth Factor-beta is Correlated with Smooth Muscle Cell Differ in vivo." (Circulation, 90, 67th Scientific Session, Abstract No. 1590, p. 1-296, (Oct., 1994) C374 Muller, B. M., et al., "Antibody Conjuguates with Morpholimodoxorubicin and Acid-Cleavable Linkers", Bioconjugate Chem. J. 325-330, (1990) C375 Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen." (1991) C376 Murphy, L.C., et al., "Structural-Activity Relationships of Nonisomerizable Derivatives of Tamoxifen." (1991) C377 Murphy, L.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains not Clear Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985) C378 Myer, R.O., et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canol Added Copper to Alter the Unsaturated-Saturated Ration of Pork Fat", J. Anim. Sci., 70, 1417-1423, (1985) C380 Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Fin Nadal," Atheroselerosis, 47, 71-75, (1983) C381 Nakagawa, et al., "A Case of Acute Myocardinal Infaction Intracoronary Arteries Due To Hormone The Angales, 45, 45, 45, 46, 46, 46, 46, 46, 46, 46, 46, 46, 46		C370	
receptors in an in vitro system," Biochem J., 343:125-133 (1999) C372 Mosedale, D.E., rothwestiny of Cambridge Ph.D. Thesis, Differentiated state of smooth muscle and its rela to TGF-B in vivo, DJG 005652-005910 (1998) and all references therein C373 Mosedale, D.E., et al., "Transforming Growth Factor-beta is Correlated with Smooth Muscle Cell Differs in Vivo", Circulation, 90, 67th Scientific Session, Abstract No. 1590, p. 1-296, (Oct., 1994) C374 Mueller, B.M., et al., "Antibody Conjugates with Morpholimodoxorubicin and Acid-Cleavable Linkers", Bioconjugate Chem. 1, 325-330, 11990) C375 Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen", Biochem, 34, 1-6 (1989) C376 Murphy, C.S., et al., "Structural-Components Necessary For The Antiestrogenic Activity of Tamoxifen", Biochem, 34, 1-6 (1989) C376 Murphy, C.S., et al., "Structura-Activity Relationships of Nonisomerizable Derivatives of Tamoxifen: In of Hydroxyl Group and Side Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 44 (1991) C377 Murphy, L.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985) C378 C378 Mayer, R.O. et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985) C379 Nable, E.G., et al., "Differential Effects of Tamoxifening Growth Factor Beta I Group large Added Copper to Alter the Unsaturated Saturated Ration of Pork Fat", J. Anim. Sci., 70, 1417-1423, (1984) C380 Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on Pork Fat", J. Anim. Sci., 70, 1417-1423, (1984) C380 Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Patelet Agragation and Composition of Fin Man", Althorosclerosis, 47, 71-75, (1983) Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Bure to Hydroxy Agraes and Acid Agraes and Acid Agraes and A			In Rat and Nonnuman Primate Recipients of Fleatt Anograns, Transplantation Proceedings, 23, 19-23, (1991)
C372 Mosedale, D.E. University of Cambridge Ph.D. Thesis, Differentiated state of smooth muscle and its rela to Torope in vivo. Dio 00552-00591 (1989) and all references therein C373 Mosedale, D.E., et al., "Transforming Growth Factor-beta is Correlated with Smooth Muscle Cell Differ in Vivo", Circutation, 90, 67th Scientific Session, Abstract No. 1590, p. 1-296, (Oct., 1994) C374 Muscler, B.M., et al., "Antibody Conjugates with Morpholinodoxorubicin and Acid-Cleavable Linkers", Bioconjugate Chem. 1, 325-330, (1990) C375 Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen: In of Hydroxyl Group and Side Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 42 (1991) C376 Murphy, C.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Profiferation in Viro". Endocrinology, 116, 1071-1078, 1985) C378 Myer, R.O., et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canol Added Copper to Alter the Unsaturated:Saturated Ration of Pork Far", J. Anim. Sci., 70, 1417-1423, (195) C379 Nabel, E.G., et al., "Different Transforming Growth Factor Beta 1 Group Into Arteries Stimulate Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993) C380 Nagakwa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of in Man", Atherosclerosis, 47, 71-75, (1983) C381 Nagakwa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of in Man", Atherosclerosis, 47, 71-75, (1983) C382 Nakagwa, Y., et al., "Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C382 Nakagwa, Y., et al., "Transforming Growth Factor in Human Aortic Smooth Muscle Cells: Journal of Biological Chemistry, 268, 22941-22947 (1993) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research — Medical Technology,		C371	
to TGF-β in vivo, DIG 005652-005910 (1998) and all references therein C373 Moscade, D.E., et al., "Transforming Growth Factor-bet is Correlated with Smooth Muscle Cell Differ in Vivo", Circulation, 90, 67th Scientific Session, Abstract No. 1590, p. 1-296, (Oct., 1994) C374 Mueller, B.M., et al., "Antibody Conjugates with Morpholinodoxorubicin and Acid-Cleavable Linkers", Bioconjugate Chem., 1325-330, (1990) C375 Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen", Biochem, 34, 1-6 (1989) C376 Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen in of Hydroxyl Group and Side Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 42 (1991) C377 Murphy, C.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985) C378 Myer, R.O, et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canoble Added Copper to Alter the Unsaturated-Saturated Ration of Pork Far", J. Anim. Sci., 70, 1417-1423, (1985) C379 Nabel, E.G., et al., "Direct Transfer of Transforming Growth Factor Beta 1 Group Into Anteries Stimulate Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993) C380 Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Find Markany, Alteroscierosis, 47, 117-5, (1983) C381 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) Nakagawa, et al., "Markany 1994) Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) Nakagawa, et al., "Particular Properties of Properties of Platelet-Derived Growth Factor Al		 	Macada D. E. University of Cambridge Ph. D. Thesis. Differentiated state of smooth muscle and its relationship.
C373 Mosedale, D.E., et al., "Transforming Growth Factor-beta is Correlated with Smooth Muscle Cell Differe in Vivo", Circulation, 90, 57h Scientific Session, Abstract No. 1590, p. 1-296, (Oct.) C374 Mueller, B.M., et al., "Antibody Conjugates with Morpholinodoxorubicin and Acid-Cleavable Linkers", Bioconjugate Chem. 1, 325-330, (1990) C375 Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen: In of Hydroxyl Group and Side Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 42 (1991) C376 Murphy, C.S., et al., "Structure-Activity Relationships of Nonisomerizable Derivatives of Tamoxifen: In of Hydroxyl Group and Side Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 42 (1991) C377 Murphy, C.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985) C378 Myer, R.O. et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canol Added Copper to Alter the Unsaturated-Staturated Ration of Pork Earl", J. Anim. Sci., 70, 1417-1423, (1985) C380 Magawa, Y., et al., "Effect of Ecosspentatenoic Acid on the Platette Aggregation and Composition of In Man", Atherosclerosis, 47, 71-75, (1983) C381 Nakagawa, Y., et al., "Effect of Ecosspentatenoic Acid on the Platette Aggregation and Composition of In Man", Atherosclerosis, 47, 71-75, (1983) C382 Nakagawa, Y., et al., "Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C382 Nakagawa, Y., et al., "Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research — Medical Technology, 10 p., (Mar. 3, 1995) Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research — Medic		C372	
in Vivo", Circulation, 90, 67th Scientific Session, Abstract No. 1590, p. 1-296. (Oct., 1994) C374 Mulphy, C.S., et al., "Antibody Conjugates with Morpholinodoxorubicin and Acid-Cleavable Linkers", Bioconjugate Chem. 1, 325-330, (1990) C375 Mulphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen". Biochem, 34, 1-6 (1989) C376 Mulphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen: In of Hydroxyl Group and Side Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 42 (1991) C377 Mulphy, L.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985) C378 Myer, R.O., et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canol Added Copper to Alter the Unsaturated:Saturated Ration of Pork Fat", J. Anim. Sci., 70, 1417-1423, (1985) C379 Nabel, E.G., et al., "Direct Transfer of Transforming Growth Factor Beta I Group Into Arteries Stimulate Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 1073-910753, (1993) C380 Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 1079-310753, (1993) C381 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C382 Nakano, "Glucocorticoid Inhibits Thromin-Induced Expression of Platelet-Derived Growth Factor A-cha Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells, Journal of Biological Chemistry, 268, 22941-22947 (1993) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research – Medical Technology, 10 p., (Mar. 3, 1995) C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasters		 	
C374 Mueller, B.M., et al., "Antibody Conjugates with Morpholinodoxorubicin and Acid-Cleavable Linkers", Bioconjugate Chem. 1, 325-330, (1990)		C373	
Bioconjugate Chem. 1, 325-330, (1990) C376 Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen." Blochem, 34, 1-6 (1989) C376 Murphy, C.S., et al., "Structure-Activity Relationships of Nonisomerizable Derivatives of Tamoxifen: In of Hydroxyl Group and Side Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 42 (1991) C377 Murphy, L.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985) C378 Myer, R.O., et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canol Added Copper to Alter the Unsaturated: Saturated Ration of Pork Fat", J. Aniim. Sci., 70, 1417-1423, (1985) C379 Nabel, E.G., et al., "Direct Transfer of Transforming Growth Factor Beta I Group Into Arteries Stimulate Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993) C380 Nagakawa, V., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Fin Man", Atherosclerosis, 47, 71-75, (1983) C381 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C382 Nakano, "Glucocorticoid Inhibits Thromin-Induced Expression of Platelet-Derived Growth Factor A-cha Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells; Journal of Biological Ch emistry, 268, 22941-22947 (1993) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research - Medical Technology, 10 p., (Mar. 3, 1995) C384 Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) C385 Nikole et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis." Cardiovasc. Pathol., 3:57-64 (1996) C3			Mystles B.M. et al. "A ptibody Conjugates with Morpholinodovorubicin and Acid-Cleavable Linkers"
C375 Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen", Biochem, 34, 1-6 (1989)	1 1	C374	
Biochem, 34, 1-6 (1989) C376 Murphy, C.S., et al., "Structure-Activity Relationships of Nonisomerizable Derivatives of Tamoxifen: In of Hydroxyl Group and Side Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 42 (1991) C377 Murphy, L.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985) C378 Myer, R.O., et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canol Added Copper to Alter the Unsaturated Saturated Ration of Pork Fat", J. Anim. Sci., 70, 1417-1423, (1985) C379 Nabel, E.G., et al., "Direct Transfer of Transforming Growth Factor Beta I Group Into Arteries Stimulate Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993) C380 Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Finds Man", Atherosclerosis, 47, 1-75, (1983) C381 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C382 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research — Medical Technology, 10 p., (Mar. 3, 1995) C384 Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Eiological Chemistry, 268, 22941-122947 (1993) C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-644 C386 OLcary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Nikol et al., "Persistently increased expression of the transforming growth-facto		0255	Murphy C.S. et al. "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen". J. Steroid
C376 Murphy, C.S., et al., "Structure-Activity Relationships of Nonisomerizable Derivatives of Tamoxifen: In of Hydroxyl Group and Side Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 42 (1991) C377 Murphy, L.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985) C378 Myer, R.O., et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canol Added Copper to Alter the Unsaturated Saturated Ration of Pork Fat", J. Anim. Sci., 70, 1417-1423, (1985) C379 Nabel, E.G., et al., "Direct Transfer of Transforming Growth Factor Beta 1 Group Into Arteries Stimulate Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993) C380 Nagakawa, Y. et al., "Effect of Eicosapentaenio Acid on the Platelet Aggregation and Composition of F in Man", Atherosclerosis, 47, 71-75, (1983) C381 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C382 Nakano, "Glucocorticoid Inhibits Thromin-Induced Expression of Platelet-Derived Growth Factor A-cha Hyparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells:, Journal of Biological Ch emistry, 268, 22941-22947 (1993) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research — Medical Technology, 10 p., (Mar. 3, 1995) C384 Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64. (2386 O'Caray, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996)	1 1	C375	
of Hydroxyl Group and Side Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 42 (1991) C377 Murphy, L.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985) C378 Myer, R.O, et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canoli Added Copper to Alter the Unsaturated:Saturated Ration of Pork Fat", J. Anim. Sci., 70, 1417-1423, (1985) C379 Nabel, E.G., et al., "Direct Transfer of Transforming Growth Factor Beta I Group Into Arteries Stimulate Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993) C380 Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Find Man", Atherosclerosis, 47, 1-75, (1983) C381 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C382 Nakano, "Glucocorticoid Inhibits Thromin-Induced Expression of Platelet-Derived Growth Factor A-cha Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells, Journal of Biological Che mistry, 268, 22941-222947 (1993) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research - Medical Technology, 10 p., (Mar. 3, 1995) C384 Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 (1018-1026, 11996) C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 (2014), 13-		(2276	Murphy C.S. et al. "Structure-Activity Relationships of Nonisomerizable Derivatives of Tamoxifen: Importance
(1991) C377 Murphy, L.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985) C378 Myer, R.O, et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canoli Added Copper to Alter the Unsaturated Stainon of Pork Fat", J. Anim. Sci., 70, 1417-1423, (1985) C379 Nabel, E.G., et al., "Direct Transfer of Transforming Growth Factor Beta 1 Group Into Arteries Stimulate Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993) C380 Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Fin Man", Atherosclerosis, 47, 71-75, (1983) C381 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C382 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C383 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C383 Navarro, S.E., et al., "Notes from Transcatheret Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research Medical Technology, 10 p., (Mar. 3, 1995) C384 Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-641 C386 O*Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26 784, (August 5, 1994) C389 Obhyyama, S., et al., "Toes Profit of the Major Tamoxifen-	1 1	C3/6	
C377 Murphy, L.C., et al., "Pifferential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985) C378 Myer, R.O, et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canoli Added Copper to Alter the Unsaturated:Saturated Ration of Pork Fat", J. Anim. Sci., 70, 1417-1423, (1985) C379 Nabel, E.G., et al., "Direct Transferr of Transforming Growth Factor Beta I Group Into Arteries Stimulate Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993) C380 Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Find Man", Atherosclerosis, 47, 1-75, (1983) C381 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C382 Nakano, "Glucocorticoid Inhibits Thromin-Induced Expression of Platelet-Derived Growth Factor A-cha Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells:, Journal of Biological Ch emitry, 268, 2294-122947 (1993) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research — Medical Technology, 10 p., (Mar. 3, 1995) C384 Nayfield, S.G., et al., "Tamoxificn-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis." Cardiovasc. Pathol., 3:57-64 (C386) O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, 1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26, 784, (August 5, 1994) C388 Okuyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Age	1 1		
Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985) C378 Myer, R.O., et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canol Added Copper to Alter the Unsaturated:Saturated Raiion of Pork Fat", J. Anim. Sci., 70, 1417-1423, (1975) C379 Nabel, E.G., et al., "Direct Transfer of Transforming Growth Factor Beta 1 Group Into Arteries Stimulate Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993) C380 Nagakwa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Fin Man", Atherosclerosis, 47, 71-75, (1983) C381 Nakagwa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C382 Nakano, "Glucoorticoid Inhibits Thromin-Induced Expression of Platelet-Derived Growth Factor A-cha Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells:, Journal of Biological Ch emistry, 268, 22941-22947 (1993) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research Medical Technology, 10 p., (Mar. 3, 1995) C384 Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc, Pathol., 3:57-641 C386 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26 784, (August 5, 1994) C388 Obuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activi Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C399 Opherk	1	C377	Murphy, L.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell
C378 Myer, R.O., et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canol Added Copper to Alter the Unsaturated:Saturated Ration of Pork Fat", J. Annim. Sci., 70, 1417-1423, (195 Nabel, E.G., et al., "Direct Transfer of Transforming Growth Factor Beta 1 Group Into Arteries Stimulate Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993) C380 Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Fin Man", Atherosclerosis, 47, 71-75, (1983) C381 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C382 Nakano, "Glucocorticoid Inhibits Thromin-Induced Expression of Platelet-Derived Growth Factor A-cha Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells:, Journal of Biological Ch emistry, 268, 22941-22947 (1993) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research — Medical Technology, 10 p., (Mar. 3, 1995) C384 Navarro, S.E., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis." Cardiovasc. Pathol., 3:57-64 (C386 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26, 784, (August 5, 1994) C388 Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activi Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C399 Opherk, D. et al., "Four-Year Follow-up Study in Patients With Angine Pector	1 1	(3//	
Added Copper to Alter the Unsaturated:Saturated Ration of Pork Fat", J. Anim. Sci., 70, 1417-1423, (195) C379 Nabel, E.G., et al., "Direct Transfer of Transforming Growth Factor Beta I Group Into Arteries Stimulate Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993) C380 Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Find Man", Atherosclerosis, 47, 71-75, (1983) C381 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C382 Nakano, "Glucoccorticoid Inhibits Thromin-Induced Expression of Platelet-Derived Growth Factor A-cha Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells:, Journal of Biological Ch emistry, 268, 22941-22947 (1993) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research — Medical Technology, 10 p., (Mar. 3, 1995) C384 Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc, Pathol., 3:57-64 (Case) C386 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26, 784, (August 5, 1994) C389 Okuyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activi Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) Opherk, D., et al., "The Resistance of Royal States and Actions, 21, 130-144, (1987) Opherk, D., et al., "The Gold Marchification of the Major Tamoxifen-Deoxyguanosine Addu	 	C378	Myer, R.O, et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canola Oil and
C379 Nabel, E.G., et al., "Direct Transfer of Transforming Growth Factor Beta 1 Group Into Arteries Stimulate Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993) C380 Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Fin Man", Atherosclerosis, 47, 71-75, (1983) C381 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C382 Nakano, "Glucocorticoid Inhibits Thromin-Induced Expression of Platelet-Derived Growth Factor A-cha Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells:, Journal of Biological Ch emistry, 268, 22941-22947 (1993) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research — Medical Technology, 10 p., (Mar. 3, 1995) C384 Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 (C386 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26 784, (August 5, 1994) C388 Okuyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activi Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C399 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Opherk, D., et al., "Altered beta-Adrenergic Regulation of Na-K-CI Cotransport in Cultured Smooth Muscle Polifera		(3/6	Added Copper to Alter the Unsaturated:Saturated Ration of Pork Fat", J. Anim. Sci., 70, 1417-1423, (1992)
Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993) C380 Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of F in Man", Atherosclerosis, 47, 71-75, (1983) C381 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C382 Nakano, "Glucocorticoid Inhibits Thromin-Induced Expression of Platelet-Derived Growth Factor A-cha Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells:, Journal of Biological Chemistry, 268, 22941-22947 (1993) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research — Medical Technology, 10 p., (Mar. 3, 1995) C384 Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vast restenosis: Analysis of 62 patients with one or more episode of restenosis." Cardiovasc. Pathol., 3:57-64 (C386) C386 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26 784, (August 5, 1994) C388 Okuyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activity Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Inference beta-Adrenergic Regulation of Nat-C-Cl Cotransport in Cultured Smooth Mus Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (19 of Rat		C379	Nabel, E.G., et al., "Direct Transfer of Transforming Growth Factor Beta Group Into Arteries Stimulates
C380 Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of f in Man", Atherosclerosis, 47, 71-75, (1983) C381 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C382 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C383 Nakarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research - Medical Technology, 10 p., (Mar. 3, 1995) C383 Navarro, S.E., et al., "Tramoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) C384 Nayfield, S.G., et al., "Tramoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 (C386) C386 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26, 784, (August 5, 1994) C388 Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activity Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1986) C390 Orlov, S.N., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C391 Oxer, et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascula	1 1	(3,7)	Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993)
in Man", Atherosclerosis, 47, 71-75, (1983) C381 Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone The Angiology, 45, 333-338, (May 1994) C382 Nakano, "Glucocorticoid Inhibits Thromin-Induced Expression of Platelet-Derived Growth Factor A-cha Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells:, Journal of Biological Che emistry, 268, 22941-22947 (1993) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Set Equity Research Medical Technology, 10 p., (Mar. 3, 1995) C384 Nayfield, S.G., et al., "Tamoxificn-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) C385 Niklol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 (C386 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26, 784, (August 5, 1994) C388 Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activi Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients Win Patients Win Agina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Guert Research, 56, 66-71, (1996) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-Binduced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of		C380	Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Fatty Acid
Angiology, 45, 333-338, (May 1994) C382 Nakano, "Glucocorticoid Inhibits Thromin-Induced Expression of Platelet-Derived Growth Factor A-cha Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells:, Journal of Biological Ch emistry, 268, 22941-22947 (1993) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Se Equity Research - Medical Technology, 10 p., (Mar. 3, 1995) C384 Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 (1986) C386 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26 784, (August 5, 1994) C388 Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activity Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-CI Cotransport in Cultured Smooth Muscle Porm the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1960) C392 Owens, G.K., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz	1 1	0300	
Angiology, 45, 333-338, (May 1994) C382 Nakano, "Glucocorticoid Inhibits Thromin-Induced Expression of Platelet-Derived Growth Factor A-cha Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells:, Journal of Biological Ch emistry, 268, 22941-22947 (1993) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Set Equity Research - Medical Technology, 10 p., (Mar. 3, 1995) C384 Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 (C386) C386 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26 784, (August 5, 1994) C388 Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activity Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-CI Cotransport in Cultured Smooth Muscle Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1960) C392 Owens, G.K., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) Ovens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of		C381	Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone Therapy.",
Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells:, Journal of Biological Ch emistry, 268, 22941-22947 (1993) C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Set Equity Research Medical Technology, 10 p., (Mar. 3, 1995) C384 Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 (1996) C386 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26 784, (August 5, 1994) C388 Okuyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activi Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-CI Cotransport in Cultured Smooth Mus Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1996) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Bioch			
Journal of Biological Ch emistry, 268, 22941-22947 (1993) C388		C382	
C383 Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Set Equity Research Medical Technology, 10 p., (Mar. 3, 1995) C384 Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 (1986) C386 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26 784, (August 5, 1994) C388 Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activity Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616 (6, 1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-CI Cotransport in Cultured Smooth Mus Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1986) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am.			
Equity Research Medical Technology, 10 p., (Mar. 3, 1995) C384 Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 (2006) C386 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26 784, (August 5, 1994) C388 Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activi Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-CI Cotransport in Cultured Smooth Musform the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1986) C390 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C394 Palmaz et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee: 147:1251-54. P396 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experi		↓	Journal of Biological Ch emistry, 268, 22941-22947 (1993)
C384 Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14 1018-1026, (1996) C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasor restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26 784, (August 5, 1994) C388 Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activity Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Nak-C-IC Cotransport in Cultured Smooth Muscle Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1980) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertension 1986 Dee: 147:1251-54. C396 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825.	1	C383	
C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasc restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 (C386 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26: 784, (August 5, 1994) C388 Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activity Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-CI Cotransport in Cultured Smooth Muscle Calls", American Journal of Hypertension, 8, 739-747, (1980) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825.	<u> </u>		
C385 Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vasor restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 (C386 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26:784, (August 5, 1994) C388 Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activity Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Ohne, et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-CI Cotransport in Cultured Smooth Mus Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1980) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee: 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog." 145 Am. Roentgenol. 1985;145:821-825.	1	C384	
restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 (C386 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26 784, (August 5, 1994) C388 Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activity Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-CI Cotransport in Cultured Smooth Musform the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1980) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog." 145 Am. Roentgenol. 1985;145:821-825.			1018-1026, (1996)
C386 O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26, 784, (August 5, 1994) C388 Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activi Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-CI Cotransport in Cultured Smooth Mus Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1990) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertension 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog." 145 Am. Roentgenol. 1985;145:821-825.	1 1	C385	
as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996) C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26, 784, (August 5, 1994) C388 Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activity Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-CI Cotransport in Cultured Smooth Muscon Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1980) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825.	+		
C387 Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 26 784, (August 5, 1994) C388 Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activity Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-CI Cotransport in Cultured Smooth Muse Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1981) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825.		C386	
784, (August 5, 1994) C388 Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activi Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-CI Cotransport in Cultured Smooth Mus Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1980) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog." 145 Am. Roentgenol. 1985;145:821-825.		_	as an index of Antioxidant Therapy", Atheroscierosis, 119, 169-179, (1996)
C388 Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activity Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-Cl Cotransport in Cultured Smooth Mus Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1981) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dec; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825.		C387	
Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987) C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-Cl Cotransport in Cultured Smooth Mus Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1980) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825.	+	+	
C389 Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-Cl Cotransport in Cultured Smooth Muster Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1980) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825. C396 Palmaz et al., "Expandable Intraluminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov		C388	
Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989) C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-Cl Cotransport in Cultured Smooth Muster Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1980) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825.	 	+	Onbork D. et al. "Four-Vear Follow-up Study in Patients With Aprina Pactoris and Marmal Coronary
C390 Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-Cl Cotransport in Cultured Smooth Mus Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1980) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825.		C389	
Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1980) C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Live of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825. C396 Palmaz et al., "Expandable Intraluminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov		+	Orlay S.N. et al. "Altered hete. Adrenergic Regulation of No. VCl Categorous in Cultured Smooth Muscle Calls
C391 Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liv of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825. C396 Palmaz et al., "Expandable Intraluminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov		C390	
of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996) C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825. C396 Palmaz et al., "Expandable Intraluminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov		1	
C392 Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertroph Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825. C396 Palmaz et al., "Expandable Intraluminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov		C391	
Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988) C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825. C396 Palmaz et al., "Expandable Intrahuminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov	 	C302	Owens G.K. et al. "Transforming Growth Factor-R-induced Growth Inhibition and Cellular Hypertrophy in
C393 Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis" Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825. C396 Palmaz et al., "Expandable Intrahuminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov		C392	
Biochem Mol. Biol. Intern, 35, 117-124, (1995) C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825. C396 Palmaz et al., "Expandable Intraheminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov	 -	C103	
C394 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertensio 1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825. C396 Palmaz et al., "Expandable Intraheminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov)	C393	
1986 Dee; 147:1251-54. C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825. C396 Palmaz et al., "Expandable Intraluminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov		C204	
C395 Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. Roentgenol. 1985;145:821-825. C396 Palmaz et al., "Expandable Intrahuminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov		C394	
Roentgenol. 1985;145:821-825. C396 Palmaz et al., "Expandable Intraluminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov	 	C305	Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. J.
Palmaz et al., "Expandable Intraluminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov		""	
	17	C396	Palmaz et al., "Expandable Intraluminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov;
1 157(P):00 A0S 150.	<i>y</i>		157(P):66 Abs 130.

		of Application No. 09/910,388
-118	C397	Palmaz et al., "Normal and Stenotic Renal Arteries: Experimental Balloon-expandable Intraluminal Stenting," Radiology 1987 Sept; 164(3):705-708.
4	C398	Palmaz et al., "Removable Biliary Endoprosthesis," Am, J. Roentgenol. 1983;140(4):812-4.
	C399	Palmaz, et al., "Atherosclerotic Rabbit Aortas: Expandable Intraluminal Grafting," Radiology 1986 Sept; 160:723-726.
	C400	Palmaz, et al., "Expandable Intrahepatic Portocaval Shunt Stents in Dogs with Chronic Portal Hypertension," American Roentgen Ray Soc'y 1986 Annual Meeting. Washington, D.C., (BT 000079) (April 13-18, 1986).
	C401	Palmaz, et al., "Intravascular Stents: Basic Physical and Biological Properties, Endoluminal Treatment: The Different Techniques.". Editors Michel Henry, Max Arnor, Edward B. Diethrich and Barry Katzen. Published by
	C402	Springer Verlag; 4:149-158 (1997). Palmaz, J.C. "Balloon-Expandable Intravascular Stent," A JR 1988 June; 150:1263-1269.
	C403	Palmaz, J.C. "Expandable Intraluminal Graft: A Preliminary Study," Radiology 1984 Nov;153(P):329 Abs. 993.
	C404	Pandey, B.L., et al., "A Study of the Effects of Tamrabhasma, an Indigenous Preparation of Copper on Experimental Gastric Ulcers and Secretion", Indian Journal of Experimental Biology, 21, 258-264, (1983)
	C405	Pardoll, D., et al., "Exposing the Immunology of Naked DNA Vaccines", Immunity, 3, 165-169, (1995)
	C406	Parthasatathy, S., et al., "A Role for Endothelial Cell Lipoxygenase in the Oxidative Modification of Low Density Lipoprotein", Proc. Nat'l Acad. Sci., USA, 86, 1046-1050, (1989)
	C407	Pedron, N. et al., "The Effect of Acetylsalicyclic Acid on Menstrual Blood Loss in Women with IUDs", Contraception, 36, 295-303, (1987)
	C408	Peng et al., "The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation," Mol. Cell Biol., 22:5575-84 (2002)
	C409	Pennisi, E., "Drug's Link to Genes Reveals Estrogen's Many Sides", Science, 273, 1171, (Aug. 30, 1996)
	C410	Peress, N.S., et al., "Differential Expression of TGF-B1, 2 and 3 Isotypes in Alzheimer's Disease: A Comparative Immunohistochemical Study with Cerebral Infarction, Aged Human and Mouse Control Brains", Journal of Neuropathology and Experimental Neurology, 54, 802-811, (November 1995)
	C411	Peress, N.S., et al., "Glial Transforming Growth Factor (TGF) -B Isotypes in Multiple Sclerosis: Differential Glial Expression of TGF-B1, 2, and 3 Isotypes in Multiple Sclerosis", Journal of Neuroimmunology, 71, 115-123, (1996)
	C412	Perez, J.R., et al., "Regulation of Adhesion and Growth of Fibrosarcoma Cells by NF - kb RelA Involves Transforming Growth Factor Beta", Molecular and Cellular Biology, 14, 5326-5332, (1994)
	C413	Pfister, W.R. et al., "Silicone Based Sustained and Controlled Release Drug Delivery Systems", 1985, 30 th National SAMPE Symposium and Exhibition, Anaheim, CA, March 19-21, 1985, pp. 490-498 (1985)
	C414	Pinto, H.C., et al., "Tamoxifen-associated Steatohepatitis C Report of Three Cases", Journal of Hepatology, 23, 95-97, (1995)
	C415	Polysciences Inc., TDMAC-Heparin Coatings, Nov. 1988, Data Sheet #172
	C416	Post et alk., "The Relative Importance of Arterial Remodeling Compared With Intimal Hyerplasia in Lumen Renarrowing After Balloon Angioplasty" Circulation 89, 2816-2821 (June 1994)
	. C417	Potter et al., "A mechanism hypothesis for DNA adduct formation following hepatic oxidative metabolism," Carcinogenesis, 15, 439-442 (1994)
	C418	Powell et al., "Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury," Science, 245:186-188 (1989)
	C419	Presentation at The Society of CV & Interventional Radiology's Twelfth Annual Course On "Diagnostic Angiography and Interventional Radiology." Includes: "The Current Status of Vascular Prostheses" by Julio Palmaz at 118-120 (March 23 - 26 1987).
	C420	Program and abstracts of the Seventh International Conference on the Adjuvant Therapy of Cancer, held in Tuscon, Arizona on March 10-13, 1993
	C421	Pupita, G., et al., "Myocardial Ischemia Caused by Distal Coronary-Artery Constriction in Stable Angina Pectoris", The New England Journal of Medicine, 323, 514-520, (1990)
	C422	Rainsford, K.D., et al., "Concerning the Merits of Copper Aspirin as a Potential Anti-Inflammatory Drug", J. Pharmac., 28, 83-86, (1976)
	C423	Rainsford, K.D., et al., "Gastric Mucus Effusion Elicited by Oral Copper Compounds: Potential Anti-Ulcer Activity", Experientia, 32, 1172-1173, (1976)
	C424	Raisz, L.G., "Estrogen and Bone: New Pieces to the Puzzle", Nature Medicine, 2, 1077-1078, (1996)
	C425	Raloff, "Tamoxifen Puts Cancer on Starvation Diet", Science News, 146, 292, (November 5, 1994)
	C426	Ray, P., et al., "Repression of interleukin-6 gene expression by 17beta-estradiol: Inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-6B by the estrogen receptor", FEBS Letters, 409, 79-85, (1997)
	C427	Razavi, M., "Unusual Forms of Coronary Artery Disease", Cleveland Clinic Consultations, 7, 25-46, (1975)
	C428	Recchia, F., et al., "Interferon-beta, Retinoids, and Tamoxifen in the Treatment of Metastatic Breast Cancer: A Phase II Study", Journal of Interferon and Cytokine Research, 15, 605-610, (1995)
1	C429	Reckless, J., et al., "Tamoxifen Decreases Cholesterol Sevenfold and Abolishes Lipid Lesion Development in

		of Application No. 09/910,388
Jac		Apolipoprotein E Knockout Mice", Circulation, 95, 1542-1548, (1997)
	C430	Reilly et al., "Antiproliferative effects of heparin on vascular smooth muscle cells are reversed by epidermal growth factor," J. Cell Physiol., 131:t 49-157 (1987)
	C431	Reilly, C.F., "Rat Vascular Smooth Muscle Cells Immortalized with SV40 Large T Antigen Possess Defined
1 1		Smooth Muscle Cell Characteristics Including Growth Inhibition by Heparin", Journal of Cellular Physiology, 142, 342-351, (1990)
	C432	Reis, G.J., et al., "Randomized Trial of Fish Oil for Prevention of Restenosis After Coronary Angioplasty", The
	(432	Lancet, 177-181, (1989)
	C433	Ribeiro, G., et al., "Adjuvant Tamoxifen for Male Breast Cancer (MBC)", Br. J. Cancer, 65, 252-254, (1992)
	C434	Rieckmann, P., et al., "Tumor Necrosis Factor-a Messenger RNA Expression in Patients with Relapsing-Remitting Multiple Sclerosis is Associated with Disease Activity", Ann. Neurol, 27, 82-88, (1996)
	C435	Riessen et al., "Prospects for Site-Specific Delivery of Pharmacologic and Molecular Therapies", J. Amer. Collago of Cardiol., 23, 1234-1244 (Apr. 1994)
	C436	Riessen et al., "Regional Differences in the Distribution of the Proteoglycans Biglycan and Decorin in the Extracellular Matrix of Atherosclerotic and Restenotic Human Coronary Ateries", Amer. J. Path 144, 962-974 (May 1994)
	C437	Roberts et al., "Type beta transforming growth factor: a bifunctional regulator of cellular growth," Proc. Natl. Acad. Sci., 82:119-123 (1985)
	C438	Robinson, J.R. (ed), "Sustained and Controlled Release Drug Delivery Systems," New York, Marcel Dekker (1978). Chapters 1-2, 4, and 7-9.
	C439	Roche Lexikon Medizin, Urban und Schwarzenberg, 1984, page 69 "Antibiotika", and page 515 "Fibrin"
	C440	Rompp Chemie-Lexikon, 9th ed., 1989-1990, pp. 206-208, & pp. 1350 and 1351
	C441	Rompp, Chemie-Lexikon, 8th ed., 1987, page 2633 "Mitosehemmer"
	C442	Roubin, "Intracoronary Stenting of Canine Coronary Arteries After Percutaneous Coronary Angioplasty (PTCA)," Circulation 1986 Oct;74(Supp. II-458):1825 Abstract.
	C443	Rowinsky et al., "Taxol: Twenty years Later, the Story Unfolds," Journal of the National Cancer Institute, 1991, Vol 83 No. 24 pp 1778-1781
	C444	Rutqvist, L.E., et al., "Cardiac and Thromboembolic Morbidity Among Postmenopausal Women with Early-Stage Breast Cancer in a Randomized Trial of Adjuvant Tamoxifen", Journal of the National Cancer Institute, 85, 1398-1406, (1993)
	C445	Rutsch, et al., "Benestent-II Pilot Study: 6 months Follow Up of Phase 1" Abstract, Society of Cardiology, (1995)
	C446	Ruygrok and Serruys, "From Bench to Bedside, Intracoronary Stenting, From Concept to Custom," Circulation 1996; 94:882-890
	C447	Ryan et al., "Transforming growth factor-beta-dependent events in vascular remodeling following arterial injury," J. Vase. Res., 40:37-46 (2003)
	C448	Saarto, T., et al., "Antiatherogenic Effects of Adjuvant Antiestrogens: A Randomized Trial Comparing the Effects of Tamoxifen and Toremifene on Plasma Lipid Levels in Postmenopausal Women with Node-Positive Breast Cancer", Journal of Clinical Oncology, 14, 429-433, (February 1996)
	C449	Sabatini et al., "RAFT1: a mammalian protein that binds to FK.BP12 in a rapamycin-dependent fashion and is homologous to yeast TORs", Cell, 78:35-43 (1994)
	C450	Saito, H., et al., "Influence of Maternal Drug Metabolism on the Fetal Toxicity Induced by Acetylsalicylic Acid", The Journal of Toxicological Sciences, 7, 177-184, (1982)
	C451	Sanchez, et al., "Control of Contact activation on end-point immobilized heparin, The role of antithrombin and the specific antithrombin-binding sequence," <i>J. Of Biomedical Materials Research</i> , pp. 655-661 (1995)
	C452	Sanderson et al., "Antibody-Coated Microspheres for Drug Delivery to Prevent Restenosis", Circulation, 90, 1 508, Abstract No. 2734 (October 1994)
	C453	Sargent, L.M., et al., "Induction of Hepatic Aneuploidy in Vivo by Tamoxifen, Toremifene and Idoxifene in Female Sprague-Dawley Rats", Carcinogenesis, 17, 1051-1056, (1996)
	C454	Schatz et al., "Balloon Expandable Intravascular Stents in Diseased Human Cadaver Coronary Arteries," Circulation 1987 Oet;70(4): Abstract 0102.
	C455	Schatz et al., "Balloon-expandable Intra-coronary Stents In The Adult Dog," Circulation 1987 Aug; 76(2):450-457.
	C456	Schatz, et al., "Balloon Expandable Intracoronary Stents In Dogs," Circulation 1986 Oct;74(Supp. II-458): 1824 Abstract,
	C457	Schatz, et al., "Clinical Experience with the Palmaz-Schatz Stent: Initial Results of A Multicenter Study," Circulation 1991 Jan;83(1): 148-161.
	C458	Schatz, R.A. Introduction to Intravascular Stents, Cardiology Clinics 1988 Aug;6(3):357-72.
	C459	Schlaak, J.F., et al., "Different Cytokine Profiles in the Synovial Fluid of Patients with Osteoarthritis, Rheumatoid Arthritis and Seronegative Spondylarthropathies", Clinical and Experimental Rheumatology, 14, 155-162, (1996)
	C460	Schmidt, E.B., et al., "Long-Term Supplementation with n-3 Fatty Acids, II: Effect on Neutrophil and Monocyte Chemotaxis", Scand. J. Clin. Lab. Invest., 52, 229-236, (1992)
$\sqrt{}$	C461	Schoenemanne, et al., "The Differential Diagnoses of Spontaneous Pneumothrax and Pulmonary Lymphangioleimyomatosis Clinical Picture Diagnoses and Theory.", Chiraq, 61, 301-303 (1990); reported in

Δ		of Application No. 09/910,388
110		Biosis, 90, 432367 (1990), English abstract only
- CHA	C462	Schulick et al, "Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia," PNAS 95:6983-6988 (1998)
	C463	Schwartz, C.J., et al., "The Pathogenesis of Atherosclerosis: An Overview", Clin. Cardiol., 14, 1-1-1-16, (1991)
	C464	Schwartz, G.G., et al., "Pathophysiology of Chronic Stable Angina", In: Atherosclerosis and Coronary Artery Disease, V. Fuster, et al., (eds.), Lippencott-Raven Publishers, Philadelphia, pp. 1386-1400, (1996)
	C465	Schlacek, S. "Estrogenic Properties of Tamoxifen on Serum Lipids in Postmenopausal Women with Breast Cancer (BCA)", Breast Cancer Research and Treatment, 14, Abstract No. 82, 153, (1989)
	C466	Sehgal et al., "Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization," J. Antibiot., 28:727-32 (1975)
	C467	Sehgal, "Sirolimus: its discovery, biological properties, and mechanism of action." Transplant. Proc., 35(3 Suppl):7S-148 (2003)
	C468	Serruys et al., "The new angiotensin converting enzyme inhibitor cilazapril does not prevent restenosis after coronary angioplasty: the results of the MERCATOR trial," JACC 19:258A, Abstract 783-2 (1992)
	C469	Serruys, et al., "A Comparison of Balloon-Expendable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease", The New England Journal of Medicine, 331, 489-495 (August, 1994)
	C470	Serruys, P.W., et al., "Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries Early Outcome of the Benestent-II Pilot Study", Circulation, 93, 412-422, (Feb. 1996)
	C471	Shanahan and Weissberg, "Smooth muscle cell heterogeneity: patterns of gene expression in vascular smooth muscle cells in vitro and in vivo," Arterioscler. Thromb. Vase. Biol., 18(2):333-338 (1998)
	C472	Shanahan, C.M., et al., "High Expression of Genes for Calcification-regulating Proteins in Human Atherosclerotic Plagues", Journal of Clinical Investigation, 93, 2393-2402, (June, 1994)
	C473	Shapiro, L.M., "Echocardographic Features of Impaired Ventricular Function in Diabetes Mellitus", British Heart Journal, 47, 439-444, (1982)
	C474	Shemon, et al., "Tamoxifen Decreases Lipoprotein(a) in Patients with Breast Cancer.", Metabolism, 43, 531-532, (May 1994)
	C475	Shewmon, et al., "Tamoxifen and Estrogen Lower Circulating Lipoprotein(a) Concentration in Healthy Postmenopausal Women", Arteriosclerosis and Thrombosis, 14, 1589-1593, (1994)
	C476	Shimaoka, I., et al., "Purification of a Copper Binding Peptide from the Mushroom Grifola Frondosa and Its Effect on Copper Absorption", J. Nutr. Biochem., 4, 33-38, (1993)
	C477	Shou et al., "Cardiac defects and altered ryanodine receptor function in mice lacking FK-BP 12," Nature, 391 (6666):489-92 (1998)
	C478	Siebenlist, U., et al., "Structure, Regulation and Function of NF-kB", Annu. Rev. Cell. Biol., 10, 405-455, (1994)
	C479	Sigwart, et al., "Intravascular Stents to Prevent Occlusion and Restenosis After Transluminal Angioplasty," N. Engl. J. Med., Mar. 19, 1987, Vol. 316, No. 12, pp.701-06
	C480	Sigwart, U., Frank, G.I., "Bioabsorbable, Drug-Eluting, Intracoronary Stents: Design and Future Applications," Coroinary Stents. Springer-Verlag (1992)
	C481	Sigwart, Ulrich, "The Self Expanding Mesh Stent" Textbook of Interventional Cardiology, (Eric J. Topol, ed) 1990, Chapter 29, pp 605-622
	C482	Silber, S. "Drug-eluting stents: aktueller Stand", internet article on sigmund-silber.com/deutsch/varia/var-2003/03-09-5-Silber-Chemnitz.pdf of August 6, 2003
	C483	Sismondi, et al., "Metabolic Effects of Tamoxifen in Postmenopause.", Anticancer Res., 14, 2237-2244, (1994)
	C484	Soderberg, L.S., et al., "Copper (II) (3,5-Diisopropylsalicylate) sub2 Accelerates Recovery of B and T Cell Reactivity Following Irradiation", Scand J. Immunol., 26, 495-502, (1987)
	C485	Soderberg, L.S., et al., "Copper (II) sub2(3, 5-diisopropylsalicylate) sub4 Stimulates Hemopoiesis in Normal and Irradiated Mice", Exp. Hematol., 18, 577-580, (1988)
	C486	Soderberg, L.S., et al., "Postirradiation Treatment with Copper (II) sub2 (3,5-diisopropylsalicylate) sub4 Enhances Radiation Recovery and Hemopoietic Regeneration", Exp. Hematol., 18, 801-805, (1990)
	C487	Soderberg, L.S., et al., "Radiation Recovery Agents", DN & P, 3, 600-605, (1990)
	C488	Sollott, S.J., et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat", The Journal of Clinical Investigation, 95, 1869-1876, (Apr., 1995)
	C489	Song "Dexamethasone-nanoparticles for intra-arterial localization in restenosis in rats," Preed. Intern. Symp. Control. Rel. Mater., 22, 444-445 (1995)
	C490	Song, J., et al., "Tamoxifen (Estrogen Antagonist) Inhibits Voltage-Gated Calcium Current and Contractility in Vascular Smooth Muscle from Rats", The Journal of Pharmacology and Experimental Therapeutics, 227, 1444-1453, (1996)
	C491	Sorenson, J.R., "Copper Complexes Offer a Physiological Approach to Treatment of Chronic Disease", Progress in Medicinal Chemistry, 26, 437-568, (1989)
	C492	Sorenson, J.R., "Essential Metalloelement Metabolism and Radiation Protection and Recovery", Radiation Research, 132, 19-29, (1992)
	C493	Sorenson, J.R., "Pharmacological Activities of Copper Compounds", In: Handbook of Metal-Ligand Interactions in Biological Fluids Bioinorganic Medicince, vol. 2, Berton, G., (ed.), Marcel Dekker, Inc., New York, 1128-1139, (1995)

				of Application No. 09/910,388
0	HR	1	C494	Sorenson, J.R., "Radiation Protection and Radiation Recovery with Essential Metalloelement Chelate", P.S.E.B.M., 210, 191-204, (1995)
			C495	Sorenson, J.R., "The Ulcerogenic Potential of Copper Aspirinate Seems to be More Imaginary than Real", Journal of Pharmaceutical Sciences, 73, Open Forum, 1875-1878, (1984)
	7		C496	Sorenson, J.R., et al., "Antieoplastic Activities of Some Copper Salicylates", In: Trace Substances in
	 -	╁	C107	Environmental Health, vol. XVI, Hemphill, D.D., (ed.), University of Missouri, Columbia, 362-369, (1982) Sorenson, J.R., et al., "Bis (3, 5-diisopropylsalicylato) copper (II), a Potent Radioprotectant with Superoxide
	_		C497	Dismutase Mimetic Activity", J. Med. Chem., 27, 1747-1749, (1984)
			C498	Sorenson, J.R., et al., "Copper Complexes as 'Radiation Recovery' Agents", Chemistry in Britain, 25, 169-171, (1989)
			C499	Sorenson, J.R., et al., "Copper-, Iron-, Manganese- and zinc-3, 5-diisopropylsalicylate Complexes Increase Survival of Gamma-Irradiated Mice", Eur. J. Med. Chem., 28, 221-229, (1993)
			C500	Sousa et al., "Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up," Circulation, 104:2007-i 1 (2001) (CYP228071-228075)
			C501	Sousa et al., "Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus- eluting stents in human coronary arteries," Circulation. 107(3):381-3 (2003) (BSX 024170-024172)
			C502	Sousa, J.E. et al., "New Frontiers in Cardiology Drug-Eluting Stens: Part I", Circulation, 2003, 107:2274-2279,
			C503	Southgate and Newby, "Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP," Atherosclerosis, 82:113-123 (1990)
			C504	Srivastava, K.C., "Effects of Dietary Fatty Acids, Prostaglandins and Related Compounds on the Role of Platelets in Thrombosis", Biochem. Exp. Biol., 16, 317-338, (1980)
			C505	Standley, P.R., et al., "Tamoxifen (an Antiestrogen) Reduces K Positive- and Agonist-Induced Vascular Contractility in Rat Resistance Vessels", Abstract No. 159
		<u> </u>	C506	Stevenson, F., et al., "Idiotypic DNA Vaccines against B-cell Lymphoma", Immunological Reviews, 145, 221-228, (1995)
			C507	Stork, G., et al., "Total Synthesis of Cytochalasin B", Journal of the American Chemical Society, 100, 7775-7777, (1978)
			C508	Stouffer, et al., "TGF beta Has a Biphasic, Concentration Dependant Effect on EFG and PDGR-BB Induced Smooth Muscle Cell Proliferation, Inflammation, Growth Regulatory Molecules and Atherosclerosis.", J. Cellular Biochem, Supplement 18A, Abstract No. A321, 288, (1994)
			C509	Strepetti, A.V., et al., "Formation of Myointimal Hyperplasia and Cytokine Production in Experimental Vein Grafts", Surgery, 123(4), 461-469, (1998)
			C510	Suckling, "Atherosclerosis Patents: Clues to the Next Drug Generation", Bio/Tech, 12 1379-1380 (December 1994)
			C511	Sudo, K., et al., "Antiestrogen-Binding Sites Distinct from the Estrogen Receptor: Subcellular Localization, Ligand Specificity, and Distribution in Tissues of the Rat", Endocrinology, 112, 425-434, (1983)
			C512	Swain, "Blazing new paths for product introductions," Medical Device & Diagnostic Industry, Sept. 2003, p. 68-81
			C513	Szekanecz, Z., et al., "Increased Synovial Expression of Transforming Growth Factor (TGF) -B Receptor Endoglin and TGF- B1 in Rheumatoid Arthritis: Possible Interaction in the Pathogenesis of the Disease", Clinical Immunology and Immunopathology, 76, 187-194, (August 1995)
			C514	Tabas et al., "the Actin Cytoskeleton in Important for the Stimulation of Cholesterol Esterification by Atherogenic Lipoprotiens in Macrophages" J. Biol. Chem., 269, 22547-22556 (Sept. 9 1994)
			C515	Takashima, K. et al., "The Hypocholesterolemic Action of TA-7552 and its Effects on Cholesterol Metabolism in the Rat", Atherosclerosis, 107, 247-257, (1994)
			C516	Tanaka et al., "lalpha 25 (OH) 303 Exerts Cytostatic effects on Murine Osteosarcoma Cells and Enhance Cytocidal Effects on Anticancer Drugs" Clinical Orthopaedics and related Research no. 247 1989 pgs. 290-296
			C517	Tanaka et al., "Prominent Inhibitory Effects of Tranilast on Migration and Proliferation of and Collagen Synthesis by Vascular Smooth Muscle Cells" Atherosclerosis, 107, 179-185 (1994)
			C518	Tanenbaum, S.W., "Microbiological, Preparative and Analytical Aspects of Cytochalasin Production", In: Cytochalasins Biochemical and Cell Biological Aspects, Tanenbaum, S.W., (ed.), Elsevier/North-Holland Biomedical Press, 2-14, (1978)
			C519	Tang et al., "Regression of collagen-induced arthritis with taxol, a microtubule stabilizer". Arthritis and Rheumatism, 36 (9) Suppl.:S45, 1993
		•	C520	Tawashi, R., "The dissolution rates of crystalline drugs", J. Mond. Pharm, 4,11,1968, pp 371-379
			C521	Teirstein (ed.), "Coronary Stents: pros and cons," Coronary Artery Disease, 5:561-600 (1994).
			C522	Tessari et al., "Antiproliferative activity of unfractioned heparin on a human smooth muscle cell line, Pharmacol." Res., 21:145-6 (1989)
			C523	Testart, J., et al., "The Action of Anti-Inflammatory Drugs to the Fertility of Female Rats with Intrauterine Contraceptive Devices", J. Reprod. Fert., 63, 257-261, (1981)
			C524	Thompson, J.T., et al., "Comparison of Recombinant Transforming Growth Factor-beta -2 and Placebo as an adjunctive Agent for Macular Hole Surgery", Ophthalmology, 15(4), 700-706, (1998)
()			C525	Thompson, N.L., et al., "Expression of Transforming Growth Factor-B1 in Specific Cells and Tissue of Adult and Neonatal Mice", Journal of Cell Biology, 108, 661-669, (1989)

		of Application No. 09/910,388
HR	C526	Tong et al., "Non-Thrombogenic Hemofiltration System for Acute renal failure Treatment: ASAIO Trans. 38: M702-M706 (1992)
	C527	Toomasian et al., "Evaluation of Duraflo II Herparin Coating in Prolonged Extracorporeal Membrane Oxygenation", ASAIO Trans 34: 410-14 (1988)
	C528	Topol, E. et al., "Frontiers in Interventional Cardiology" Circulation, 1998, 98:1802-1820,
	C529	Treasure, C.B., et al., "Hypertension and Left Ventricular Hypertrophy Are Associated With Impaired Endothelium-Mediated Relaxation in Human Coronary Resistance Vessels", Circulation, 87, 86-93, (1993)
	C530	Treiber, A., et al., "Chemical and Biological Oxidation of Thiophene: Preparation and Complete Characterization of Tiophene S-Oxide Dimers and Evidence for Thiophene S-Oxide as an Intermediate in Thiophene Metabolism vivo and In Vitro", J. Am. Chem. Soc., 119, 1565-1571, (1997)
	C531	Tucker et al., "Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor Science, 226:705-707 (1984)
	C532	Ulman, et al., "Drug Permeability of Modified Silicone Polymers," Journal of Controlled Release 1989; 10:276-281
	C533	Ulman, K.L. et al., "Drug Permeability of Modified Silicone Polymers", J. Controlled Release, 10:251-260 (1989)
	C534	Van Der Giessen, et al., "Coronary Stenting With Polymer-Coated And Uncoated Self-Expanding Endoprosthes In Pigs" Coron. Art. Disease 1992; 3:631-40
	C535	Van Der Giessen, et al., "Self-expandable Mesh Stents: an Experimental Study Comparing Polymer Coated and Uncoated Wallstent Stents in the Coronary Circulation of Pigs" "Circulation 82:III-542 (1990)
	C536	Van Sickle, W.A., et al., "An Alternative Mechanism for the Inhibition of Cholesterol Biosyntesis in HepG2 Cel by N- [(1,5,9) -Trimethyldecyl] -4alpha, 10-dimethyl 8-aza-trans-decal-3beta-ol (MDL 28, 815)", The Journal of Pharmacology and Experimental Therapeutics, 267, 243-1249, (1993)
	C537	Vawter, M.P., et al., "TGF B1 and TGF B2 Concentrations are Elevated in Parkinson's Disease in Ventricular Cerebrospinal Fluid", Experimental Neurology, 141, 313-332, (1996)
	C538	Vidensek N., et al., "Taxol Content in Bark, Wood, Root, Leaf, Twig, and Seedling from Several Taxus Species' Journal of Natural Products, 53, 1609-1610, (Nov./Dec., 1990)
	* C539	Voigt, R., Lehbuch der pharmazeutischen Technologie, 5 th . edition VEB Verlag Volk und Gesundheit Berlin, 1984, p 689
	C540	Von Schacky, C., et al., "Long-Term Effects of Dietary Marine omega-3 Fatty Acids upon Plasma and Cellular Lipids, Platelet Function, and Eicosanoid Formation in Humans", J. Clin. Invest., 76, 1626-1631, (1985) Waksman, R., et al., "Intracoronary Radiation Before Stent Implantation Inhibits Neointima Formation in Stente
	C541	Porcine Coronary Arteries", Circulation, 92, 1383-1386, (1995) Wallace, et al., "Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical
	C542	Applications," RADIOLOGY 1986 Feb;158(2):309-12.
	C543	Wallace, J.M., et al., "Dietary Fish Oil Supplementation Alter Leukocyte Function and Cytokine Production in Healthy Women", Arteriosclerosis, Thrombosis and Vascular Biology, 15, 185-189, (1995)
	C544	Waller et al., "Crackers, Breakers, Stretchers, Drillers, Scrappers, Shavers, Burners, Welders and Melters: The Future Treatment of Atherosclerotic Coronary Artery Disease?" A Clinical-Morphologic Assessment," JACC 13:969-87 (1989)
	C545	hyperplasia," Transpl. Int. 17:9-14 (2004)
	C546	Waller et al., "Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration," Transplant Proc. 37(1): 164-6 (2005).
	C547	Waller, B.F. X.L., et al., "Atherosclerotic and Nonatherosclerotic Coronary Artery Factors in Acute Myocardial Infarction", In: Acute Myocardial Infarction, Pepine, C.J., (ed.), F.A. Davis Company, Philadelphia, 29-104 (1989)
	C548	Walternberger, "Modulation of growth factor action: implications for the treatment of cardiovascular diseases," Circulation, 96:4083-4094 (1997)
	C549	Wang, X.L., et al., "Circulating Transforming Growth Factor Betal and Coronary Artery Disease", Cardiovascul Research, 34, 404-410 (1997)
	C550	Ward et al., "Inhibitory effects of translast on expression of transforming growth factor-beta isoforms and receptors in injured arteries," Atherosclerosis, 137:267-275 (1998)
	C551	Ward et al., "Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting," Arterioscler. Thromb. Vasc. Biol. 22:940-948 (2002)
	C552	Watson, et al., "TGF-B1 and 25-Hydroxcholesterol Stimulate Osteoblast-Like Vascular Cells to Calcify", J. Clin Invest., 93, 2106-2113 (May 1994)
	C553	Wei, C.M. et al., "Binding of Trichodermin to Mammalian Ribosomes and Its Inhibition by Other 12, 13- Epoxytrichotheces", Molecular & Cellular Biochemistry, 3, 215-219 (May 30, 1974)
	C554	Weissberg, P.L., et al., "Is Vascular Smooth Muscle Cell Proliferation Beneficial?", Lancet, 347, 305-307 (Feb. 1996)
	C555	West, G.B., "Comments on 'The Ulcerogenic Potential of Copper Aspirinate Seems to be More Imaginary than Real'", Journal of Pharmaceutical Sciences, 74, Open Forum, 700 (1985)

			of Application No. 09/910,388
£10	2	C556	West, G.B., "Testing for Drugs Inhibiting the Formation of Gastric Ulcers", Journal of Pharmacological Methods, 8, 33-37 (1982)
181-		C557	Wickremesinhe, E.R., et al., "Taxus Callus Cultures: Initiation, Growth, Optimization, Characterization and Taxol Production", Plan Cell, Tissue and Organ Culture, 35, 181-193 (1993)
			Wickremesinhe, E.R., et al., "Taxus Cell Suspension Cultures: Optimizing Growth and Production of Taxol", J.
		C558	Plant Physiol., 144, 183-188 (1994)
		C559	Wilensky, et al., "Regional and Arterial Localization of Radioactive Microparticles after Local Delivery by Unsupported Porous Balloon Catheters", American Heart Jounal, 129, 852-859 (May 1995)
·		C560	Wilensky, R.L., et al., "A Prospective, Randomized, Double-Blind, Dose-Escalation Study Evaluating the Safety and Tolerability of Cytochalasin B to Reduce Vascular Remodeling Following Percutaneous Transluminal Coronary Angioplasty", Abstract, 46 th Annual Scientific Session of the American College of Cardiology, 1 p. (1997)
		C561	Williams, J.K., et al., "The Estrogen Receptor Agonist/Antagonist Tamoxifen Inhibits Progression of Coronary Artery Atherosclerosis in Monkeys", Circulation, 92, November 1995, AHA Meeting (October 15, 1995)
		C562	Willson, T.M., et al., "Dissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen Receptor Ligand, Provides Insights into the Role of Estrogen Receptor in Bone", Endocrinology, 138(9) (September 1997)
		C563	Winokur et al., "Expression of transforming growth factors β 1, 2, and 3 following vascular injury," J. Cell Biochem., Suppl. 15C:G414 (Abstr.) (1991)
		C564	Winslow, R., "Going for the Flow", The Wall Street Journal (Oct. 23,1995)
		C565	Winternitz, C.I. et al., "Development of a Polymetric Surgical Paste Formulation for Taxol", Pharmaceutical Research, 13 368-375 (1996)
	\dashv	C566	Wiseman, H., "Tamoxifen as an Antioxidant and Cardioprotectant", Biochem. Soc. Symp., 61, 209-219 (1995)
	\top	C567	Wiseman, L.R., et al., "Toremifene A Review of its Pharmacological Properties and Clinical Efficacy in the Management of Advanced Breast Cancer", Drugs, 54, 141-160 (July 1997)
		C568	Witherup, K.M., et al., "Taxus Spp. Needles Contain Amounts of Taxol Comparable to the Bark of Taxus brevifolia: Analysis and Isolation", Journal of Natural Products, 53, 1249-1255 (Sep./Oct., 1990)
	\dashv	C569	Wolf, Y.G., et al., "Antibodies Against Transforming Growth Factor Betal Suppress Intimal Hyperplasia in a Rat
		C570	Model", J. Clin. Invest., 93, 1172-1178 (Mar. 1994) Wrana, et al., "Mechanism of Activation of the TGF-B Receptor", Nature, 370 341-347 (August 4, 1994)
		C571	Wright et al., "Cytoclasin Inhibition of Slow Tension Increase in Rat Aortic Rings", Am. J. Physion., 267 H1437-H1446 (1994)
		C572	Wright et al., "Percutaneous Endovascular Stents: An Experimental Study," Radiology 1984 Nov;153(P):206 Abs 593.
		C573	Wright et al., "Percutaneous Endovascular Stents: An Experimental Evaluation," Radiology 1985;1:69-72.
		C574	Wu et al., "Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cylokine production and lymphoproliferation," Transplant. Porc., 23:238-240 (1991)
		C575	Wu et al., "The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscel cell proliferation: an in vitro and in vivo study," J. Pharmacol. Sci. 94:252-60 (2004)
		C576	Wu, et al., "Silicone-covered Seft-expanding Metallic Stents for the Palliation of Malignant Esophageal Obstruction and Esophagorespiratory Fistulas: Experience in 32 Patients and a Review of the Literature," Gastrointest. Endosc. 1994; 40:22-33
		C577	Yamamoto et al., "Ribozyme oligonucleotides against transforming growth facotr-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease," Circulation, 102(11):1308-14 (2000)
		C578	Yang, N., et al., "Developing Particle-mediated Gene-transfer Technology for Research Into Gene Therapy of Cancer", Molecular Medicine Today, 476-481, (1996)
		C579	Yang, N.N., et al., "Estrogen Receptor: One Transcription Factor, Two Genomic Pathways", Calcified Tissue Intl., 54, 342, (1994)
		C580	Yang, N.N., et al., "Identification of an Estrogen Response Element Activated by Metabolites of 17Beta-Estradiol and Raloxifene", Science, 273, 1222-1225, (Oct. 30, 1996)
		C581	Young H., et al., "Pharmacokinetics and Biodistribution of Radiolabelled Idoxifene: Prospects for the Use of PET in the Evaluation of a Novel Antioestrogen for Cancer Therapy", Nucl. Med. Biol., 22, 405-411, (May 1995)
		C582	Zhang, L. et al., "MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized and tamoxifcn-treated nude mice", Oncogen, 15, 2093-2108, (1997)
		C583	Ziegler, J. "Raloxifene, Retinoids, and Lavender: AMe Too@ Tamoxifen Alternatives Under Study", Journal of the National Cancer Institute, 88, 1100-1102, (1996)
1		C584	Zohlnhofer et al., "Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties," Mol. Pharmacol. 65:880-889 (2004)
		C585	Answering Memorandum In Opposition To Plaintiffs' Motion For A Preliminary Injunction, Civil Action No. 03-283 Dated 4/3/03, U.S. District Court for the District of Delaware
Y		C586	Appendix To Answering Memorandum In Opposition To Plaintiffs' Motion For A Preliminary Injunction, Volume 1, Civil Action No.03-283 Dated 4/3/03, U.S. District Court for the District of Delaware

		of Application No. 09/910,388
Apr	C587	Appendix To Answering Memorandum In Opposition To Plaintiffs' Motion For A Preliminary Injunction, Volume 2, Civil Action No.03-283 Dated 4/3/03, U.S. District Court for the District of Delaware
	C588	BSC's Answering Brief in Opposition to Cordis' Motion for Summary Judgment Barring BSC from Asserting Equivalents for Certain Limitations of the '536 Patent. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
	C589	BSC's Reply Brief in Further Support of its Motion for Summary Judgment that Claims 6 and 8 of the '536 Patent are Not Anticipated by the Asserted Prior Art. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
	C590	BSC's Reply Brief in Further Support of its Motion for Summary Judgment that the Cypher Stent Infringes Claims 6 and 8 of U.S. Patent No. 6.120.536. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
	C591	Complaint, Civil Action No. 03-283, Filed 3/13/03, U.S. District Court for the District of Delaware
	C592	Cordis' Answering Brief in Opposition to BSC's Motion for Summary Judgment that Claims 6 and 8 of the Ding '536 Patent are Not Anticipated by the Asserted Prior Art. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
	C593	Cordis' Answering Brief in Opposition to BSC's Motion for Summary Judgment that the Cypher Stent Infringes Claims 6 and 8 of U.S. Patent No. 6.120,536. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
	C594	Cordis' Answering Markman Brief on the Construction of Terms in the Ding '536 Patent. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
	C595	Declaration Of Brian G. Firth, Civil Action No. 03-283 SLR, Dated 3/31/03, U.S. District Court for the District of Delaware
	C596	Declaration Of Dr. Jeffrey W. Moses, M.D., Civil Action No. 03-283 SLR, Dated 3/31/03, U.S. District Court for the District of Delaware
	C597	Declaration Of Dr. Martin B. Leon, M.D., Civil Action No. 03-283 SLR, Dated 3/31/03, U.S. District Court for the District of Delaware
	C598	Declaration Of Dr. Paul S. Teirstein, M.D., F.A.C.C., Civil Action No. 03-283 SLR, Dated 3/28/03, U.S. District Court for the District of Delaware
	C599	Declaration Of Dr. Peter Fitzgerald, M.D., Ph.D., Civil Action No. 03-283 SLR, Dated 3/31/03, U.S. District Court for the District of Delaware
	C600	Declaration Of Dr. Richard E. Kuntz, M.D. M.Sc., Civil Action No. 03-283 SLR, Dated 3/21/03, U.S. District Court for the District of Delaware
	C601	Declaration Of Eric Simso, Civil Action No. 03-283. Dated 3/20/03, U.S. District Court for the District of Delaware
	C602	Declaration Of Jermone Segal, M.D., Civil Action No. 03-283 Dated 3/20/03, U.S. District Court for the District of Delaware
	C603	Declaration Of Kinam Park, Ph.D., Civil Action No. 03-283 Dated 3/20/03, U.S. District Court for the District of Delaware
	C'604	Defendants' Answer, Counterclaim And Demand For Jury Trial, Civil Action No. 03-283, Filed 4/7/03, U.S. District Court for the District of Delaware
	C605	Opening Expert Report Of Robson F. Storey, Ph.D., Civil Action No. 03-283 SLR, Dated 5/23/03, U.S. District Court for the District of Delaware
	C'606	Opening Expert Report Of Stephen R. Hanson, Ph.D., Civil Action No. 03-283 SLR, Dated 5/23/03, U.S. District Court for the District of Delaware
	C607	Plaintiffs Boston Scientific Scimed, Inc. and Boston Scientific Corporation's Opening Claim Construction Brief. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
	C608	Plaintiffs Boston Scientific Scimed, Inc. and Boston Scientific Corporation's Rebuttal Claim Construction Brief, Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
	C609	Plaintiffs BSC's Memorandum in Support of its Motion for Summary Judgment that Claims 6 and 8 of the '536 Patent are Not Anticipated by the Asserted Prior Art. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
	C610	Plaintiffs BSC's Memorandum in Support of its Motion for Summary Judgment that the Cypher Stent Infringes Claims 6 and 8 of U.S. Patent No. 6,120,536 Patent. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
	C611	Plaintiffs' Opening Brief In Support Of Their Motion For Preliminary Injunction, Civil Action No. 03-283 Filed 3/20/03, U.S. District Court for the District of Delaware
	C612	Plaintiffs' Reply Brief In Support Of their Motion For Preliminary Injunction, Civil Action No. 03-283 SLR, Dated 4/10/03, U.S. District Court for the District of Delaware
V	C613	Plaintiffs' Reply To Defendant's Counterclaim, Civil Action No. 03-283 Filed 4/21/03, U.S. District Court for the

	.		of Application No. 09/910,388
4	N		District of Delaware
		C614	Preliminary Injunction Hearing Transcript, Volume A, Civil Action No. 03-27 (SLR), Dated 7/21/03, U.S. District Court for the District of Delaware
		C615	Preliminary Injunction Hearing Transcript, Volume B, Civil Action No. 03-27 (SLR), Dated 7/22/03, U.S. District Court for the District of Delaware
		C616	Preliminary Injunction Hearing Transcript, Volume C, Civil Action No. 03-27 (SLR), Dated 7/23/03, U.S. District Court for the District of Delaware
		C617	Rebuttal Expert Report Of Kiman Park. Ph.D., Civil Action No.03-283 SLR, Dated 6/2/03, U.S. District Court for the District of Delaware
		C618	Redacted Public Version: Cordis' Opening Markman Brief on the Construction of Terms in the Ding '536 Patent. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
		C619	Redacted Public Version: Opening Brief in Support of Cordis' Motion for Summary Judgment Barring BSC from Asserting Equivalents for Certain Limitations of the Ding Patent. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
		C620	Reply Brief in Support of Cordis' Motion for Summary Judgment Barring BSC from Asserting Equivalents for Certain Limitations of the Ding Patent. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
		C621	Second Declaration Of Jerome Segal, M.D., Civil Action No. 03-283 SLR, Dated 4/10/03, U.S. District Court for the District of Delaware
	-	C622	Second Declaration Of Kinam Park, Ph.D., Civil Action No. 03-283 SLR, Dated 4/10/03, U.S. District Court for the District of Delaware
	\/	C623	Goodnight, S.H., "The Effects of n-3 Fatty Acids on Atherosclerosis and the Vascular Response to Injury", Arch. Pathol. Lab. Med., 117, 102-106, (January, 1993)

EXAMINER Plones	DATE CONSIDERED	11/10/07
*EXAMINER: Initial if reference considered, whether or not citation is in conformar considered. Include copy of this form with next communication to applicant.	nce with MPEP 609; Draw line	through citation if not in conformance and not

	ATTY, DOCKET NO. 10177-211-999	APPLICATION NO.	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Kunz et al.		
	FILING DATE July 20, 2001	ART UNIT	

U.S. PATENT DOCUMENTS							
*Examiner Optials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document			
DOM	Α01	5,405,919	04 11 1995	Keefer et al.			
X	A02	5,464,650	11 07 1995	Berg et al			
1	A03	5.516.781	05 14 1996	Morris et al.			
	A04	5.525.357	06-11-1996	Keefer et al.			
	A05	5.632.981	05/27/1997	Stavedra et al.			
	A06	5.6811.447	07/22/1997	Keefer et al.			
	1117	6.200,558	03/13/2001	Saavedra et al.			
	A08	6,379,660	04/30/2001	Saavedra et al.			
	A09	2002/0119115	08/29/2002	Keefer et al.			

FOREIGN PATENT DOCUMENTS						
*Evaminer Initials)	Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document		
	B01	WO 91/12779	09/05/1991	Medtronic, Inc.		
	B02	WO 94/13268	06/23/1994	Kaplan	 -	
	B03	WO 94/21308	09/29/1994	tedars-Sinai Medical Center	-	

	NON PATENT LITERATURE DOCUMENTS						
*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	·r				
	C01						
	C02						
	C03						
	1/114						
	-		l				

NY1-3944007v1

EXAMINER AND RANGE

DATE CONSIDERED

11/10/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with AIPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet Lof 33

REVISED LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ALLY DOCKLENO	APPERCATION NO
10177-211-999	09:910.388
APPLICANT	
Kunz et al.	
HENG DATE	GROUP
July 20, 2001	1652

U.S. PATENT DOCUMENTS

1 31 4 3 4 3 5 1 1 1	1	T	7				
I NAMINER INITIAI		DOCUMENT NUMBER	DATE	NAMI:	CLASS	SUBCLASS	FILING DA IF APPROPRI
	A01	6.783,543	08 31 04	Jang			
	A02	6.764.507	07 20 04	Shanley, et al.			
	A03	6.689,159	02 10 04	Lau, et al.			
	A04	6.663.881	12/16/03	Kunz. et al.			
	A05	6,656,216	12:02:03	Nossainy, et al.			
	700	6,656,162	12/02/03	Santini Jr., et al.			
	107	6.616,765	09/09/03	Castro, et al.			
	Α08	6.616.690	09/09/03	Rolando, et al.			
	.\09	6.599,928	07/29/03	Kunz, et al.			
	A10	6.596.022	07/22/03	Lau, et al.			
	AH	6,575,993	07/10/03	Yock			
	A12	6.562.065	05/13/03	Shanley			
	A13	6,555,138	04/29/03	Karlsson			
	A14	6,544,790	Q4/08/03	Sabatini	50		
	A15	-6,544,544	04:08/03	Hunter, et al.			
	.116	6.527,789	03/04/03	Lau, et al.			
	A17	6,515.009	02/04/03	Kunz, et al.			
	A18	6.497,647	12/24/02	Tucker TXP	 		
	Δ19	6,492,106	12/10/02	Sabatini et al.			
	Α20	6,491,617	12/10/02	Ogle, eNgl.			
	A21	6.488,694	12/03/02	Lau, et al.			
	A22	6.485.511	11/26/02	Lau, et al.			
	A23	6,476,200	11 05 02	Sabatini, et al.			
	A24	6.461.381	10.08.05	Israel, et al.			
	A25	6.443.982	09 03 02	Israel, et al.			
	A26	6.432,133	08/13/02	Lau. et al.			
	.127	6.429,232	08 06 02	Kinsella, et al.			
	A28	6.395.326	05 28 02	Castro, et al.			
	.129	6,309,414	10 30 01	Rolando, et al.			
	A30	6.309,412	10 30 01	Lau, et al.	-		
	A31	6.306.421	10/23/01	Kunz, et al.			~~~~ ~
	.132	6.251,920	06 26 01	Grainger, et al.		$\overline{}$	
	Λ33	6,241,762	06 05 01	Shanley	—— <u>-</u>		\
· · · · · · · · · · · · · · · · · · ·	.134	6.210,393	04 03 01	Brisken, et al.			
	.\	6,203,536	03 20 01	Berg, et al.			

			-,				or application	i No. 09/910,388
		A36	6,198,016	03/06/01	Lucast, et al.		<u>.</u>	
		Α37	6.187.370	02 13 01	Dinh, et al.			
\		A38	6.168.619	01/02/01	Dinh, et al.			
		A39	6.152.869	11-28-00	Park, et al.			
		.\40	6.146.358	11 14 00	Rowe		†···	
_		.\41	6.133.242	10 17 00 .	Zalewski, et al.			
		.142	6.129.757	10 10 00	Weadock			
		A43	6.120.536	09 19 00	Ding, et al.	-		
		.\44	6.110.483	08 29 00	Whitbourne, et al.	1		
	1	145	6,106,454	08 22 00	Berg, et al.			
		1/4	6,099,562	08 08 00	Ding. et al.			
		147	6,099,499	08 08 00	Ciamacco, et al.			
		A48	0096,070	08 01 00	Ragheb, et al.			
		A49	6,093,142	07/25:00	Kunz, et al.	 	ļ	
	-	A50	6,086,040	07 11 00	Howard, et al.			<u> </u>
		A51	6.074.659	06/13/00	Kunz, et al.			
	+	A52	6.074,337	06:13/00	Tucker et al.		 	
		A53	6.066,167	05/23/00	Lau, et al.	<u> </u>	<u> </u>	·
	+	Λ54	6,042.875	03/28/00	Ding, et al.			
	+	A55	6.036,715	03/14/00	Yock		0 -	
		A56	6,033.866	02/08/08	Falk, et al.			
		Λ57	6.013.099	01/11/00	Dinh, et al.	9		
		A58	6.001,622	12/14/99	Dedhar, et al.	120		
		A59	5,990,095	11/23/99	Falk, et al.	N		
		A60	5.981,568	11/09/99	Kunz, et al.	!		
		Д61	5,980,972	11/09/99	Ding			
		A62	5.972.018	10/26/99	Israel, et al.			
		A63	5.948.639	09/07/99	Ginemo, et al.			
		Α64	5,902,332	05/11/99	Schatz			
			5.900,246	05 '04 '99	Lambert			
		A66	5.877,224	03/02/99	Brocchini, et al.			
	+	Λ67	5.873,904	02/23/99	Ragheb, et al.			
	+	A68	5,863,285	01/26/99	Coletti	$\overline{}$		
	+	A69	5,849,034	12/15/98	Schwartz			
	+	A70	5.847,007	12 08.98	Grainger, et al.			
	+-1	A71	5.843.120	12 01 98	Israel, et al.		\ 	
	++	Λ72	5.837.313	11 17 98	Ding, et al.			
	++	A73	5,837,008	11 17 98	Berg, et al.			
	$\dashv \dashv$	A74	5.824.647	10 20 98	Postlethwaite, et al.			
	+ 1	A75	5.824.054	10 20 98	Khosravi, et al.			\
***************************************	+-+		5.824.049	10 20 98	Ragheb, et al.		<u> </u>	$\overline{}$
	++		5.821,234	10 13 98	Dzau.			
	++		5.811.447	09 22 98	Kunz, et al.		· · · · · ·	
	11		5,800,507	09 01 98	Schwartz			
^-+			5,797,898	08 25 98	Santini Jr., et al.			

		···			of Application	n No. 09 910,388
	.481	5,779,732	07 14 98	Amundson		
7	182	5.773.479	06/30/98	Grainger, et al.		١
	. 183	5.770.609	06 23 98	Grainger, et al.		
	.184	5.767.079	06 16 98	Glaser, et al.		
	A85	5.749.915	05 12 98	Slepian		
	.186	5,749,888	05 12 98	Yock		
	.187	5.747.510	05 05 98	Draper .		
	/188	5.735.897	04 07 98	Buirge		
	170	5,733,303	03 31 98	Israel, et al.		
	A90	5.731.424	03 24 98	Toothman, et al.		
	A91	\$.731,200	03 24 98	Ichijo, et al.		
	.192	5.75(1.144	03 24 98	Toothman, et al.		
	A93	5.726.186	03 10 98	Grese		
	A94	5.722.98-	03 03 98	Fischell, et al.		
	A95	5.705.609	01 06:98	Ruoslahti, et al.		
	A96	5.705.477	01/06/98	Sporn, et al.		}
	A97	5,700,559	12/23/97	Sheu, et al.		
	A98	5,697,967	12.16/97	Dinh, et al.	e	
	A99	5.693.607	12:02:97	Segrini, et al.		
	A100	5,688,855	11/18/97	Stoy, et al.		
	A101	5.688,813	11/18/97	Sall, et al.	-	***
	A102	5,686,476	11/11/97	May		
	A103	5.686,467	11/11/97	Burnol, et al.		
	A104	5,681,835	10/28/97	Willson		
	A105	5.679,400	10/21/97	Tuch		
	A106	5,667,764	09:16:97	Kopia, et al.		
	A107	5,662,712	09/02/97	Pathak, et al.		
	A108	5.660,873	08/26/97	Nikolaychik, et al.		
	A109	5.658.951	08/19.97	Magarian, et al.		
	A110	5,658,927	08/19/97	Magarian, et al.		
	AHI	5.658.883	08/19/97	Ogawa, et al.		
	A112	5.656,587	08:12:97	Sporn, et al.		
	A113	5,656,450	08/12/97	Boyan, et al.		
	AH4	5.652.259	07:29-97	May		
		5.651.627	07 29 97	Dowzall, et al.		
		5.643.580	07 01 97	Subramanian		
	1	5.641,790	06 24 97	Draper		
		5.639.738	06 17 97	Falk, et al.		
		5.639,274	06 17 97	Fischell, et al.		
	A120	5,637,113	06 10 97	Tartaglia, et al.		
		5,635,489	06 03 97	Haley		
	111111	5.632,840	05 27 97	Campbell		
		5,629,077	05-13-97	Turnlund, et al.		
	1 [5,626,600	05 06 97	Horzewski, et al.		
			04 22 97			Į.

		T				of Applica	tion No. 09 910,388
	A126		03 11 97	Draper			
_		5.610.166	03 11 97	Singh			
		5,609,629	03 11 97	Fearnot, et al.			
	.\129	5,607,463	03 04 97	Schwartz, et al.			
	A130	5,605,700	02 25 97	DeGregorio, et al.			
	A131	5,605,696	02 25 97	Eury, et al.			
	A132	5.599.844	02 04 97	Grainger, et al.			
	A133		01 28 97	Brown, et al.			
	A134	5,595,722	11 21 97	Grainger, et al.			
	A\(\)35	5,591,224	01 07 97	Schwartz, et al.			
	A136	5.583,153	12 10 96	Brahn			
	A137	5.580,898	12 03 96	Trojanowski, et al.			
	A138	578,703	11 16 96	lchijo, et al.	1.		
	A139		11 26 96	Dayton	T		
	A140	5,576345	11.19.96	Mansson, et al.			
	A141		11/12/96	Bumol, et al.			
	A142	5.571,808	11/05/96	Leeds			
	Δ143		11/05/96	Dasch, et al.			
	Δ144	5.571,166	11/05/96	Dinh, et al.			
	A145	t	10/29/96	Helmus, et al.			
		5,567,713	18/22/96	Cullinan, et al.			
		5.563.054	10/08/96	Briggs, et al.			
	A148	5,562,922	10/08/98	Lambert			·
	A149	5.556,876	09/17/96	Bryant, et al.		0	
		5,554,182	09/10/96	Dinh, et al.			
		5,552,433	09/03/96	Bryant, et al.		(A)	
		5,552,415	09/03/96	May	1-0		
	A153	5,551,954	09/03/96	Buscemi, et al.	2		
		5.545,569	08/13/96	Grainger, et al.	01		
		5.545,409	08/13/96	Laurencin, et al.			
		5.545,208	08:13:96	Wolff, et al.			
		5.543.155	08:06:96	Fekete, et al.			
		5.541.174	07/30/96	Sorenson			
		5.538.892	06:23:96	Donahoe, et al.			
		5.534.527	07 09 96	Black, et al.			
		5.525.624	06 11 96	Gitter, et al.			
		5.523.092	06 04 96	Hanson, et al.			
		5.521,198 5.521,191	05 28 96	Zuckerman			
		5.521.171	05 28 96	Greenwald			
		5.521.171	05 28 96 05 28 96	Bryant, et al.			
		5.516.807	05 14 96	Sorenson			\
		5.514,154	05 14 96	Hupe, et al. Lau, et al.			
		5.510,370	04 23 96	Hock, et al.			
		5.510.077	04 23 96 7	Dinh, et al.			
	A170 .			Monte Clan.			

						of Application	n No. 09/910,388
	A171	5.508.292	04 16 96	Sall, et al.			
		5,500,013	03 19 96	Buschemi, et al.			
$\overline{}$	A173	5.498.775	03 12 96	Novak, et al.:			
$\overline{}$.\1-4		03-05-96	Grinnell			***************************************
	1 1	5,496,828	03-05-96	Cuttinan	1	1	
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		03 05 96	Feijen, et al.	†		
	Ni I	5.496.346	03 05 96	Horzewski, et al.	 	<u> </u>	
		5.492.927	02 20 96	Gitter, et al.			
	179		02 20 96	Cultinan, et al.	1		
	3180	5,492,922	02 20 96	Pałkowitz			
	A181	5.492.921	02 20 96	Bryant, et al.			
	A182	5,492.895	02 20:96	Vlasuk, et al.			
	A183	5.491.173	02 13 96	Toivola, et al.	1		
	A184	5,491,159	02:13 96	Malamas	 		
	A185	5.489.587	02'06'96	Fontana	 		<u> </u>
	A186	5,486,357	01/23/96	Narayanan	 	·	
<u> </u>	A187	5,484.808	01/16/96	Grinell	 		
	A188	5,484.798	01/16/96	Bryant, et al.			
	A189	5,484,797	Q1/16/96	Bryant, et al.	1		
	A190	5,484,796	01 16/96	Bryant, et al.		 	
<u> </u>	A191	5,484,795	01/16/96	Bryant, et al.		 	
	A192	5,482,950	01/09/96	Bryant, et al.	12	-	
	A193	5,482,949	01/09/96	Black, et al.	4		
	A194	5.482,851	01/09/96	Dorynck, et al.	}/		-
	A195	5,480,904	01/02/96	Bryant, et al.			
	A196	5,480,903	01/02/96	Piggott. et al.			
	A197	5,480,888	01/02/96	Kodama, et al.			
	A198	5.478.847	12/26/95	Draper			
· · · · · · · · · · · · · · · · · · ·	A199	5,472,985	12/05/95	Grainger, et al.	 		
 		5,470,883	11/28/95	Stromberg	 	 	
	A201	5,470,876	11/28/95	Proctor	<u> </u>		
·-·····	1,202	5,466,810	11 14:95	Godfrey			
	A202	5,464,450	11 07 95	Buscemi, et al.			
	A204	5.462.950	10/31/95	Fontana			
	A204	5,462,949	10 31 95	Jones, et al.			
	A205	5.462,937	10 31 95	Cullinan, et al.	\		
	A207	5.461.065	10 24 95	Black, et al.			
	1,7207	5.461.064	10 24 95	Cullinan, G.J.			
	1,3208	5.457.117	10 10 95	Black, et al.			
	A210	5.457,116	10 10 95	Black, et al.			\
	A210	5.457.113	10 10 95	Cullinan, et al.			
	A212	5.455.275	10 03 95	Fontana			\
	A212		09 26 95	Butzow, et al.			
	.\213	5.453.442	09 26 95	Bryant, et al.			
	1 1.32141	- · · · -		•			

		,	· · · · · · · · · · · · · · · · · · ·	·,···	от Аррисаног	No. 09 910,388
	5,451,590	09 19 95	Dodge			
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	5.451,589	09 19 95	Dodge			
.1218	5,451,414	09 19 95	Steward			
.1219	5.451.233	09 19 95	Yock			
.\220	5.449.382	09 12 95	Dayton			· · · · · · · · · · · · · · · · · · ·
1,1221	5.447.941	09 05 95	Zuckerman			
A222	5.447.724	09 05 95	Helmus, et al.			····
A223	5,446.070	08 29 95	Mantelle			
.\224	5.446,053	08 29 95	Keohane			
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	5,445,941	08 29 95	Yang			
1 1 226	5,443,458	08 22 95	Eury			
A227	5,441,986	08:15:95	Thompson			·- · · · · · · · · · · · · · · · · · ·
	5.441.966	08:15:95	Dodge			
I ! I	5,411.965	08/15/95	Sall, et al.			
L	5.44 1964	08/15/95	Bryant, et al.			
A231	5,441.734	08/15/95	Reichert, et al.			·····
1 1 1 2 2 2	5,439,931	08/08/95	Sales			
	5,439,923	08/08/95	Cullinan			
	5.439.689	08/08/95	Hendrickson, et al.			
A235 S	5,436,243	07/25/95	Sachs, et al.			
	5,434.166	0X/18/95	Glasebrook			
	5,429.634	07/04/95	Narcisco, et al.			
		07/04/93	Keogh	١. ٥	į.	
A239 5	5,426.123	06/20/95	Fontana	X		
A240 5	5,424,331	06/13/95	Shlyankevich	0		
		06/06/95	Lau, et al.	V		
		05/30/95	Ogawa, et al.	1		
		05/30/95	Narciso, Vr.			
		05/23/95	Williams	1		
		05/16/95	Lee, et al.			
		05/02/95	Bockow, et al.			
			Hattner .			
			Tice, et al.			
	i		Sauvage, et al.			
			Hanson			
			Labrie, et al.			
			Labrie, et al.			
			Cullinan, et al.			
			Sanderson			
			Fontana			
<u></u>			Fontana		-	
L			Scott, et al.			
			Fearnot, et al.			
A259 5.			Smith, et al.			\
A260 5.	.526.455	10 18 94	Rowland, et al.			1

,						of Applicat	tion No. 09 910,388
		5.354.801	10 11 94	O'toole, et al.			
	.120	52 5.344,926	09 13 94	Murakata, et al.			
	.\20	5.342.926	08 30 94	Hattner			
	* .\20	5.342.348	08 30 94	Kaplan			
	120	55 5.338.770	08 16 94	Winters, et al.		-	
	.120		07 26 94	Mantelle			
	1,120	,= 5.324.739	06 28 94	Germick, et al.	† <i>*</i>	 	
	1,120		06 07 94	Hakamatsuka, et al.			
	120	5.308.889	05 03 94	Rhee, et al.		<u> </u>	
•••	1/2		04 19 94	Sahatjian		-	
	A2°	5,302,584	04 12 94	Kao, et al.			
	1/27	2 5.292.802	03 08 94	Rhee, et al.			
	Λ27	 	03.01.94	Jernberg		<u> </u>	+
	.\27		02:01:94	Schwartz, et al.	1	 	
	Λ27	·	01 18 94	Labroo, et al.			
	A27		11/16/93	Winters, et al.		-	
	A27		11/16/93	Iwata, et al.			
	A27	<u> </u>	11/02/93	Froix			
	1,127		Q8/10/93	Mantelle	 		+
	* A28		08/10/93	Silverstrini		 	-
	A28		07/13/93	Pinchuk	-	-	_
	A28		06/29/93	Willard, et al.	 		
	A28		06/01/93	Sorenson		 	
	A28	1.5.1.5.0	05/18/93	Ishiguro, et al.		<u> </u>	
	A28	5 5.199.951	04/06/93	Spears	6.0		
	Α28	6 5.195.984	03/23/93	Schatz			
	.128	7 5.185,408	02/09/93	Tang, et al.	2		
	A28	8 5,182,317	01/26/93	Winters, et al.	KY-		
	A28	9 5.180,376	01/19/93	Fischell	12		
	.129	0 5.167,960	12/01/92	Ito, et al.			
	A29	1 5.166,191	11/24/92	Cronin, et al.			
	A29	2 5,163,952	11-17-92	Froix			
	A29	3 5.145.838	09/08/92	Pickart			
	A29	5.145.684	09 08 92	Liversidge, et al.			
	A29	5 5,126,348	06.30/92	McMurray.		•	
	A29	5.118.791	06 02 92	Burnier, et al.			
	A29	5.114.847	05 19 92	Jungfer, et al.			
	.329	5.108,989	05 28 32	Amento, et al.		T-01-1	
	.\29'	5.102.417	04 07 92	Palmaz	1	$\overline{}$	
	. A300	5,100,885	03 31 92	Abrams, et al.		$\overline{}$	
	. \. \. \. \. \. \. \. \. \. \. \. \. \.	5.099,504	03 24 92	Pettit	,		
	. \. \. \. \. \. \. \. \. \. \. \. \. \.	5.092,877	03 03 92	Pinchuk			
	. \. \. \	5.082,834	01 21 92	Sorenson			
	.\\ \.\\ \.\\ \.\.\.\.\.\.\.\.\.\.\.\.\		12 24 91	Schreiber			
	A305	5.064.435	11 12 91	Porter			

		,	·			or Application	n No. 09/910.388
	A306	5.061.275	10 29 91	Wallsten, et al.			
	A307	5.061.273	10/29/91	Yock			
	A308		10 01 91 -	Pinchuk, et al.			
	.\309	5.040.548	08 20 91	Yock			
	1310	5.037.641	08 06 91	Juhos, et al.			
	A341	5.034.265	07 23 91	Hoffman, et al.			
	A312	5.030,637	07 09 91	Einzig, et al.			
	A313	5.023.237	06 11 91	Pickart, et al.			
	V 314	5.019,504	05 28 91	Christen, et al.			
	1.715	5,008,279	04 16 91	Franckowiak, et al.			
	.1316	5.002,531	03 26 91	Bonzel			
	A317	4099.347	03 12 91	Sorenson			
	.3318	4,996,225	02:26 91	Toivola, et al.			
	A319	4.994.384	02 19/91	Prather, et al.			
	A320	4.994.071	02-19/91	McGregor			
	л321	4,990,158	02/05/91	Kaplan, et al.			
	A322	4,984,594	01/15/91	Vinegar, et al.			
	A323	4,973,755	11/27/90	Gafe. et al.			
	A324	4,973,601	1/27/90	Dowd, et al.			
	Λ325	4,959,355	09/25/90	Fischbarg, et al.			
	A326	4,956,188	09/11/90	Anderson			
	Λ327	4.954.126	09/04/90	Wallsten			
	A328	4.952,607	08/28/90	Sorenson			
	A329	4.922.905	05/08/90	Strecker			
	A330	4,916,193	04/10/90	Tang, at al.	V	フ	
,	A331	4.900.561	02/13/90	Abdel-Mouem, et al.	3		*
	A332	4.886.062	12/12/89	Wiktor	()		
	4333	4.872,867	10/10/89	Joh, et al.	5		
		4.853,377	08/01/89	Pollack,			
	1335	4,840,939	06/20/89	Leveen, et al.			
/	1336	4.824,661	04/25/89	Wagner			
		4.793.348	12/27/88	Palmaz			
		4.786.500	11/22/88	Wong			
		4,776,337	10.11/88	Palmaz			
/			08/30/88	Breccia, et al.			
			08 09:88	Bonzel			
			07 26 88	Pickart			
			07 19 88	Sorenson			
			07 19 88	Sorenson, et al.			
				Sorenson			
				Langer, et al.			
1 1 1				Horzewski, et al.			
				Palmaz			
				Palmaz			
	1350	4.705.647	11 10 87	Yamaguchi, et al.			

,		T	T	T	1	1
		4.696.949	08 29 87	Toivola, et al.		
		4.689.046	08 25 87	Bokros	ļ	
		4.687.482	08 18 87	Hanson		
		4.678.466	07 07 87	Rosenwald		
	A355	4.670.428	06 02 87	Sorenson		
	. \. \. \. \. \. \. \. \. \. \. \. \. \.	4.664.097	05 12 87	McGrath, et al.		
	A357	4,657,928	04 14 87	Sorenson		
	.1358	4.656.083	04 07 87	Hoffman, et al.		
	359	4.655.771	04 07 87	Wallsten		
	A304	4.629.694	12 16 86	Harpel		
	A361	4.613.665	09 23 86	Larm		
	A362	4.805.644	08:12:86	Foker		
	A363	4,536,516	08/20-85	Harper, et al.		
	A364	4,491.574	01/01/85	Seifter, et al.		
	A365	4.487.780	12/11/84	Scheinberg		
	A366		04/03.84	Sorenson		
	A367	4,428,963	01/31/84	Confalone, et al.		
	A368	4,418,068	11/29/83	Jones		
	A369	4,382,143	05/03/83	Shepherd		
	A370	4.380.635	04/19/83	Peters		
	Α371	4.339,429	07/13/82	Raaf, et al.		
	A372	4,332,791	06/01/82	Raaf, et al.		
	A373	4.323.707	04/06/82	Suarez, et al.	0/	
	A374	4,317,915	03/02/82	Confalone, et al.	X	
	A375	4.315,028	02/09/82	Scheinberg		
	A376	4,310,523	01/12/82	Neumann		
		4,307,111	12/22/81	Crawley		
		4,300,244	11/17/81	Bokros '\		
		4,292,965	10/06/81	Nash, et al.		
	A380	4.287.190	09/01/81	Boettcher, et al.		
	A381	4,282,246	08-04/81	Holland		
	.3382	4,239,778	12/16/80	Venton, et al.		
	A383	4,230,862	10/28/80	Suarez, et al.		
	A384	4,221.785	09.00.80	Sorenson		
	A385	4.219.656	08/26/80	Press, et al.		
	.1386	4.219.520	08/26/80	Kline		
	A387	4,205,685	06 03 80	Yoshida, et al.		
	.\388	4.133.814	01 09 79	Jones, et al.		
	A389	3.952.334	04 27 76	Bokros, et al.		
	A390	L	01-13-76	Margaf		
	. \. \. \. \. \. \. \. \. \. \. \. \. \.	3,879,516	04 22 75 .	Wolvek		
	.\392	3.738.365	06 12 73	Schulte		
	. \. \. \. \. \. \. \. \. \. \. \. \. \.	3.634.517	01 11 72	Palopoli, et al.		
·	.\394	3,526,005	09 01 70	Bokros, et al.	•	
	A395	3.445.473	05/20/69	Ruschig, et al.		

					The state of the s
2	.\396	3.288.806	11 29 66	Dewald, et al.	
	A397	3.279.996	10 18 66	Long, et al.	
	A398	3.168.565	02 02 65	Palopoli, et al.	
	.\399	3.010.965	11 28 61	Elpern	
	1400	2.914.563	11 24 59	Allen, et al.	
1	1401	2004 0236416	11 25 04	Falotico	
	1402	2002 0091433	07 11 02	Ding, et al.	
	11403	2002-0032477	03 14 02	Helmus, et al.	
	7407	2002 0013275	01 31 02	Kunz, et al.	

	7404	2002 0013273	01.710=	Kunz. Ct ar.		LL		
		\						
			FOREIG	N PATENT DOCUMENTS				
	I	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	IRANSL.	AHO
					γ · ·		YES	N.
<u> </u>	<u> </u>	31079-93	07 15 93	Australian Patent Application	<u> </u>		·	!
	. B02	03-297469	12 27:91	Japan (with English abstract)				,
	B03	06-121828	06/05/94	Japan (with English abstract)			<u> </u>	<u></u>
<u> </u>	B04	06-205838	07/26/94	Japan (with English abstract)				
	1 B05	08-33718	02/06/96	Japan (with English abstract)				<u>.</u>
	306	09-255570	03/21/96	Japan				! !
	B07	59-042375	03/08/84	Japan	i		!	
	B08	60-25288	02/01/94	Japan		-		
!	B09	1 015 787	01/05/96	United Kingdom				
i	Bio	1 587 084	05/25/81	United Kingdom	7			
	B11	2 273 873	06/07/94	United Kingdom		101	i	
	B12	: 1 205 743	07/15/96	United Kingdom		7		
	B13	2 153 253	01/25/85	United Kingdom	0	0		
	B14	2.231,727	09/14/04	Canada	12	J		
	B15	2.079.205	03/26/94	Canada				
	! B16	2.086.642	07/10/93	Canada	71			
	B17	2.207.659	06/13/96	Canada	$\mathcal{M}_{\mathcal{A}}$:	
	B18	2255063	07:18:75	France	4			
	B19	4320896	01/05/95	Germany				
	B20	4320898	01/05/95	Germany		··· · · · · · · · · · · · · · · · · ·	······································	
	821	4401554	08 18 94	Germany	/ <u>,</u> ,			· · · · ·
	. ;	DE A 3 918 736	. 12/13/90	Germany (with English abstract)				·
!	B23	DE A 40 22 956	02 06 92	Germany (with English abstract)				
	B24	: - 1247527	04 24 91	Italy	· /.	· · · · · · · · · · · · · · · · · · ·		
	B25	EP 0 095 875 A2	12 07 83	Europe		\ :	•	
•	B26	ËP 0 002 341	06 13 79	Europe		\ ·	•	
•	B27	EP 0 024 096	02 25 81	Europe		/		
•	B28	- EP 0-054-168-A1	06 23 82	Hurope		. ;	\ ·	
	. B29	EP 0 524 093	01 20 93	Europe			/	
. '	B30	- EP 0 566 245 A1	10/20/93	Europe			,	
• •	. B31	EP 0 578 998	01 1994	Lurope			•	`
•	B32	EP 0 604 022 A1	06 29 94	Europe	•	•	, ,	
•	B33	EP 0 619 314	: : 10:12 94	Europe	: 4	•	•	
:					. :	!	. :	

				•			Sheet 11 of 3.	3 of fast of Refere	inces
						·· · · · · · ·	of Applic	cation No. 09 910	1,388
	B34	EP 0 621 015 A1	04 23 04	Europe					
\	B35	EP 0 623 345 A1	05 03 94	Europe					
\	. B36	EP 0 639 577	02 22 95	Europe	,				
\	. B37	EP 0 673 936	09 27 95	Europe					_
	B38	EP 6 701 802 A4	03/20/93	Europe					
	B39	EP 0 706 376 BT	06 25 97	Europe	·				•
	B40	EP 0 716 836 A1	12 11 95	Europe					-
*	B41	EP 0 717 041 B1	06 19 96	Europe				, ,, 	
	1,42	EP 0 734 721 A2	10 02 96	Europe					 ·
*	B4.	EP 0 747 069	12 11 96	Europe			· · · · · · · · · · · · · · · · · · ·	· ··	
	1344	EP 0 975 340	10 08 98	Europe					1
	.,	ER 1 360 967 A1	11.12:03	Europe		·····			1
	B46	EP \ 0.430.542	11 20 90	Europe					·
<u></u>	B47	EP A 0435 518	12 13-90	Europe					
, - ·· —————————————————————————————————	: B48	EP 0 290 012	11/09/88	Europe				·	!
<u> </u>	1 B49	EP 0 302 034	02:01:89	Europe	·				ļ .
; :	B50	EP 0 635 270	01/25-95	Europe	* ***				<u></u>
	÷	EP 0 377 526B1	107/11/90	Europe			·· i		<u></u>
	-B51	EP 0 524 093	01/20/93	Europe					
	B52	EP 0 542 679	05/19/93	Europe					
· · · · · · · · · · · · · · · · · · ·	B53	EP 0 551 182	07/14/93	Europe					<u> </u>
*	B54	EP 0 623 354	11/09/94	<u> </u>					
	B55	EP 0 629 697	12/21/94	Europe					
····	B56	1	<u> </u>	Europe					
	B57	EP 0 639 577	02/22/95	Europe					
	B58	EP 0 659 413 A2	06/28/95	Europe					
	B59.	EP 0 659 415 A2	06/28/95	Europe					
	B60	EP 0 659 418	06/28/95	Europe			ا(ه_		
	B61	EP 0 659 419 A1	06/28/95	Europe		<u> </u>	<i>y</i>		
	B62	EP 0 659 429 A1	06/28/95	Europe		N	<u> </u>	: 	
	B63	EP 0 664 121	1.7/26/95	Europe	\\{\				
	B64	EP 0 664 122	07/26/95	Europe	/ ///				
	B65	EP 0 664 123	07:26/95	Europe	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		i		
. <u> </u>	B66	EP 0 664 124 A1	07 26/95	Europe		i			
	В67	EP 0 664 125	07 26 95	Europe			,		
1	B68	EP 0 664 198	07 26 95	Europe	7		!	: :	
:	: В69	EP 0 665 015 A2	08 02 95	Europe	\	·- • • ·- ·		!	
	B70	EP 0 668 075 A2	08 23 95	Europe					
	B71	EP 0 670 162	09 06 95	Europe		· · · · ·			
***	B72	EP 0 673 936	09 27 95	Europe	<u> </u>	./.			
•	В73	EP 0 674 903	10 04 95	Europe	•	/	•		
	 . B74	EP 0 675 121	10 04 95	Europe	•	. \			
•	B75	EP 0 684 259 AT	11 29 95	Europe		•	/.		
•	. 1376 - 1376	EP 0 699 673	03 06 96	Europe		•		•	
	. 1770 . 1877	EP 0 734 721 A2	02 10 96	Europe			. /	• -	
	В78	WO 00 00238	01 06 00	PCT		•	\		
	. 1773 . B79	WO 0047197	. 08 17 00	PCT			•		
NYI-3900293V7				•	•	;	•		

•					She		ist of References
<u> </u>	J			1207		of Application	No. 09 910,388
	380	WO 89 03232	04 20 89	PCT			
		WO 90 07328	07 12 90	PCT			
	\ B82	WO 91 08291	06 13 91	PCT			
	$\sqrt{883}$	- WO 91 17789 AT	11 28 91	PCT			
	1384	- WO 91 18940 A1	12 12 91	PCT			
	B8.	WO 92 00330	01 09 92	PCT		,	
	B86	WO 92 06068	04 16 92	PCT			
	B87	NO 92 13867	08 20 92	PCT			
	B88	W 0 92 19612	11 12 92	PCT			
,	B89	WO 98 02065	02 04 93	PCT			
Townsenson	B90	. N.O 33 g-1151	03 04 93	PCT			
	B91	WO 93 09 2 28	05-13-93	PCT	-q	!	:
	B92	WO 93 09790	05:27 93	PCT			· · · · · · · · · · · · · · · · · · ·
	, B93	WO 93/09800	05 27 93	PCT	· †	1	:
	B94	WO 93-09802	05.27 93	РС"Г	!	· ! -	1
	B95	WO 93/10808	06/10/93	PCT	1		
	B96	WO 93/11757	06/24/93	PCT		†	
	B97	WO 93/16724	09:02 93	PCT	 	<u> </u>	· i
	B98	WO 93/19746	10/14/93	· PCT	<u> </u>		
	B99	WO 93/19769	10/14/93	РСТ	-		
	B100	WO 94/01056	01/20/94	РСТ		<u> </u>	
	B101	WO 94/02595	02/03/94	РСТ	-		
	B102	WO 94/07529	04/14/94	PC.1	18/		
	B103	WO 94/09010	04/28/94	PCT		 	
	B104	WO 94/09764	05/11/94	PCT	<i></i>		
	B105	WO 94/09812	05/11/94	PCT	` 		
	B106	WO 94/10187	05/11/94	PCT	:		
*	B107	WO 94/13706	06/23/94	PCT		 	
	B108	WO 94/15589	07/21/94	PCT	T	 	
	B109	WO 94'16706	08:04:94	PCT V	!	 -	
	B110	WO 94/20098	09/15/94	PCT	 	<u> </u>	
	B111	WO 94/20099	09:15:94	PCT	 	·	i i
	B112;	WO 94/20116	09/15/94	PCT		 	
i	B113	WO 94 20117	09/15/94	PCT	†	<u> </u>	
	B114;	WO 94 20126	09:15:94	PCT	<u></u>	.	 !
ļ	A	WO 94 20127	09 15 94	PCT	./		,
	B116	WO 94 21309	09-29-94	PCT	/		4
		WO 94 23068	: 10 13 94	PCT	· · · · · · · · · · · · · · · ·	··· ·· · · · · · · · · · · · · · · ·	
		WO 94 23699	10 27 94	PCT	• .	-\ .	
		WO 94 24961	 11 10 94	PCT	•	. /	
•		WO 94 25053	11 10 94	PCT	•	. \	
•	B121	WO 94 25588	- 11-10-94	PCT	•	. /	
•		WO 94 26291	- 11 24 94	PCT	•		
		WO 94 26303	11 24 94	PCT			
		WO 94 26888	10 06 95	PCT	•	: .	
•			12 08 94	PCT	•		
NVL-1900293C7		;		•	•	•	: ~

			Sheet 13 of 35 of 1 ist of References
	B126 WO 95 04544	02 16 95	Of Application No. 09 916,388
	1127 WO 95 05191	02 23 95	PCT
	BIES WO 95 10611	04 20 95	PCT
	B128 WO 95 17095	06 29 95	PCT
•	B130 WO 95 19987	07 27 95	PCT
	B131 VO 95 20582	08 03 95	PCT
	B132 W 95 30900	11 16 95	PCT
	B133 WO 95 33736	12 14 95	PCT
	B134 WO % 01102	01 18 96	PCT
	* B135 WO 96 03092	02 08 96	PCT
	B136 WO 96 0 402	03 14 96	PCT
	B137 WO 96:15-24	05 23 96	PCT
	B138 WO 96 20698	07 11 96	PCT
	B139 WO 96 21442	07.18.96	PCT
!	B140 WO 96/21443	07 18-96	PCT
·	B141 WO 96/24356	08/15/96	PCT
1	* B142 WO 96/25176	08/22/96	PCT
	B143 WO 96/32907	10/24/96	PCT
	B144 WO 96/36349	11/2//96	PCT
 	B145 WO 96/40098	12/19/06	PCT P D
	B146 WO 97/10011	03/20/97	PCT
ļ <u>.</u>	B147 WO 97/10334	03/20/97	PCT
	B148 WO 97/15319	05/01/97	PCT
	B149 WO 97/21455	06/19/97	PCT
	B150 WO 97/22697	06/26/97	PCK
	B151 WO 97/33552	09/18/97	PCT
	B152 WO 97/45105	12/04/97	PCT
	OTHER REFER	ENCES (In.i.)	Juding Code Tide Date Date D

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
C.01	"Breast Cancer Prevention Trial Should Resume. ODAC Says". The Breast Cancer Letter, 20, 4-5, (June 17, 1994)
C02	"Churchill's Medical Dictionary", definition of "cytostytic", 473, (1989)
C03	"Coronary Artery Disease: Restenosis and Reocclusion After Surgical and Nonsurgical Interventions, Part 1", Durg and Market Development, 5, 121-129 (Sept. 26, 1994)
C'04	"Glaxo Wellcome Preclinical Data: Preclinical studies conducted with GW 5638, a selective estrogen receptor modulator developed by Glaxo Wellcome, indicate that the compound acts both as an agonist and antagonist at estrogen receptor within specific", R & D Focus Drug News (September 8, 1997)
C05	"Growth Factor Via Gene Therapy Abates Sore Rheumatoid Join's", BioWorld Today: The Daily Biotechnology Newspaper, 9(115), Leff, David N., Editor, T. (June 17, 1998)
C06	"Health Report The Good News", Time, 23, (Apr. 1, 1996)
C07	"Heparin", In: Modern Pharmacology, Craig, C.R., et al., (eds.), Little, Brown and Company, Boston, MA, p. 399, (1982)
C 08	"ICLU nited States, Inc., Tamoxifen citrate, Summary For Basis of Approva", (December 30, 1977)
C'09	"Johnson & Johnson receives FDA approval to market Palmaz Balloon-expandable Stent for iliac arteries," Business Wire, Oct. 2, 1991.
C10	"Micellar and Lyotropic Liquid Crystalline Phases Containing Nonionic Active Substances". In: Lyotropic Liquid Crystals and the Structure of Biomembranes. S. Fribert, (ed.), Advances in Chemistry Series, No. 152, American Chemical Society, 28-42, (1976)
CH	"Muscle-Binding Gene Sees Two-Track Payoff: Human Therapies, Animal Meat", BioWorld Today: The Daily Biotechnology Newspaper, 8(85), Leff, David N., Editor, 1-3, (May 2, 1997)
C12	"Prevention of Coronary Heart Disease". In: Avery's Drug Treatment — Principles and Practice of Clinical Pharmocology and Therapeutics. Speight. T. M., (ed.). Williams and Wilkins, Baltimore, 594-59, (1987)
C13	"Quantikine Human TGF-betal Immunoassay", Product Brochure, Catalog No. DB100, R&D Systems, Inc., pp. 1-

(of Application No. 09 910,3X8
		19 (3 1996)
	C14	"Schering Orion Fareston Anti-Estrogen for Treatment of Metastatic Breast Cancer 'Similar' to Tamoxifen, FDA Oncologic Committee Says in Approval Vote", F-D-C Reports, 15-16, (Oct. 23, 1995)
	C15	"Shiga Medical Center for Adult Diseases, "The Impact of Tranilast on Restenosis Following Coronary Angioplasty: The Tranilast Restenosis Following Angioplasty Trial (TREAT)", Circulation, 90, 1-82, Abstract No. 0, (October 1988)
	C16	"Tamoxifen therapy found safe for survivors of breast cancer", Fred Hutchinson Cancer Research Center Newsletter, 1(21), (October 1995)
	C17	"Toprol NETM Tablets", In: Physician's Desk Reference., 658-660, (Probably 1992)
	C18	Agarwal, A.K., et al., "Estrogen Receptor-Binding Affinity of Tamoxifen Analogs with Various Side Chains and their Biologic Profile in Immature Rat Uterus", Steroids, 56, 486-489, (1991)
	(/19	AinMelk, Y., et al., "Tamoxifen Citrate Therapy in Male Fertility", Fertility and Sterility, 48, 113-117, (July 1987)
	C39	Alberts, B. et al., "Molecular Biology of the Cell" 2 nd edition 1989, p653
	C21	Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of Alberts, B., et al., "Actin Filaments are Continually Fi
	C22	Adderson, T. 1990 "New targets for cancer chemotherapy poly(ADP-ribosylation) processing and polyisoprene metabolism." Biol. Rev. 65:623-641
	C23	Aldridge, D.C., et al., "The Structures of Cytochalasins A and B", J. Chem. Soc., 17, 1667-1676, (1967)
	C24	Alich, A.A., et al., "Comparison of Aspirin and Copper Aspirinate with Respect to Gastric Mucosal Damage in the Rat", Journal of Pharmaceutical Sciences, 72, 1457-1461, (Dec. 1983)
	C25	Alich, A.A. et al., "Gastric Mucosal Damage Due to Aspirin and Copper Aspirinate Assessed by Gastric Mucosal Potential Difference Changes", Journal of Pharmacological and Toxicological Methods, 27, 245-250, (Jul. 1992)
	C26	Alich, A.A., et al., "Response to: 'The Ulcerogenic Potential of Copper Aspirinate Seems to be More Imaginary than Real", Journal of Pharmaceutical Sciences, 73, Open Forum, 1876-1877, (Dec. 1984)
	C27	Allemann, et al., "Distribution, Kinetics, and Elimination of Radioactivity after Intravenous and Intramuscular Injection of 14C-Savoyepoine Loaded Poly (D.Llactic acid) Nanospheres to Rats", J. Controlled Release, 29, 97-104, (1994)
	C28	Allen, K.E., et al., "Evidence For The Metabolic Activation of Non-Steroidal Antioestrogens: A Study of Structure-Activity Relationships", Br.J. Pharmac., 71, 83-91, (1980)
	(29	Allen, R.E. & Boxhor, L.K. "Inhibition of skeletal muscle satellite cell differentiation by gransforming growth factor-beta," J Cell, Physiol. 133:567-572,(1987)
·	C30	Allgemeine und spezielle Pharmakologie und Toxikolgie, by W. Forth et al. 1984, pages 524-531 and 627-633
	C31	Alvarado, et al. "Evaluation of Polymer-Coated Balloon Expandable Stents in Hile Ducts." Radiology 165 (suppl.):33 1 (1987)
	C32	Anderson et al., "Restenosis after coronary angioplasty," J. Interv. Card ol., 6(3)187-202 (1993)
	C33	Ando et al., "Chimeric DNA-RNA hammerhead ribozyme talgating transforming growth factor-beta 1 mRNA inhibits neointima formation in rat carotid artery after balloon/in/ury", Eur. J. Phamacol., 438:207-14 (2004)
	C34	Anker, et al., "Plasma Levels of the Atherogenic Amino Acid Homocysteine in Post-Menopausal Women with Breast Cancer Treated with Tamoxifen", Int. J. Cancer, 60, 365-368, (1995)
	C35	Arao, Y., et al., "A synthetic oestrogen antagonist, amoxifen, inhibits oestrogen-induced transcriptional, but not post-transcriptional, regulation of gene expression", Biochem, J., 313, 269-274, (1996)
	C36	Askelband et al., "Rapamycin Inhibits Spontaneous and Fibroblast Growth Factor Beta-Stimulated Prolifereation of Endothelial Cells and Fibroblasts," Transplantantion Proceedings, 23 2833-2836 (1991)
	C37	Assoian et al., "Transforming growth factor-beta in human platelets: identification of a major storage site, purification, and characterization", J. Biol. Chem. 258:7155-7160 (1983)
	C38	Assoian, R.K., et al., "Cellular Transformation by Coordinated Action of Three Peptide Growth Factors from Human Platelets", Nature, 309, 804-806, (June 28, 1984)
	C39	Babaev, et al., "Heterogeneity of smooth muscle cells in atheromatous plaques of human aorta," Am J. Pathol. 136:1031-1042. (1990)
	C40	Bailey et al., "Polymer Coating of Palmaz-Schatz Stent Attenuates Vascular Spasm after stent placement," Circulation 82:III-541 (1990)
	C41	Baim, D.S., et al., "Nonatherosclerotic Coronary Heart Disease", In: The Heart Arteries and Veins, Sixth Edition, Logue, R.B., et al., (eds.), McGraw-Hill Book Company, New York, 1016-1025 (1986)
	C42	Bang, H.O., et al., "The Composition of the Eskimo Food in North Western Greenfund", Am. J. Clin, Nutr., 33, 2657-2661, (1980)
	C43	Baquial, J.G., et al., "Down-Regulation of NADPH-Diaphorase (Nitrie Oxide Synthase May Account for the Pharmacological Activities of Cu(II)sub2G.5-Diisopropylsalicylate)sub4J. Inorganic Bibchem., 60, 133-148, (1995)
	(.11	Baral, E., et al., "Modulation of Lymphokine-Activated Killer Cell-Mediated Cytotoxicity By Extradiol and Tamoxifen", Int. J. Cancer. 66, 214-218, (1996)
	C45	Barbucci, et al., Coating of Commercially available materials with a new heparinizable material, 199 pp. 1259-

1)		Sheet 15 of 33 of Fist of References
		of Application No. 09 910,388
		Baringa, "Gene Therapy for Clogged Arteries Passes Test in Pigs", Science, 265, 738 (Aug. 5, 1994)
	C46	Barmard, et al., "Regulation of intestinal epithelial cell growth by transforming growth factor-beta," Proc. Natl
	(47	Acad. Sci. USA 86:1518-1582.(1989)
	C48	Bassing et al., "FKBP12 is not required for the modulation of transforming growth factor beta receptor I signaling activity in embryonic fibroblasts and thymocytes", Cell Growth Differ., 9(3):223-8 (1998)
	CY"	Battegay et al., "TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop", Cell, 63(5):5-524 (1990)
· · · · · · · · · · · · · · · · · · ·	C50	"Duraflo Biocompatible Treatment", Baxter Healthcare Corp., 1995
	C51	Beck, L., et al., "Vascular Development: Cellular and Molecular Regulation", The FASEB Journal, 11, 365-373, (1997)
	C52	Benita et al., "Submicron Emulsions as Colloidal Drug Carries for Intravenous Administration: Comprehensive Physicochemical Characterization", Journal of Pharmaceutical Sciences, 82, (November 1993)
	C53	Bergstrom, Reduction of fibrinogen adsorption on PEG-coated polystyrene surfaces, 1992, p. 779-790, Baxter Healthceare Corp. Duraflo Biocompatible Treatment
	C'54	Bernhardt et al., "Acetylsalicylic acid, at high concentrations, inhibits vascular smooth muscle cell proliferation", J. Cardiovasc, Pharmacol., 21(6):973-6 (1993)
	C55	Berven, L.A., et al., "Cellular Function of p70\$6K: A Role in Regulating Cell Motility", Immunology and Cell Biology, 78, 447-45 \(\) (2000)
	C56	Bier et al., "Arterial Remodeling: Importance in Primary Versus Restenoic Lesions", JACC, p. 139A, Abstract No. 875-96 (February 1994)
	C57	Billmeyer, F., Textbook of Polymer Science (2d ed.) John Wiley & Sons, Inc. (1971)
	C58	Binmoeller, et al., "Silicone-Covered Expandable Metallic Stents in the Esophagus: An Experimental Study" Endoscopy 1992; 24:416-20.
	C59	Bittiner, S.B., et al., "A Double-Blind, Randomised, Placebo-Controlled Trial of Fish Oil in Psoriasis", The Lancet, 1, 378-380, (Feb. 20, 1988)
	C60	Bjorkerud, "Effects of transforming growth factor-betal on human arterial smooth muscle cells in vitro", Arterioscler, Thromb., 11(4):892-902 (1991)
	C61	Block, P.C. "Coronary-artery stents and other endoluminal devices," New Engl. J. Mod 1991: 324-52-3
	C62	Bluming. "Hormone Replacement Therapy: Benefits and Risks for the General Postmenopausal Female Population and for Women with a History of Previously Treated Breast Chice.". Seminars in Oncology, 20, 662-674, (December 1993)
	C63	Bohmova et al., "Effect of sirolimus on ischemia/reperfusion injury in transpenic hypertensive rat", Transplant Proc., 34(8):3051-3052 (2002)
	C,94	Border, W.A., et al., "Targeting TGF-Beta for Treatment of Disease", Nature Medicine, 1(10), 1000-1001, (October 1995)
	C65	Boscoboinik et al., "Alpha-tocopherol (vitamin E) regulates vascular smooth muscle cell proliferation and protein kinase C activity", Arch. Biochem. Biophys., 286(1):264-9 (1991)
·	C.00	Boyle, "Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture", Curr. Vasc. Pharmacol., 3(1):63-8 (2005)
	C'67	Brand, C., et al., "Transforming Growth Factor Betal Decreases Cholesterol Supply to Mitochondria via Repression of Steroidogenic Acute Regulatory Protein Expression", The Journal of Biochemistry, 273(11), 6410-6416, (1998)
	('68	Braun-Dullaeus et al., "Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin". Arterioscler Thromb Vasc
	C.9a	Biol. 21(7):1152-58 (2001) Brem et al., "Polymers as Controlled Drug Delivery Devices for the Treatment of Malignant Brain Tumours." European Journal of Pharmaceuticals and Biopharmaceutics, 1993, Vol. 39, No. 1, pp 2-7
	C70	Brody, J.E., "Study Finds New Estrogen Offers Benefit Without Risk", The New York Times, A32, (December 4, 1997)
	C71	Brott et al., "Vessel Remodeling After Angioplasty: Comparative Anatomic Studies", JACC, p. 138A, Abstract No. 875-43 (February 1994)
	C72	Burr, M.L., et al., "Effects of Changes in Fat, Fish and ibre Intakes on Death and Myocardia Reinfarction: Diat and Reinfarction Trial (DART)", The Lancet, 757-761, (Sep. 30, 1989)
	C73	Burton, T.M., "Lilly Osteoporosis Treatment Shows Promise", The Wall Street Journal, p. A3, A6 (June 6, 1997)
	C74	C. Chamsangavej et al., A New Expandable Metallic Stent for Dilation of Stenotic Tubular Structures. Experimental and Clinical Evaluation, Houston Medical Journal 1987;2:41-51
	C75	C. F. Dotter, "Transluminally Placed Coil Spring Endarterial Tube Grafts Long Term Patency in Canine Pupliteal Arteries," Investigative Radiology 1969;4:329-332.
	C76	Calver et al. "Intracoronary Multi-link stents: experience in 218 patients using aspirin alone," Heart 1998;80/499-504
	C77	Camenzind, et al., "Use of Locally Delivered Conventional Drug Therapies", Semin. Intervent. Cardiol., 1, 67-78

			(1996)
<u> </u>			
		€78	Cannon, M., et al., "Competition Between Trichodermin and Several Other Sesquiterpene Antibiotics for Bindi
\			to their Receptor Site(s) on Eukaryotic Ribosomes", Biochem, J., 160, 137-145, (1976)
./		(*79	Castellot et al., "Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth", J. Ce Biol., 90:372-379 (1981)
		C.80	Castellot et al., "Effect of heparin on vascular smooth muscle cells. I. Cell metabolism", J. Cell, Physiol., 124:2 28 (1985)
		()	Castellot et al., Heparin selectively inhibits a protein kinase e-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells, J Cell Biol., 109:3147-3155 (1989)
		C.83	Chamberlain, 'Transforming growth factor-beta; a promising target for anti-stenosis therapy'', Cardiovasc, Drug Rev., 19(4):329-344 (2001)
		C83	Chamley-Campbell and Campbell, "What controls smooth muscle phenotype?". Atherosclerosis, 40:347-357
		C84	Chamsangavej et al., "Endovascular Stent for Vena Caval Stenosis: Laboratory Experiment and Potential Clinic Applications," Radiology 1985 Nov;157(P):66 Abs. 129.
		1.05	Chandrasekar, B., et al., "Dietary Omega-3 Lipids Delay the Onset and Progression of Autoimmune Lupus
		C85	Nephritis by Inhibiting Transforming Growth Factor Beta mRNA and Protein Expression", Journal of
	-	C86	Autoimmunity, 8, 381-393, (1995) Chandy, T., et al., "Chitosan Matrix for Oral Sustained Delivery of Ampicillin", Biomaterials, 14, 939-944, (19
		C87	Chang, M.P., et al., "Comparison of the Intoxication Pathways of Tumor Necrosis Factor and Diphtheria Toxin Infection and Immunity, 58, 2644-2650, (Aug., 1990)
		C88	Charles Dotter et al., "Transluminal Treatment of Arteriosclerotic Obstruction Description of a New Technique
	-	C89	and a Preliminary Report of its Application." Circulation 1964:30:654-669 Charlier, C., et al., "Tamoxiten and Its Active Metabolite Inhibit Growth of Estrogen Receptor-Negative MDA-
		(0)	MB-435 cells", Biochemical Rharmacology, 49(3), 351-358. (January 1995)
		C90	Charlier, et al., "Tamoxifen in the Treatment of Breast Cancer", J. Gynecol. Obstet Biol, Reprod., 23, 751-756, (1994).
		C91	Charnsangavej, et al., "Stenosis of the Vena Cava: Preliminary Assessment of Freatment with Expandable Metallic Stents," Radiology 1986 Nov 161:295.
		C92	Chauhan et al., "Activation of Transforming Growth Factor-B is Inversely Correlated with Three Major Risk Factors for Coronary Artery Disease: Lipoprotein(ar. LDL-Cholesterol and Plasminogen Activator Inhibitor-1",
			Circulation, 90 1-623, Abstract No. 3354 (October 1994)
	_	C93	Cheitlin, M.D., et al., "Myocardial Infarction without Approsclerosis", JAMA, 231, 951-959, (1975)
		(.01	Chen et al., "Transforming growth factor type beta specifically stimulates synthesis of proteoglycan in human adult arterial smooth muscle cells", Proc. Natl. Acad. Sci., 84:5287-5291 (1987)
		C95	Clark, D.A., et al., "Coronary Artery Spasm: Medical Management, Surgical Denegration, and Autotransplantation", The Journal of Thoracic and Cardiovascular Surgery, 73, 332-339, (1977)
		C96	Clarke, S.C., et al., "Tolerance and Responses To Tamoxifen and Toremifene in Male Patients with Coronary Artery Disease." Abstract for ACC Meeting, March 1999
		C97	Clinton, S.K., et al., "Induction in vivo of Interleukin-1 (IL-1) Gene Expression in Rabbit Aortic Tissue".
ĺ		ļ	Abstracts of the 61st Scientific Sessions of the American Heart Association, Washington, D.C., November 14-17, 198
	_		Circulation, 78 (4 Part 2): p II65 (1988)
1	- (C98	Clowes and Kamowsky, "Suppression by heparin of smooth muscle cell proliferation in injured arteries", Nature 265:625-626 (1977)
	(('99	Clowes et al., "Heparin and cilazapril together inhibit injury-induced intimal hyperplasia", Hypertension, 18:II-69 (1991)
	1	C100	Colletta, A.A. et al., "Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts", Br. J. Cancer, 62, 405-409, (1990)
	(101	Columbo et al., "A Novel Strategy for Stent Deployment in the Treatment of Acute or Threatened Closure Complicating Balloon Coronary Angioplasty," JACC 1993 Dec;22(7):1887-91.
	+,	102	Comezoglu, F.T. et al., "Serum Stability and Cytotoxicity of the Macrocyclic Trichothecenes Roridin A.
	- [`	` ' -	Verrucarin A and Their Monoclonal Antibody Conjugates", Proceedings of the American Association for Cance
	_ _		Research, 31, Abstract No. 1723, p. 291, (Mar., 1990)
	(Coombes, R.C., et al., "Idoxifene: Report of a Phase I Study in Patients with Metastatic Breast Cancer", Cancer Research, 55, 1070-1074, (Mar. 1, 1995)
	(Coreos, et al., "Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty", Am. Heart J., 109(5):926-931 (1985)
		105	Cotton, P., "Restenosis Trials Suggest Role for Remodeling", JAMA, 271, 1302-1305, (May 4, 1994)
	(,	Craig et al., "Anticoagulant Drugs" in Modern Pharmacology: Little, Brown & Co.; Boston; p. 399 (1982)
	(107	Csernok, E., et al., "Transforming Growth Factor-beta (FGF-beta) Expression and Interaction with Proteinase 3 (PR3) in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis", Clin, Exp. Immunol., 105, 104
	\perp		111. (1996) Cunningham, A., et al., "A Study of the Structural Basis of the Carcinogenicity of Tamoxifen, Toremifene and

ut.	Annl	watton	No.	097910.	388
	1447	ic annuar		11.7 7111,	, ,,,,,

 ·	of Application No. 097910.388
C.100	Currier et al., "Low molecular weight heparin (enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbit", J. Am. Coll. Cardiol., 17(6):118B-125B (1991)
C110	Currier, "Restenosis After Percutaneous Transluminal Coronary Angioplasty: Have We Been Aiming at the Wrong Targer?", JACC, 25 516-520 (February 1995)
(111	Dangas, G., et al., "Management of Restenosis after Coronary Intervention", American Heart Journal, 132, 428-436, (1996)
CH	Davies, A.M., et al., "Peroxidase Activation of Tamoxifen and Toremifene Resulting in DNA Damage and Covalently Bound Protein Adducts", Carcinogenesis, 16, 539-545, (1995)
C113	deAlvare, L.R., et al., "Mechanism of Superoxlde Anion Scavenging Reaction by Bis-(Salicylato)-Copper(II) Complex", Biochemical and Biophysical Research Communications, 69, 687-694, (1976)
C114	Dehmer, G.J., et al., "Reduction in the Rate of Early Restenosis After Coronary Angioplasty by a Diet Supplemented with n-3 Fatty Acids", N. Engl. J. Med., 319, 733-740, (1988)
 CH5	Del Vecchis et al., "Inhibition of human scleral fibroblast proliferation with heparin, Invest"., Ophthalmol, Vis. Sci., 29:1272 (276 (1988)
C116	Delmas, P.D., "Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women". The New England Journal of Medicine, 337(23), (1997)
C117	Chenoweth, D. E., "Complement Activation in Extracorporeal Circuits" Annals of the New York Academy of Sciences Vol. 516 (pp. 306-313 (1987)
CH8	DiGiacomo, R.A., et al., "Kish-Oil Dietary Supplementation in Patients with Raymand's Phenomenon: A Double-Blind, Controlled, Prospective Study", Am. J. Med., 86, 158-164, (Feb. 1980)
C119	DiLuccio, R.C., et al., "Sustained-Release Oral Delivery of Theophylline 19, Use of Polyvinyl Alcohol and Polyvinyl Alcohol-Methyl Acrylage Polymers", Journal of Pharmaceutical Sciences, 83, 104-106, (January 1994)
C120	DiMario, "Is the Mechanism of Restenosis Device-Independent," Serial Assessment with Intracoronary Ultrasound", Circulation, 90, 1-24, Abstract 115 (October 1994) Donnelly, J., et al., "Protective Efficacy of Intransuscular Immunization with Naked DNA: DNA Vaccines: A New
C121	tra in Vaccinology, Margaret A. Liu et al., eds. "Annuls of the New York Academy of Sciences, 772, 40-44, (1995)
C122	Dotter, "Intraventional Radiology - Review of an Enterging Field," Seminars In Roentgenology 1982;16(1):7-8,
C123	Dove, C.R., et al., "Effect of Vitamin E and Copper on the Vitamin E Status and Performance of Growing Pigs", J. Anim. Sci., 69, 2516-2523, (1991)
C124	Dowsett, M., "New Developments in the Hormonal Treatment of Breast Cancer", In: The Treatment of Cancer: Beyond Chemotherapy, Conference Documentation, The Glouster Hotel, London, 7 p., (Mar. 13-14, 1995)
C125	Dragan, Y.P., et al., "Comparison of the Effects of Tamexifen and Toremifene on Liver and Kidney Tumor Promotion in Female Rats", Carcinogenesis, 16, 2733-2741. (1995)
C126	Draper, M.W., et al., "Antiestrogenic Properties of Raloxifène", Pharmacology, 50, 209-217, (April 1995) Dyerberg, J., "PlateletVessel Wall Interaction: Influence of Diet", Phil. Trans. R. Soc. Lond., B 294, 372-381,
C128	(1981) Dyerberg, J., et al., "The Effect of Arachidonic- and Eicosapentaenoic Acid on the Synthesis of Prostacyclin-like
C128	Material in Human Umbilical Vasculature", Artery, 8, 12-17, (1980) Edelman, E.R., et al., "Effect of Controlled Adventitial Heparin Delivery on Smooth Muscle Cell Proliferation
C130	Following Endothelial Injury", Proc. Natl. Acad. Sci. USA, 87, 3773-3787, (May, 1990) Ellis et al., "Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated
	coronary angioplasty", Am. Heart J., 117(4):777-782 (1989)
 C131	Ellis, S.G., et al., "In-Hospital Cost of Percutaneous Coronary Revascularization: Critical Determinants and Implications", Circulation, 92, 741-747, (1995)
 C132	Endres, S., et al., "The Effect of Dietary Supplementation with n-3 polyunsaturated Fatty Acids on the Synthesis of Interleukin-1 and Tumor Necrosis Factor by Mononuclear Cells", N. Engl. J. Med., 320, 265-271, 1989)
 C133	Esnouf, M.P., et al., "The Inhibition of the Vitamin K-Dependent Carboxylation of Glutamyl Residues in Prothombin by Some Copper Complexes", FEBS Letters, 107, 146-150. (1979)
C134	Espinosa, E., et al., "17-Estradiol and Smooth Muscle Cell Proliferation in Aortic Cells of Male and Female Rats". Biochemical and Biophysical Research Communication, 221, 8-14, (1996)
	Evans, G.L., et al., "Tissue-Selective Actions of Estrogen Analogs", Bone, 17, 1815-1905, (October 1995)
	Faxon et al., "Enozaprain, a low molecular weight heparin, in the prevention of restenosis after angioplasty; results of a double blind randomized trial", JACC 19:258A, Abstract 783-3 (1992)
	Ferrari, R.P., et al., "Changes of Serum Iron Transferrin and Copper Ceruloplasmin in Rats Given Cu(II) 3ub2 (Acetylsalicyate) sub4 During Acute Inflammation", Anticancer Res., 9, 771-774, (1989)
 i l	Fett-Neto, A.G., et al., "Effect of White Light on Taxol and Baccatin III Accumulation in Cell Cultures of Taxos Cuspidata Sieb and Zucc.", J. Plant Physiol., 146, 584-590, (1995)
 1	Fischell, et al., "Low-Dose, beta-Particle Emission From 'Stent' Wire Results in Complete, Localize Inhibition of Smooth Muscle Cell Profiferation", Circulation, 90 2956-2963 (December, 1994)
1	Fischman, et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease:, The New England Journal of Medicine, 331, 496-501 (August, 1904)
 C141	Fisher, M., et al., "Dietary n-3 Fatty Acid Supplementation Reduces Superoxide Production and Chemituminescence in a Monocyte-Enriched Preparation of Leukocytes", Am. J. Clin. Nutr., 51, 804-808, (1990)

C142 Flanders, K. C. et al., "Transforming Growth Factor-Bit Indicohemical Localization With Antibodies to Different Epitoges," Localization of the Machine State of Pathway (18), 633–640, 1985. 1889.			of Application No. 09 910,388
 [143] Slandees, K.C., et al., "Transforming Growth Factor-B1: Histochemical Localization With Antibodies to Different Epipope," Journal of Cell Biology, 108, 653-660. (Feb.) 1980. [144] Fockens, J.A., et al., "I rokinase-Type Plasminogen Activator and Irs Inhibitor PAI-1: Predictors of Proceedings of Proceed	C	C142	Flanders, K.C., et al., "Altered Expression of Transforming Growth Factor-B in Alzheimer's Disease", Neurology,
C144 Fockens, J.A., et al., "Lokinse-Type Pissmingert Avisator and Its labilistor PAI-1: Predictions of Poor Response to Jamosisten Breage in Recurrent Pressest Care." A printed of the Astinand Career Institute, 87 (11), 251-750. (May 1995). C145 Forey, Pressent et al., "Angiotensin-converting curyane inhibitor versus angiotensin II, AT1 receptor antagonists: effects on smooth muscle cell migration and proliferation after balloon cathering in," A m J Pathod, 139:1291-1290 (1996). C146 For and DiCorfect. "Fish oils insbist endothelial cell production of platelet-derived growth factor-like protein". Science, 211:488-1433-451-1881. C147 Frantschy, S. A., et al., "Rodocan Voldes of Alzheimers' Diseases: Rat A Infusion Approaches to Amyloid Opensis". Neurobiology of Aging, 17, 311-321, 1996). C148 Natire Assent. et al., "Estrogen Modulation of JF. Monocytic Chemoatraction Protein-1 inRNA Expression in Natire Assenting Science, 231, 1333-1344, 11994. C150 Fixball, L., et al., "Oxiolamosterol Oxinese: Dual-action Inhibitors of Cholesterol Biosynthesis", Journal of Lipid Research, S. 1313-1344, 11994. C151 Fixball, et al., "Induction of Circulating Myelin Basic Protein and Proteolipid Protein-Specific Transforming Growth Factor-B Receptor Subtypes on Vascular Smooth Visicle Colls fronk-pontaneously Hypertensive Rats and Wistar-Kylu Blaz. "Lin. Exp. Pharmacol. Physiol. Supply. 1, 5120, 1042 C152 Fixball, et al., "Distinct Expression of Transforming Growth Factor-B Receptor Subtypes on Vascular Smooth Visicle Colls fronk-pontaneously Hypertensive Rats and Wistar-Kylu Blaz. "Lin. Exp. Pharmacol. Physiol. Supply. 1, 5120, 1042 C153 Gebhardt, R. et al., "Differential hibitory, Effects of Cyrlic-Physiol Grapmost Introduction Compounds on Cholesterol Biosynthesis in Primace Ray Reparacyce Cultures". Lipid Apr. 2126, 1296-1276, (1996) C154 Gebhardt, R. et al., "Differential hibitory, Effects of Cyrlic-Physiol Grapmost in Resourcesis After Balloon Augioplassy". Circulation, 99, 3001-3005 (1995) C155 Gebhardt, R. et a		C143	Flanders, K.C., et al., "Transforming Growth Factor-B1: Histochemical Localization With Antibodies to Different
C145 Fromes-Pressont et al., "Angisterisis-converting enzyme inhibitic versus angiotensin II, ATI receptor antaigness i fefects on smooth muscle cell migration and proliferation after hallown catheter injur." Am J Pathol. 139:1291-1296 [1991] 14 Fox and DC orlete. "Fish oils inhibit endothelial cell production of platelet-derived growth flactor-like protein", Science. 241 (1804):1453-456 (1988) 15 Francisco, S. A., et al., "Redment Models of Alzheimer's Disease: Rat A Infusion Approaches to Amyloid Opposits", Neurobiology of Aging. 17, 311-321-11996. 15 Production, S. A., et al., "Redment Models of Alzheimer's Disease: Rat A Infusion Approaches to Amyloid Opposits", Neurobiology of Aging. 17, 311-321-11996. 15 Production of Production of Circulating Myelin Basic Protein and Proteolipid Protein-Specific Transforming Growth Fadors B. Institute of Cholesterol Biosynthesis", Journal of Lipid Resembly, 35, 1133-1344, 11994. 15 Production of Circulating Myelin Basic Protein and Proteolipid Protein-Specific Transforming Growth Fadors B. Insciences, Resembly, 35, 1133-1344, 11994. 15 Production of Protein Specific Transforming Growth Factor-B Receptor Subtypes on Vascular Smooth Muscle Cells from Sponatomocyll Systemises Rats and Wistars-Kyalu (Pat. Cin. Exp. Pharmacol. Physiol. Supply. 1, 1812), 1938. 15 Prof. B. L. et al., "The Pharmacology and Clinical Uses of Transocity", Pharmac. Ther., 25, 127-205, 11984. 15 Gebrard, R. et al., "Inhibitionly Cholesterol Biosynthysis Pharmac. Ther., 25, 127-205, 11984. 15 Gebrard, R. et al., "The Pharmacology and Clinical Uses of Transocity", Pharmac. Ther., 25, 127-205, 11984. 15 Gebrard, R. et al., "Differential inhibitory, Effects of Chica. Physiol. Supply. 1, 18120, 1984. 16 Gebrard, R. et al., "Differential inhibitory, Effects of Chica. Physiol. Supply. 2015 (1997). 16 Gebrard, R. et al., "Inhibitionly Cholesterol Biosynthysis and January Physiol. Supply. 2015 (1997). 16 Gebrard, R. et al., "The Charmacology and Clinical Uses of Transocity Physiol. Supply. 2016 (C144	Fockens, J.A., et al., "Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer", Journal of the National Cancer Institute, 87(10).
Total Dicorletts, "Fish oils infibite and attlefield cell production of platefer-derived growth factor-like protein", Science, 2214 (364) 4354-3461 [1988]		C145	Forney-Prescott et al., "Angiotensin-converting enzyme inhibito" versus angiotensin II, ATI receptor antagonist: effects on smooth muscle cell migration and proliferation after balloon catheter injury". Am J Pathol. 139:1291-
Fruitschy, S.A., et al., "Rodem Models of Alzheimer's Disease: Rat A Infusion Approaches to Amyloid Deposits," Neurobiology of Aging, 17, 311-321, (1904)		9,140	Fox and DiCorleto, "Fish oils inhibit endothelial cell production of platelet-derived growth factor-like protein",
C148 First LL. et al. "Storogare Modulation of JF Monocytic Chemoatrractant Protein-1 mRNA Expression in Nhytine Manrophages". J. Jimmunol., 1828-1845		C14.	Frautschy, S.A., et al., "Rodent Models of Alzheimer's Disease: Rat A Infusion Approaches to Amyloid
C140 Fixed, L.L. et al., "Oxodamosterol Oximes: Dual-Action Inhibitors of Cholesterol Biosynthesis", Journal of Lipid Resembly, 35, 1133-1344, 1994) C150 Fukaura, M., et al., "Induction of Circulating Nyelin Basic Portein and Proteolipid Protein-Specific Transforming Growth Factor- B I-secreting Th3 T Cells by Oral Administration of Myelin in Multiple Sclerosis Patients", J. Clin. Invest., 98, 70-77, 1996) C151 Fukuda, et al., "Distinct Expression of Transforming Growth Factor-B Receptor Subtypes on Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats and Wistar-Kybu R&s. Clin. Exp. Pharmacol. Physiol. Supply., 1, 15120, 1903 C152 Furr, B.J., et al., "The Pharmacology and Clinical Uses of Tamosticy" Pharmac. Ther., 25, 127-205,(1984) C153 Gebhardt, R., et al., "Differential Inhibitory Clinical Uses of Tamosticy" Pharmac. Ther., 25, 127-205,(1984) C154 Gebhardt, R., et al., "Enhibitional Choisertoel Biosynthesis in Primary Rat Hepatocyte Cultures". Lipids 35, 129-1276, (1996) C155 Gebhardt, R., et al., "Inhibitional Choisertoel Biosynthesis and Ajoene in Rat Hepatocytes and HepG2 Cells". Biochimica et Biophysick-Acta., 1213, 27-62, (1994) C155 Gebhardt, R., et al., "Enhibitional Choisertoel Biosynthesis and Ajoene in Rat Hepatocytes and HepG2 Cells". Biochimica et Biophysick-Acta., 1213, 27-62, (1994) C156 Giachelli, et al., "Oscometric Remodeling is Not the Pring-Pay-Rathogenic Process in Restocnosis After Balloon Angioplasty". Circulation, 90, 3001-3008 (Pocchiped 1993) C156 Giachelli, et al., "Oscopontinis Elevanda Durrugh-Veolonitima Formation in Rat Arteries and is a Novel Component of Human Atherosclerosis Plaques". J. Chin. Invest., 92, 1686-1696. (Oct. 1993) C156 Gibbons et al., "The emerging concept of viscular remodeling". New Engl. J., of Nedicine, 330 1431-1437 (1994) (1995) C159 Glagovs. S. "Intimal Hyperplasia, Vascular Modeling, and the Restenosis Problem". Circulation, 89, 2888-2891, 1997. C160 Grainger and Metallic. "Transforming growth factor-beta adynamically regulati		C.148	Yeazier-Jessen, et al., "Estrogen Modulation of JE Monocytte Chemoattractant Protein-1 mRNA Expression in
C150 Growth Fabor. B 1-secreting Th3 17 Cells by Oral Administration of Nyelin in Multiple Sciencis Facinis Transforming Growth Fabor. B 1-secreting Th3 17 Cells by Oral Administration of Nyelin in Multiple Sciencis Patients", J. Clin. Invest., 98, 70-77, (1996) C151 Fukuda, et al., "Distinct Expression of Transforming Growth Factor-B Receptor Suhtypes on Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rals and Wistar-Ny-Rio Bot." Clin. Exp. Pharmacol. Physiol. Supply, 1, 5120, 1983 C152 Fur., B.J., et al., "The Pharmacology and Clinical Uses of Tamoxifery" Pharmac. Ther., 25, 127-205, (1984) C153 Gebhardt, R., et al., "Differential Inhibitory Effects of Chyric-Pelipki Organosulfur Compounds on Cholesterol Biosynthesis in Primary Ral departocyte Cultures", Lipida (1), 220-1276, (1996) C153 Gebhardt, R., et al., "Inhibitionly Cholesterol Biosynthesis Mallicin and Ajoene in Rat Hepatocytes and HepG2 Cells", Biochimica et Biophysich-Acta, 1213, 27-62, (1904) C154 Gebhardt, R., et al., "Inhibitionly Cholesterol Biosynthesis Mallicin and Ajoene in Rat Hepatocytes and HepG2 Cells", Biochimica et Biophysich-Acta, 1213, 27-62, (1904) C155 Grate et al., "Geometric Remodeling Is Not the Propendy Pathogenic Process in Restoenosis After Balloon Angiophasty", Circulation, 90, 3001-3008 (December 1993) C156 Glacelli, et al., "Osteoponthia is Elevand Durkgh Venotinian Formation in Rat Arteries and is a Novel Component of Human Atherosclerosis Plagues", J. Chp. Invest., 92, 1686-1696, (Oct. 1993) C157 Gibbons et al., "The emerging concept of viscular modeling". New Engl. J. of Medicine, 330 1431-1437 (1994) C158 Gibbons et al., "The inhibitor of Plagues", J. Chp. Invest., 92, 1686-1696, (Oct. 1993) C159 Glagoy, S., "Intimal Hyperplasia, Vascular Modelheg, and the Restenosis Problem", Circulation, 89, 2888-2891, (1994) C160 Gratistar, W.J. et al., "Clinical Potential of New Ambestrogens", Journal of Clinical Oncology, 15, 840-852, (1997) C161 Grainer and Metcalle, "Transforming growth factor-β and card		C149	Fryex L.L., et al., "Oxolanosterol Oximes: Dual-Action Inhibitors of Cholesterol Biosynthesis", Journal of Lipid
C151 Fukuda, et al., *Distinct Expression of Transforming Growth Factor-B Receptor Subtypes on Vascular Smooth Supply. 1, \$120, 1925 C152 Furr, B.J., et al., *The Qharmacology and Clinical Uses of Tamosifery Pharmac. Ther., 25, 127-205, 1984) C153 Gebhardt, R., et al., *Diffeential Inhibitory Effects of Gynic-Deriyed Organosulfur Compounds on Cholesterol Biosynthesis in Primary Ranklepatocyte Cultures." Lipids 33, 1269-1276, (1996) C154 Gebhardt, R., et al., *Diffeential Inhibitory Effects of Gynic-Deriyed Organosulfur Compounds on Cholesterol Biosynthesis in Primary Ranklepatocyte Cultures." Lipids 33, 1269-1276, (1996) C154 Gebhardt, R., et al., *Inhibitiony Cholesterol Biosynthesis and Ajoene in Rat Hepatocytes and HepG2 Cells." Biochimica et Biophysics Acta. 1213, 27-62, (1997) C155 Gertz et al., "Geometric Remodeling Is Not the Program Pathogenic Process in Restoenosis After Balloon Angioplasty." Circulation, 90, 3001-3008 [Developer 1993) C156 Giachelli, et al., "Osteopontin is Elevated Durlugh Ceontina Formation in Rat Arteries and is a Novel Component of Human Atherosclerosis Plaques". J. Chp., Invest., 92, 1686-1696, (Oct. 1993) C157 Gibbons et al., "The emerging concept of vascular remodeling". New Engl. J. of Medicine, 330 1431-1437 (1994) C158 Gibson, D.M., et al., "Inhibition and Growth ox Cell Lines of Taxus Brevifolia Pacific Vewy", Plant Cell Reports. 12, 479-482, (1993) C159 Glagov, S., "Intimal Hyperplasia, Vascular Modeling, and the Restenosis Problem". Circulation, 89, 2888-2891, (1994) C160 Gradishar, W.J., et al., "Clinical Potential of New Ambestrogens", Journal of Clinical Oncology, 15, 840-852, (1997) C161 Grainger and Metcalfe. "Transforming growth factor-β and cardiovascular protection, draft" (NeoRx 019151-0192) C162 Grainger and Metcalfe. "Transforming growth factor-β and cardiovascular protection, draft" (NeoRx 019151-0192) C163 Grainger and Metcalfe. "Transforming growth factor-beta dynamically regulates vascular protection of the vascular endothelium a		 C150	Fukaura, H., et al., "Induction of Circulating Myelin Basic Protein and Proteolipid Protein-Specific Transforming Growth Factor- B1-secreting Th3 T Cells by Oral Administration of Myelin in Multiple Sclerosis Patients", J.
C152 Furr, B.J., et al., "The Pharmacology and Clinical Uses of Tamoxifer," Pharmac. Ther., 25, 127-205, (1984) C153 Gebhardt, R., et al., "Differential Inhibitory Effects of Grite," Priped Organosulfur Compounds on Cholesterol Biosynthesis in Primary Rai Vegatocyte Cultures". Lipida J. Tu-50-1276, (1996) C154 Gebhardt, R., et al., "Inhibition of Cholesterol Biosynthesis (No. 1906) 1206 (1996) C155 Gertz et al., "Geometric Remodeline Is Not the Prince Pharmacy Allicin and Ajoene in Rat Hepatocytes and HepG2 Cells". Biochimica et Biophysica Acta. 1213, 47-62, (1904) C155 Gertz et al., "Geometric Remodeline Is Not the Prince Pharmacy and Pharmacy College (1904) C156 Gertz et al., "Geometric Remodeline Is Not the Prince Pharmacy and Angeloplasty". Circulation, 90, 3001-3008 (1904) C156 Gibson, D.M., et al., "Inhibition and Growth of Cell Lines of Taxus Brevifolia Pharific Vewy". Plant Cell Reports, 12, 479-482, (1903) C157 Gibson, D.M., et al., "Inhibition and Growth of Cell Lines of Taxus Brevifolia (Pacific Vewy", Plant Cell Reports, 12, 479-482, (1903) C159 Gibson, D.M., et al., "Clinical Potential of New Ambestrogens". Journal of Clinical Oncology, 15, 840-852, (1904) C160 Gradishar, W.J., et al., "Clinical Potential of New Ambestrogens". Journal of Clinical Oncology, 15, 840-852, (1904) C161 Graham et al., "Dexamethasone Inhibits Grown and Nat-Nexchange in Vascular Smooth Muscle Cells" Journal of Endocrinology, 129 (Suppl.) Abstract 180, 10" Joint Metting of British Endocdrine Societies. Brighton, England, UK. April 15-18., (1901) C162 Grainger and Meticalfe. "Transforming growth factor-β and cardiovascular protection, draft" (NeoRx 01915) - 019213) C163 Grainger and Meticalfe. "Fransforming growth factor-beta substitution of Prince Societies. Brighton England. UK. April 15-18., (1901) C164 Grainger and Mosedale. "TGF-β and the cardiovascular system. TGF-Ŋ and Related Cytokines in Inflammation." Breit. SN and Wahl. SN red., Brikhauser Verlug, 91-146 (2001) r(DiG Moi34-40010). C165 Grainger and Nosedale. "TGF		C151	Fukuda, et al., *Qistinct Expression of Transforming Growth Factor-B Receptor Subtypes on Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats and Wistar-Kydu Ross." Clin. Exp. Pharmacol. Physiol.
Biosynthesis in Primary Rat Repatocyte Cultures". Lipids 3 (1906). C154 Gebhardt, R., et al., "Inhibition of Cholesterol Biosynthesis Mallcin and Ajoene in Rat Hepatocytes and HepG2 Cells". Biochimica et BiophysichActa. 1213. 47-62. (1921). C155 Gertz et al., "Geometric Remodeline is Not the Principal Pathogenic Process in Restoenosis After Balloon Angioplasty". Circulation. 90, 3001–3008 (1904 (1904 [December 1993)). C156 Giachelli, et al., "Osteopontin is Elevated Durly Neointima Formation in Rat Arteries and is a Novel Component of Human Atheroselerosis Plaques". J. Chr. Invest., 92, 1686-1696. (Oct., 1993). C157 Gibbons et al., "The emerging concept of Neocular remodeling". New Engl. J. of Medicine, 330 (1431-1437 (1994)). C158 Gibson, D.M., et al., "Initiation and Growth ox Cell Lines of Taxus Brevifolia (Pacific Yew)". Plant Cell Reports. 12, 479-482, (1993). C159 Glagov, S., "Intimal Hyperplasia, Vascular Modeling, and the Restenosis Problem". Circulation, 89, 2888-2891, (1994). C160 Gradishar, W.J., et al., "Clinical Potential of New Antestrogens". Journal of Clinical Oncology, 15, 840-852, (1997). C161 Graham et al., "Dexamethasone Inhibits Grown and Nat-Rexchange in Vascular Smooth Muscle Cells" Journal of Endocrinology, 129 (Suppl.). Abstract 180, 10° Joint Metring of British Endocdrine Societies, Brighton, England. UK. April 15-18, (1991). C162 Grainger and Metcalfe, "Transforming growth factor-β and cardiovascular protection, draft" (NeoRx 019151-01213). C163 Grainger and Motecalfe, "GF-beta: implications for human vascular disease. J Hum Hypertens., 9(8):679 (1995). C164 Grainger and Motecalfe, "GF-beta: implications for human vascular disease. J Hum Hypertens., 9(8):679 (1995). C165 Grainger and Motecalfe, "GF-beta: implications for human vascular disease. J Hum Hypertens., 9(8):679 (1995). C166 Grainger and Motecalfe, "GF-beta: implications for human vascular disease. J Hum Hypertens., 9(8):679 (1995). C167 Grainger and Motecalfe, "GF-beta: implications for human vascular disease.		C152	Furr, B.J., et al., "The Pharmacology and Clinical Uses of Tamoxiter," Pharmac. Ther., 25, 127-205, (1984)
Cells", Biochimica et Biophysica Acta, 1213, 27-62, U193) C155 Gertz et al., "Geometric Remodeling Is Not [he Practical Pathogenic Process in Restoenosis After Balloon Angioplasty", Circulation, 90, 3001-3008 [December 1934) C156 Giachelli, et al., "Osteopontin is Elevated Durlysh Jeointima Formation in Rat Arteries and is a Novel Component of Human Atherosclerosis Plaques", J. Chi, Invest., 92, 1686-1696, (Oct., 1993) C157 Gibbons et al., "The emerging concept of vascular remodeling", New Engl. J. of Medicine, 330 1431-1437 (1994) C158 Gibson, D.M., et al., "Initiation and Growth of Cell Lines of Taxus Brevifolia (Pacific Yewy)", Plant Cell Reports. 12, 479-482, (1993) C159 Glagov, S., "Intimal Hyperplasia, Vascular Modeling, and the Restenosis Problem", Circulation, 89, 2888-2891, (1994) C160 Gradishar, W.J., et al., "Clinical Potential of New Ambestrogens", Journal of Clinical Oncology, 15, 840-852, (1997) C161 Gradishar, W.J., et al., "Clinical Potential of New Ambestrogens", Journal of Clinical Oncology, 15, 840-852, (1997) C161 Gradishar, M.J., et al., "Clinical Potential of New Ambestrogens", Journal of Clinical Oncology, 15, 840-852, (1997) C162 Grainger and Metalle, "Transforming growth factor-β and cardiovascular protection, draft" (NeoRx 019151-019213) C163 Grainger and Metcalfe, "Transforming growth factor-β and cardiovascular protection, draft" (NeoRx 019151-019213) C164 Grainger and Metcalfe, "TGF-βeta: implications for human vascular disease. J Hum Hypertens., 918;679 (1995) C165 Grainger and Mosedale, "TGF-βeta and reduced levels of TGF-βeta act synergistically to promote activation of the vascular endothelium and formation of lipid lesions", J. Cell Sci., 111:2355-2361(2000) C165 Grainger et al., "Dietary fat and reduced levels of TGF-βeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions", J. Cell Sci., 111:2977-2988 (1998) C160 Grainger et al., "Transforming growth factor-beta dynamically regulates vascular spootal price protec		C153	Biosynthesis in Primary Rat Lepatocyte Cultures". Lipids 3 (1269-1276, (1996)
Angioplasty", Circulation, 90, 3001-3008 (Delychlor 1998) (156) Giachelli, et al., "Osteopontin is Elevabed During Newtimms Formation in Rat Arteries and is a Novel Component of Human Atherosclerosis Plaques", J. Chp. Invest., 92, 1686-1696, (Oct. 1993) (157) Gibbons et al., "The emerging concept of vascular remodeling", New Engl. J. of Medicine, 330 1431-1437 (1994) (158) Gibson, D.M., et al., "Initiation and Growth ox Cell Lines of Taxus Brevifolia (Pacific Yew)", Plant Cell Reports, 12, 479-482, (1993) (159) Glagov, S., "Initinal Hyperplasia, Vascular Modeling, and the Restenosis Problem", Circulation, 89, 2888-2891, (1994) (160) Gradishar, W.J., et al., "Clinical Potential of New Anhestrogens", Journal of Clinical Oncology, 15, 840-852, (1997) (161) Graham et al., "Dexamethasone Inhibits Grown and Na. Hexchange in Vascular Smooth Muscle Cells" Journal of Endocrinology, 129 (Suppl.). Abstract 180, 10 th Joint Metting of British Endocdrine Societies, Brighton, England, UK, April 15-18, (1991) (162) Grainger and Metcalfe. "Transforming growth factor-β and cardiovascular protection, draff" (NeoRx 019151-019213) (163) Grainger and Metcalfe. "TGF-beta: implications for human vascular disease. J Hum Hyperiens., 9(8):679 (1995) (164) Grainger and Mosedale. "TGF-β and the cardiovascular system. TGF-β and Related Cytokines in Inflammation," Breit. SN and Wahl, SM (ed.), Birkhauser Verlag, 91-146 (2001) (1016 006134-006) (90). (165) Grainger et al., "Dietary fat and reduced levels of TGFbetal act synergistically to promote activation of the vascular endothelium and formation of lipid lesions", J. Cell Sci., 113:235-8, 261(2000) (166) Grainger et al., "Transforming growth factor-beta dynamically regulates vascular smooth muscele cell differentiation in vivo", J. Cell Sci., 111:2977-2988 (1998) (167) Grainger et al., "Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis", Artriviscler, Thomb, Vass, Biol., 24:399-2404 (2004) (1016 006208-006218) (169)		C154	Cells", Biochimica et Biophysica Acta. 1213_57-62, (1903)
C157 Gibbons et al., "The energing concept of vascular remodeling", New Engl. J. of Medicine, 330 1431-1437 (1994) C158 Gibbon, D.M., et al., "Initiation and Growth of Cell Lines of Taxus Brevifolia (Pacific Yew)", Plant Cell Reports, 12, 479-482, (1993) C159 Glagov, S., "Intimal Hyperplasia, Vascular Modeling, and the Restenosis Problem", Circulation, 89, 2888-2891, (1994) C160 Gradishar, W.J., et al., "Clinical Potential of New Amestrogens", Journal of Clinical Oncology, 15, 840-852, (1997) C161 Gradishar, W.J., et al., "Clinical Potential of New Amestrogens", Journal of Clinical Oncology, 15, 840-852, (1997) C161 Graham et al., "Dexamethasone Inhibits Grown and Nat-Rexchange in Vascular Smooth Muscle Cells" Journal of Endocrinology, 129 (Suppl.) Abstract 180, 10" Joint Metring of British Endocdrine Societies, Brighton, England, UK, April 15-18, (1991) C162 Grainger and Metcalfe, "Transforming growth factor-β and cardiovascular protection, draft" (NeoRx 019151-019213) C163 Grainger and Mosedale, "TGF-β and the cardiovascular system, TGF-β and Related Cytokines in Inflammation." Breit, SN and Wahl, SM (ed.), Birkhauser Verlag, 91-146 (2001) (DJG 0d6134-006190). C165 Grainger et al., "Dietary fat and reduced levels of TGF-betal act synergistically to promote activation of the vascular endothelium and formation of lipid lesions", J. Cell Sci., 113:2355-2361(2000) C166 Grainger et al., "Red wine, but not white wine, elevates circulating TGF-β levels -possible role of a salicylate complex" C167 Grainger et al., "Transforming growth factor-beta dynamically regulates vascular knooth muscele cell differentiation in vivo", J. Cell Sci., 111:2977-2988 (1998) C169 Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis". Biol. Rev., 70, 5718-96, (1995) C160 Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis". Biol. Rev., 70, 578-96, (1995) C170 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apalipoprotein tan Micc", Nature,		C155	Angioplasty", Circulation, 90, 3001-3008 (December 1994)
C158 Gibson, D.M., et al., "Initiation and Growth ox Cell Lines of Taxus Brevifolia (Pacific Yew)", Plant Cell Reports, 12, 479-482, (1993) C159 Glagov, S., "Initinal Hyperplasia, Vascular Modefing, and the Restenosis Problem", Circulation, 89, 2888-2891, (1994) C160 Gradishar, W.J., et al., "Clinical Potential of New Annestrogens", Journal of Clinical Oncology, 15, 840-852, (1997) C161 Gradishar, W.J., et al., "Clinical Potential of New Annestrogens", Journal of Clinical Oncology, 15, 840-852, (1997) C162 Gradishar, W.J., et al., "Dexamethasone Inhibits Grown and Nat-Nexchange in Vascular Smooth Muscle Cells" Journal of Endocrinology, 129 (Suppl.) Abstract 180, 10 th Joint Metting of British Endocdrine Societies, Brighton, England, UK, April 15-18, (1991) C162 Grainger and Metcalfe, "Transforming growth factor-β and cardiovascular protection, draft" (NeoRx 019151- 019213) C163 Grainger and Mosedale, "TGF-β and the cardiovascular system, TGF-β and Related Cytokines in Inflammation," Breit, SN and Wahl, SM (ed.), Birkhauser Verlag, 91-146 (2001) (DJG 0(6134-006190). C164 Grainger et al., "Dietary fat and reduced levels of TGFbetal act synergistically to promote activation of the vascular endothelium and formation of lipid lesions", J. Cell Sci., 113:2355-83561(2000) C165 Grainger et al., "Dietary fat and reduced levels of TGFbetal act synergistically to promote activation of the vascular endothelium and formation of lipid lesions", J. Cell Sci., 113:2355-83561(2000) C166 Grainger et al., "Transforming growth factor-beta dynamically regulates vascular mooth muscele cell differentiation in vivo", J. Cell Sci., 111:2977-2988 (1998) C167 Grainger, D.J., "Transforming growth factor-beta and atherosclerosis: so far, so good for the protective cytokine hypothesis", Arterioscler, Thromb. Vasc, Biol., 24:399-404 (2004) (1006 (006-208-006218) C169 Grainger, D.J., et al., "A Pivotal Role for LGF-Beta in Atterogenesis". Biol. Rev., 70, 578-596, (1995) C170 Grainger, D.J., et al., "Activation of Transforming Gr		C156	of Human Atherosclerosis Plaques", J. Chin. Invest., 92, 1686-1696. (Oct. 1993)
 (159 Glagov, S., "Intimal Hyperplasia, Vascular Modeling, and the Restenosis Problem", Circulation, 89, 2888-2891, (1994) (160 Gradishar, W.J., et al., "Clinical Potential of New Ambestrogens", Journal of Clinical Oncology, 15, 840-852, (1997) (161 Graham et al., "Dexamethasone Inhibits Grown and Na:H-Exchange in Vascular Smooth Muscle Cells" Journal of Endocrinology, 129 (Suppl.) Abstract 180, 10th Joint Metting of British Endocdrine Societies, Brighton, England, UK, April 15-18, (1991) (162 Grainger and Metcalfe, "Transforming growth factor-β and cardiovascular protection, draft" (NeoRx 019151-019213) (163 Grainger and Metcalfe, "TGF-beta: implications for human vascular disease. J Hum Hypertens., 9(8):679 (1995) (164 Grainger and Mosedale, "TGF-β and the cardiovascular system. TGF-β and Related Cytokines in Inflammation." Breit, SN and Wahl, SM (ed.), Birkhauser Verlag, 91-146 (2001) (DJG 06)(34-006)(90). (165 Grainger et al., "Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions", J. Cell Sci., 113:2355-8361(2000) (166 Grainger et al., "Red wine, but not white wine, elevates circulating TGF-β levils -possible role of a salicylate complex" (167 Grainger et al., "Transforming growth factor-beta and atherosclerosis: so far, so good for the protective cytokine hypothesis", Arerioscler, Thromb. Vasc. Biol., 24:399-404 (2004) (DJG 006208-00621N) (169 Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis" Biol. Rev., 70, 57N-96, (1995) (170 Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis" Biol. Rev., 70, 57N-96, (1995) (171 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) Nice". Nature, 370-460-462, (Aug. 11, 1994) (172 Grainger, D.J., et al., "Activation of Transf		C157	
 (1994) C160 Gradishar, W.J., et al., "Clinical Potential of New Ambestrogens", Journal of Clinical Oncology, 15, 840-852, (1997) C161 Graham et al., "Dexamethasone Inhibits Grown and Na:H-Exchange in Vascular Smooth Muscle Cells" Journal of Endocrinology, 129 (Suppl.) Abstract 180, 10th Joint Metting of British Endocdrine Societies, Brighton, England, UK, April 15-18, (1991) C162 Grainger and Metcalfe, "Transforming growth factor-β and cardiovascular protection, draft" (NeoRx 019151-019213) C163 Grainger and Mosedale, "TGF-β and the cardiovascular system, TGF-β and Related Cytokines in Inflammation." Breit, SN and Wahl, SM (ed.), Birkhauser Verlag, 91-146 (2001) (DJG 006134-006190). C164 Grainger et al., "Dietary fat and reduced levels of TGFbetal act synergistibally to promote activation of the vascular endothelium and formation of lipid lesions", J. Cell Sci., 113:2355-2361(2000) C166 Grainger et al., "Red wine, but not white wine, elevates circulating TGF-β levels-possible role of a salicylate complex" C167 Grainger et al., "Transforming growth factor-beta dynamically regulates vascular smooth muscele cell differentiation in vivo", J. Cell Sci., 111:2977-2988 (1998) C168 Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atheroselerosis: so far, so good for the protective cytokine hypothesis". Arterioscler, Thromb. Vasc, Biol., 24:399-404 (2004) (DJG 006208-00621.5) C170 Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis," Biol. Rev., 70, 571-596, (1995) C171 Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis," Biol. Rev., 70, 578-596, (1995) C172 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) Mice", Nature, 370 460-462, (Aug. 11, 1994) C172 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Mice", Nature, 370 460-462, (Aug.		C158	12, 479-482, (1993)
 C161 Graham et al "Dexamethasone Inhibits Grown and Na:HAExchange in Vascular Smooth Muscle Cells" Journal of Endocrinology, 129 (Suppl.) Abstract 180, 10th Joint Metting of British Endocdrine Societies, Brighton, England, UK. April 15-18. (1991) C162 Grainger and Metcalfe. "Transforming growth factor-β and cardiovascular protection, draft" (NeoRx 019151-019213) C163 Grainger and Mosedale. "TGF-beta: implications for human vascular disease. J Hum Hypertens 9(8):679 (1995) C164 Grainger and Mosedale. "TGF-β and the cardiovascular system. TGF-β and Related Cytokines in Inflammation." Breit. SN and Wahl, SM (ed.). Birkhauser Verlag. 91-146 (2001) (DJG 0)(6134-006190). C165 Grainger et al., "Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions". J. Cell Sci., 113:2355-2361(2000) C166 Grainger et al., "Red wine, but not white wine, elevates circulating TGF-β levels -possible role of a salicylate complex" C167 Grainger et al., "Transforming growth factor-beta dynamically regulates vascular smooth muscele cell differentiation in vivo". J. Cell Sci., 111:2977-2988 (1998) C168 Grainger, D.J., "Transforming growth factor-beta and atherosclerosis: so far, so good for the protective cytokine hypothesis". Arterioscler. Thromb. Vasc. Biol., 24:399-404 (2004) (DJG 006208-006218) C169 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) in vivo". Circulation, 90, 67th Scientific Session, Abstract No. 3353, p. 1-623, (Oct., 1994) C171 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Mice". Nature, 370, 460-462, (Aug., 11, 1994) C172 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Mice". Nature, 370, 460-462, (Aug., 11, 1994) C172 Grainger,		C159	(1994)
Endocrinology, 129 (Suppl.) Abstract 180, 10th Joint Metting of British Endocdrine Societies, Brighton, England. UK, April 15-18, (1991) C162 Grainger and Metcalfe, "Transforming growth factor-β and cardiovascular protection, draft" (NeoRx 019151-019213) C163 Grainger and Metcalfe, TGF-beta: implications for human vascular disease. J Hum Hypertens., 9(8):679 (1995) C164 Grainger and Mosedale, "TGF-β and the cardiovascular system, TGF-β and Related Cytokines in Inflammation," Breit, SN and Wahl, SM (ed.), Birkhauser Verlag, 91-146 (2001) (DJG 006134-006190). C165 Grainger et al., "Dietary fat and reduced levels of TGFbetal act synergistically to promote activation of the vascular endothelium and formation of lipid lesions", J. Cell Sci., 113:2355-2361(2000) C166 Grainger et al., "Red wine, but not white wine, elevates circulating TGF-β levels -possible role of a salicylate complex" C167 Grainger et al., "Transforming growth factor-beta dynamically regulates vascular smooth muscele cell differentiation in vivo", J. Cell Sci., 111:2977-2988 (1998) C168 Grainger, D.J., "Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis", Arterioscler, Thromb. Vasc., Biol., 24:399-404 (2004) (DJG 006208-006218) C169 Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis?", Biol. Rev., 70, 578-596, (1995) C170 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) in vivo", Circulation, 90, 67th Scientific Session, Abstract No., 3353, p. 1-623, (Oct., 1994) C171 Grainger, D.J., et al., "Activation of Fransforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Micc", Nature, 370 460-462, (Aug. 11, 1994) C172 Grainger, D.J., et al., "Activation of Fransforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Micc", Nature, 370 460-462, (Aug. 11, 1994)		C160	(1997)
C162 Grainger and Metcalfe. "Transforming growth factor-β and cardiovascular protection, draft" (NeoRx 019151-019213) C163 Grainger and Metcalfe. TGF-beta: implications for human vascular disease. J Hum Hypertens 9(8):679 (1995) C164 Grainger and Mosedale. "TGF-β and the cardiovascular system. TGF-β and Related Cytokines in Inflammation." Breit. SN and Wahl. SM (ed.), Birkhauser Verlag, 91-146 (2001) (DJG 0(6134-006190). C165 Grainger et al., "Dietary fat and reduced levels of TGFbetal act synergistically to promote activation of the vascular endothelium and formation of lipid lesions". J. Cell Sci., 113:2355-2361(2000) C166 Grainger et al., "Red wine, but not white wine, elevates circulating TGF-β levels -possible role of a salicylate complex" C167 Grainger et al., "Transforming growth factor-beta dynamically regulates vascular smooth muscele cell differentiation in vivo". J. Cell Sci., 111:2977-2988 (1998) C168 Grainger. D.J., "Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis". Arterioscler. Thromb. Vasc. Biol., 24:399-404 (2004) (DJG 006208-006213) C169 Grainger. D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis?". Biol. Rev., 70, 573-596, (1995) C170 Grainger. D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) in vivo". Circulation, 90, 67% Scientific Session, Abstract No. 3353, p. 1-623, (Oct., 1994) C171 Grainger. D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Mice". Nature, 370 460-462, (Aug. 11, 1994) C172 Grainger. D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Mice". Nature, 370 460-462, (Aug. 11, 1994)		C161	Endocrinology, 129 (Suppl.) Abstract 180, 10th Joint Metting of British Endocdrine Societies, Brighton, England,
C164 Grainger and Mosedale, "TGF-β and the cardiovascular system, TGF-β and Related Cytokines in Inflammation," Breit, SN and Wahl, SM (ed.), Birkhauser Verlag, 91-146 (2001) (DJG 0)(6134-0)(6190). C165 Grainger et al., "Dietary fat and reduced levels of TGFbetal act synergistically to promote activation of the vascular endothelium and formation of lipid lesions", J. Cell Sci., 113:2355-2361(2000) C166 Grainger et al., "Red wine, but not white wine, elevates circulating TGF-β levels -possible role of a salicylate complex" C167 Grainger et al., "Transforming growth factor-beta dynamically regulates vascular smooth muscele cell differentiation in vivo", J. Cell Sci., 111:2977-2988 (1998) C168 Grainger, D.J., "Transforming growth factor beta and atheroselerosis: so far, so good for the protective cytokine hypothesis", Arterioseler, Thromb. Vasc. Biol., 24:399-404 (2004) (DJG 006208-00621X) C169 Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis". Biol. Rev., 70, 570-596, (1995) C170 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) in vivo", Circulation, 90, 67" Scientific Session, Abstract No. 3353, p. 1-623, (Oct., 1994) C171 Grainger, D.J., et al., "Activation of Fransforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Mice", Nature, 370 460-462, (Aug. 11, 1994) C172 Grainger, D.J., et al., "Active and Acid-Activatable TGF-beta in Human Sera, Platelets and Plasma", Chnica Chemica Acta., 235, 11-31, (Feb., 1995)		C162	Grainger and Metcalfe, "Transforming growth factor-β and cardiovascular protection, draft" (NeoRx 019151-
Breit, SN and Wahl, SM (ed.), Birkhauser Verlag, 91-146 (2001) (DJG 0(6134-006190). C165 Grainger et al., "Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions", J. Cell Sci., 113:2355-2361(2000) C166 Grainger et al., "Red wine, but not white wine, elevates circulating TGF- β levels -possible role of a salicylate complex" C167 Grainger et al., "Transforming growth factor-beta dynamically regulates vascular smooth muscele cell differentiation in vivo", J. Cell Sci., 111:2977-2988 (1998) C168 Grainger, D.J., "Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis", Arterioscler, Thromb. Vasc. Biol., 24:399-404 (2004) (DJG 006208-006213) C169 Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis?", Biol. Rev., 70, 57 k,596, (1995) C170 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) in vivo", Circulation, 90, 67° Scientific Session, Abstract No. 3353, p. 1-623, (Oct., 1994) C171 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Mice", Nature, 370-460-462, (Aug. 11, 1994) C172 Grainger, D.J., et al., "Active and Acid-Activatable TGF-beta in Human Sera, Platelets and Plasma", Clinica Chemica Acta., 238, 11-31, (Feb., 1995)		C163	Grainger and Metcalfe, TGF-beta: implications for human vascular disease. J Hum Hypertens., 9(8):679 (1995)
 vascular endothelium and formation of lipid lesions", J. Cell Sci., 113:2355-2361(2000) C166 Grainger et al., "Red wine, but not white wine, elevates circulating TGF- β levels -possible role of a salicylate complex" C167 Grainger et al., "Transforming growth factor-beta dynamically regulates vascular smooth muscele cell differentiation in vivo", J. Cell Sci., 111:2977-2988 (1998) C168 Grainger, D.J., "Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis", Arterioscler, Thromb. Vasc. Biol., 24:399-404 (2004) (DJG 006208-006213) C169 Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis?", Biol. Rev., 70, 57 k-596, (1995) C170 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) in vivo", Circulation, 90, 67° Scientific Session, Abstract No., 3353, p. 1-623, (Oct., 1994) C171 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Mice", Nature, 370 460-462, (Aug., 11, 1994) C172 Grainger, D.J., et al., "Activation Acid-Activatable TGF-beta in Human Sera, Platelets and Plasma", Chnica Chemica Acta, 235, 11-31, (Feb., 1995) 		C164	Breit, SN and Wahl, SM (ed.), Birkhauser Verlag, 91-146 (2001) (DJG \(\delta \) 06134-006190).
complex" C167 Grainger et al., "Transforming growth factor-beta dynamically regulates vascular smooth muscele cell differentiation in vivo", J. Cell Sci., 111:2977-2988 (1998) C168 Grainger, D.J., "Transforming growth factor beta and atherosclerosis: so far. so good for the protective cytokine hypothesis", Arterioscler, Thromb. Vasc. Biol., 24:399-404 (2004) (DJG 006208-006213) C169 Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis?", Biol. Rev., 70, 571-596, (1995) C170 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) in vivo", Circulation, 90, 67" Scientific Session, Abstract No., 3353, p. 1-623, (Oct., 1994) C171 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Mice", Nature, 370, 460-462, (Aug., 11, 1994) C172 Grainger, D.J., et al., "Active and Acid-Activatable TGF-beta in Human Sera, Platelets and Plasma", Clinica Chemica Acta, 235, 11-31, (Feb., 1995)		C165	vascular endothelium and formation of lipid lesions", J. Cell Sci., 113:2355-2361(2000)
differentiation in vivo", J. Cell Sci., 111:2977-2988 (1998) C168 Grainger, D.J., "Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis", Arterioscler, Thromb. Vasc. Biol., 24:399-404 (2004) (DJG 006208-006213) C169 Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis?", Biol. Rev., 70, 571-596, (1995) C170 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) in vivo", Circulation, 90, 67th Scientific Session, Abstract No., 3353, p. 1-623, (Oct., 1994) C171 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Mice", Nature, 370, 460-462, (Aug., 11, 1994) C172 Grainger, D.J., et al., "Active and Acid-Activatable TGF-beta in Human Sera, Platelets and Plasma", Clinica Chemica Acta, 235, 11-31, (Feb., 1995)		C166	complex"
hypothesis", Arterioscler, Thromb. Vasc. Biol., 24:399-404 (2004) (DJG 006208-006213) C169 Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis?", Biol. Rev., 70, 571-596, (1995) C170 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) in vivo", Circulation, 90, 67th Scientific Session, Abstract No. 3353, p. 1-623, (Oct., 1994) C171 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Mice", Nature, 370 460-462, (Aug. 11, 1994) C172 Grainger, D.J., et al., "Active and Acid-Activatable TGF-beta in Human Sera, Platelets and Plasma", Clinica Chemica Acta, 235, 11-31, (Feb., 1995)		C167	differentiation in vivo", J. Cell Sci., 111:2977-2988 (1998)
C170 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) in vivo", Circulation, 90, 67th Scientific Session, Abstract No. 3353, p. 4-623, (Oct., 1994) C171 Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Mice", Nature, 370 460-462, (Aug. 11, 1994) C172 Grainger, D.J., et al., "Active and Acid-Activatable TGF-beta in Human Sera, Platelets and Plasma", Chrica Chemica Acta, 235, 11-31, (Feb., 1995)		C168	hypothesis", Arterioseler, Thromb. Vasc. Biol., 24:399-404 (2004) (DJG 006208-006213)
Circulation, 90, 67th Scientific Session, Abstract No. 3353, p. 1-623, (Oct., 1994) C171 Grainger, D.J., et al., "Activation of Fransforming Growth Factor-beta is Inhibited in Transgenic Applipoprotein (a) Mice", Nature, 370 460-462, (Aug. 11, 1994) C172 Grainger, D.J., et al., "Active and Acid-Activatable TGF-beta in Human Sera, Platelets and Plasma", Chinica Chemica Acta, 235, 11-31, (Feb., 1995)		C169	
(a) Mice", Nature, 370 460-462, (Aug. 11, 1994) C172 Grainger, D.J., et al., "Active and Acid-Activatable TGF-beta in Human Sera, Platelets and Plasma", Chnica Chemica Acta., 235, 11-31, (Feb., 1995)		C170	Circulation, 90, 67th Scientific Session, Abstract No. 3353, p. 1-623, (Oct., 1994)
Chemica Acta., 235, 11-31. (Feb., 1995)		C171	(a) Mice", Nature, 370 460-462, (Aug. 11, 1994)
C173 Grainger, D.J., et al., "Active TGF-beta is Depressed Five-fold in Triple Vessel Disease Patients Compared with		(172	Chemica Acta., 235, 11-31, (Feb., 1995)
		 C173	Grainger, D.J., et al., "Active TGF-beta is Depressed Five-fold in Triple Vessel Disease Patients Compared with

			of Application No. 09-910,388
7	Γ		Syndrome X Patients", Journal of Cellular Biochemistry, 18A, Abstract No. E111, p. 267, (1994)
		C174	Grainger, D.J., et al., "Active Transforming Growth Factor-beta is Depressed in Patients with Three Vessel Coronary Artery Disease", Circulation, 90, 67 th Scientific Sessions, Abstract No. 2754, p. 1-512, (Oct., 1994)
		C175	Grainger, D.J., et al., "Mitogens for Adult Rat Aortic Vascular Smooth Muscle Cells in Scrum-Free Primary Culture", Cardiovascular Research, 28, 1238-1242, (1994)
	1	C176	Grainger, D.J., et al., "Proliferation of Human Smooth Muscle Cells Promoted by Lipoprotein(a)", Science, 260, 1655-1658, (June 11, 1993)
		21-7	Grainger, D.J., et al., "Release and Activation of Platelet Latent TFG-Beta in Blood Clots During Dissolution with Plasmin", Nature Medicine, 1, 932-937, (1995)
		C1.3	Grainger, D.J., et al., "Famoxifen Elevates Transforming Growth Factor-beta and Suppresses Diet-Induced Formation of Lipid Lesions in Mouse Aorta", Nature Medicine, 1, 1067-1073, (Oct., 1995)
		C179	Grainger, D.J., et al., "Tamoxifen: Teaching an Old Drug New Tricks?", Nature Medicine, 2, 381-385, (Apr., 1996)
		C180	Grainger, D.J., et al., "The Serum Concentration of Active Transforming Growth Factor-beta is Severely Depressed in Advanced Atherosclerosis", Nature Medicine, 1, 74-80, (Jan., 1995)
		C181	Grainger D.J., et al., "Transforming Growth Factor beta Decreases the Rate of Proliferation of Rat Vascular Smooth Muscle Cells by Extending the G2 Phase of the Cell Cycle and Belays the Rise in Cyclic AMP Before Entry into M Rhase", Biochemical Journal, 299, 227-235, (1994)
		C182	Grainger, D.J., et al., "Transforming Growth Factor-beta and Cardiovascular Protection", In: The Eendothelium in Clinical Practice, Rubanyi, G.M., et al., (eds.), Marcel Dekker, Ing. New York, 203-243, (1997)
		C183	Grainger, D.J., et al., "Fransforming Growth Factor-beta is sequestered into an Inactive Pool by Lipoproteins", Journal of Lipid Research, 38, 117-125, (1997)
		C184	Grainger, D.J., et al., "Transforming Growth Factor-beta: The Key to Understanding Lipoprotein(a)?", Current Opinion In Lipidology, 6, 81-85, (1995)
		C185	Grainger, D.J., University of Cambridge Ph.D. Ness, Control of the proliferation and differentiation of vascular smooth muscle cells, DJG 0059 1-006102 (1992) and all references therein
,		C186	Gravlee, G.P. MD, Heparin-Coated Cardiopulmonary Bypass Circuits, Journal of Cardiothoracic and Vascular Anesthesia, Vol. 8, No. 2, April 1994, pp. 213-222
	_	C187	Gref. et al., "Biodegradable Long-Circulating Polymeric Nanoshoeres", Science, 263, 1600-1603, (March 18, 1994)
		C188	Gregory et al., "Rapamycin Inhibits Arteria Intimal Thickening Caused by Both Alloimmune and Mechanical Injury:, Transplantation, 55 1409-1418 (1993)
· · · · · · · · · · · · · · · · · · ·		C.186	Gregory et al., "Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury", Transplant. Proc., 25:120-21 (1993) Grese, T.A., et al., "Structure-Activity Relationships of Selective Estrogen Receptor Modulators: Modification to
· · · · · · · · · · · · · · · · · · ·		C190	the 2-Arylbenzothiophene Core of Raloxifene", J. Med. Chem., 40, 146-167, (1997) Grey, A.B., et al., "The Effect of the Anti-Estrogen Tamoxifen on Cardiovascular Risk Factors in Normal
		C.161	Postmenopausal Women", J. Clinical Endocrinology and Metabolism, 80, 3191-3195, (1995) Grigg, L.E., et al., "Determinants of Restenosis and Lack of Effect of Dietary Supplementation with
		C192	Eicosapentaenoic Acid on the Incidence of Coronary Artery Restenosis After Angioplasty", JACC, 13, 655-672, (1989)
		C193	Gruntzig, et al., "Nonoperative Dilatation of Coronary-Artery Stendsis," New England J. Med., 1979 Jul 12:301(2):61-68.
		C194	Guba et al., "Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor", Nat. Med., 8(2):128-35 (2002)
		C195	Guetta, V., et al., "Effects of the Antiestrogen Tamoxifen on Low-Density Lipoprotein Concentrations and Oxidation in Postmenopausal Women", The American Journal of Cardiology, 76, 1072-1073, (November 15, 1995)
		CT96	Gulino, A., et al., "Heterogeneity of Binding Sites for Tamoxifen and Tamoxifen Derivatives in Estrogen Target and Nontarget Fetal Organs of Guinea Pig. Cancer Research 42, 1913-1921, (May 1982)
		(*197	Guyton et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparin: In vivo studies with anticoagulant and noncoagulant heparin", Circ. Res., 46(5):625-634 (1980)
		C198	Gylling, H., et al., "Tamoxifen and Toremifene Lower Serum Cholesterol by Inhibition of Relta8-Cholesterol Conversion to Lathosterol in Women with Breast Cancer", Journal of Clinical Oncology, 13, 2000-2005, (1995)
		C199	Gylling, H., et al., "Tamoxifen Decreases Serum Cholesterol by Inhibiting Cholesterol Synthesis". Atherosclerosis, 96, 245-247, (1992) Hafzi et al., "Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth
		C200	muscle cell proliferation and signalling", Vascul, Pharmacol., 41;167-76 (2004) Hahn, L., et al., "The Influence of Acetylsalicylic Acid and Paracetamol on Menstrual Blood Loss in Wortan With
		(20)	and Without an Intrauterine Contraceptive Device", Am. J. Obstet. Grecol., 135, 393-396, (1979)
		C 202	Hall, I.H., et al., "Hypolipidemic Activity of Tetrakis-mu-(trimethylamine-boranecarboxylato)-bis (trimethylamine-carboxyborane) -dicopper (II) in Rodents and Its Effect on Lipid Metabolism", J. Pharmaceur Sci., 73, 973-977, (1984)
		C203	Hanson, et al., "In vivo evaluation of artificial surfaces with a nonhuman primate model of arterial thrombosis, "J. Lab. Clin. Med. 95:289-304; 1980

			of Application No. 49 910,388
9		C204	Hanson, et al., "Testing of Blood – Materials Interactions," Biomaterials Science (B.D. Ratner, Ed.), Academic Press, 222-238 (1996).
		C205	Hanson, S., "Device Thrombosis and Thromboembolism," Cardiovasc Pathol. 2(3) (Suppl.): 157S-165S (July-Sept. 1993)
		C206	Harpel, et al., "Lp(a) Inhibitor of Plasminogen," Proc. Natl. Acad. Sci. USA, 86, 3847 (1989)
		C207	Harrison, D.C., "Nonatherosclerotic Coronary Artery Disease", In.: Atherosclerosis and Coronary Artery Disease, V. Fuster, et al., (eds.), Lippencott-Raven Publishers, pp. 757-772, (1996)
		\(208\)	Hayden, L.J., "Inhibitors of Gastric Lesion in the Rat", J. Pharm. Pharmac., 30, 244-246, (1978)
		C340	Hayes, D.F., et al., "Randomized Comparison of Tamoxifen and Two Separate Doses of Toremifene in Postmenopausal Patients with Metastatic Breast Cancer", Journal of Clinical Oncology, 13, 2556-2566, (Oct. 1995)
		C210	Hehrlein, C., et al., "Low-Dose Radiactive Endovascular Stents Prevent Smooth Muscle Cell Proliferation and Neointimal Hyperplasia in Rabbits", Circulation, 92, 1570-1575, (1995)
		C211	Hehrlein, C., et al., "Pure Beta-particle-emitting Stents Inhibit Neointima Formation in Rabbits", Circulation, 93, 641-643 (1996)
		C212	Hermann and Hirshfeld, Jr., "Clinical Use of the Palmaz-Schatz Intracoronary Stent," Futura Publishing Co. (1993).
		C213	Hoffman, A., Modification of Material Surfaces to Affect Flow They Interact with Blood, Blood in Contact with Natural and Artificial Surfaces," Leonard, E. et al., (eds.), Annals of the New York Academy of Sciences, 516:96-100 (1987)
	ļ	C214	Holmes, et al., "Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis", Circulation, 109:634-640 (2004)
		C215	Holmes, Jr., D.R., "Remodeling Versus Smooth Muscle Cell Hyperpasia", Restenosis Summit VI, The Cleveland Clinic Foundation, 222-22, (1994)
		C216	Hoover, et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparia; ID by vitro studies", Circ. Res., 47(4):578-83 (1980)
		C217	Hopfenberg, H., "Transport Through Polymers, 7 Encyclopedia of Materials, Science and Engineering," (Michael B. Bever, (ed.); The MIT Press, 5 N1-5145 (1986)
		C218	Howell, A., et al., "New Endocrine Nierapies for Breast Cancer". European Journal of Cancer, 32A, 576-588, (1996)
		C219	Hsu, Li-Chien "Principles of Heparin-Coating Techniques", Perfusion 6 209-219 (1991)
	1	C220	Huang, et al., "Rapamycins: mechanism of action and collular resistance," Cancer Biol. Ther., 2(3):222-32 (2003)
		C221	Huang, S.S., et al., "Transforming Growth Factor Beta peptide Antagonists and Their Conversion to Partial Agonists", The Journal of Biological Chemistry, 272(43), 271-5-57159, 1997
		C222	Huehns, et al., "Adventitia as a Trarget for Intravascular Local Drug Delivery", Heart, 75, 437-438 (1996)
MIN 1		C223	Hughes, D.E., et al., "Estrogen Promotes Apoptosis of Murine Osteoclasts Mediated by TFG-beta", Nature Medicine, 2, 1132-1136, (1996)
		(,554	Ishihara, et al., "Synthesis of phospholipid polymers having a urethane bond in the side chain as coating material on segmented polyurethane and their platelet adhesion-resistant properties,"Biomaterials, 1995-16(11): 873-879
		C225	Isner, "Vascular Remodeling: Honey, I Think I Shrunk the Arrery", Circulation, 89 2937-2841 (June 1994).
		C226	Jacinto and Hall, "Tor signalling in bugs, brain and brawn", Nature Rev. Mol. Cell Biol., 4:117-126 (2003)
		C227	Jande et al., "Effects of cytochalasin B and dihydrocytochalasin B on calcium transport by intestinal absorptive cells", Calcif. Tissue Int. 33, 143-151 (1981); Chem. Abs. 94 Abstract No. 189223e (1981)
	.	C228	Hubbell, J.A., "Pharmacologic Modification of Materials", Cardiovasc Patrol., Vol. 2, No.3 (Suppl.), July-Sept. 1993, pp. 1215-1278
		C229	Jeng, et al., "Regulation of the levels of three transforming growth factor beta mRNAs by estrogen and their effects on the proliferation of human breast cancer cells", Mol. Cell Endocrinol., 92:115-123 (1993)
		C230	Jenkins et al., "Local Delivery of Taxol Inhibits Neointimal Regrowth Following Balloon Injury of the Rat Carotid Artery: , Circulation, 90, p. 1-297, Abrstract No. 1596 (Oct. 1994)
		C231	Johnston, S.R., et al., "Changes in Estrogen Receptor, Progesterone Receptor, and ps2 Expression in Tamoxifen- resistant Human Breast Cancer", Cancer Research, 55, 3331-3338, (August 1995)
		C232	Jones, R.H., et al., "Increased Susceptibility to Metal Catalysed Oxidation of Diabetic Lens Beta subl. Crystallin: Possible Protection by Dietary Supplementation with Acetylsalicyclic Acid", Exp. Eye Res., 57x783-790, (1993)
		C233	Jordan, A. et al., "Tubulin as a Target for Anticancer Drugs: Agents which Interact with the Mitotic Spindle", Medicinal Research Reviews, 18, 259-296, (1998)
		C234	Jordan, V.C., et al., "A Mutant Receptor as a Mechanism of Drug Resistance to Tamoxifen Treatment". Annals New York Academy of Science, 761, 138-147, (1995)
		C235	Jordan, V.C., et al., "Structural Requirements for the Pharmacological Activity of Nonsteroidal Antiestrogens in Vitro", Molecular Pharmacology, 26, 272-278, (1984)
		C236	Jordan, V.C., et al., "Tamoxifen: Toxicities and Drug Resistance During the Treatment and Prevention of Breast Cancer", Annu. Rev. Pharmacol. Toxicol., 35, 195-211, (1995)
		C237	Joswig, B.C., et al., "Transmural Myocardial Infarction in the Absence of Coronary Arterial Luminal Narrowing in

A MARKAN MARKAN STATE OF THE ST

		of Application No. 09 910,388
		a Young Man with Single Coronary Arterial Anomaly", Catheterization and Cardiovascular Diagnosis, 4, 297-304, (1978)
	C238	Kakuta, T., et al., "Differences in Compensatory Vessel Enlargement, Not Intimal Formation, Account for Restenosis After Angioplasty in the Hypercholesterolemic Rabbit Model", Circulation, 89, 2809-2815, (1994)
	C239	Kakuta, T., et al., "The Impact of Arterial Remodeling on the Chronic Lumen Size After Angioplasty in the Atherosclerotic Rabbit", JACC, Abstract No. 875-95, p. 138A, (Feb., 1994)
	C240	Kanzaki, et al., "In vivo effect of TGF-beta1: enhanced intimal thickening by administration of TGF-beta1 in rabbit arteries injured with a balloon catheter". Arterioscler, Thromb. Vasc. Biol., 15(11):1951-57 (1995)
	(241	Kardami et al., "Heparin Inhibits Skeletal Muscle Growth in Vitro", Dev. Biol., 126:19-28 (1988)
	(5)	Kariya et al., "Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells". Atherosclerosis, 80:143-147 (1989)
	C243	Kaski, J.C., et al., "Local Coronary Supersensitivity to Diverse Vasoconstrictive Stimuli in Patients with Variant Angina", Circulation, 74, 1255-1265, (1996)
	C244	Kastrati et al., "Restenosis after coronary placement of various stent types," Am. J. Cardiol., 87:34-49 (2001)
	C245	Ke, H.A. et al., "Comparative Effects of Droloxifene, Tamoxifen, and Estrogen on Bone, Serum Cholesterol, and Uterine Histology in the Ovariectomized Rat Model", Bone, 20, 31-39, (1997)
	C246	Keen, C.L., et al., "Hypertension Induced Alterations in Copper and Zinc Metabolism: A Link to Vascular Disease?", In: Biology of Copper Complexes, Sorenson, J.R.J., (ed.), Humana Press, Clifton, New Jersey, 141-153, (1987)
	C247	Kellen, J.A., "Tanhaoxifen Beyond the Antiestrogen", Birkh∑user, 392 pages, (1996)
	C248	Kellen, J.A., et al., "The Effect of Toremifene on the Expression of Genes in a Rat Mammary Adenocarcinoma", In Vivo, 10, 511-514, (1996)
	C249	Kemp, P.R., et al., "Cloning and Analysis of the Promoter Region of the Rat SM11-Alpha Gene", Biochem, J., 310, 11043, (1995)
	C250	Kemp, P.R., et al., "Inhibition of PDGF BB Stimulated DNA Synthesis in Rat Aortic Vascular Smooth Muscle Cells by the Expression of a Truncated PDGF Receptor", FEBS Letters, 336, 119-123, (Dec., 1993)
	C251	Kemp, P.R., et. al., "ID A Dominant Negative Regulator of Skeletal Muscle Differentiation is Not Involved in Maturation or Differentiation of Nascular Smooth Muscle Cells", FEBS Letters, 368, 81-86, (1995)
	C252	Kim, et al., "Suppression of Vascular Transforming Growth Factor-B1 and Extracellular Matrix Gene Expressions by Cilazapril and Nifedipine in Hypertensive Rats", Clin. Exp. Pharmacaol. Physiol. Suppl., 1, S355 (1995)
-	C253	Kim, J. et al., "Production of Taxol and Related Taxanes in Taxus brevifolia Cell Cultures: Effect of Sugar. Biotechnology Letters, 17, 101-106, (Jan., 1995)
	C254	Kingston, D.G., et al., "Synthesis and Structure-Activity Relationships of Taxol Derivatives, anticancer Agents". In: New Trends in Natural Products Chemistry, Atta-ur-Rahman, et al., (eds.), Studies in Organic Chemistry, Vol. 26. Elsevier Science Publishes, B.V., Amsterdam, 209-235, (1986)
*	C255	Kirk-Othmer, Encyclopedia of Chemical Technology, 33rd edition, Vol. 17, 1981 John Wiley & Sons, pp. 281-310
	C256	Kirschenlohr, H.L., et al., "Cultures of Proliferating Vascular Smooth Mascle Cells from Adult Human Aorta", In: Human Cell Culture, Jones, G.E., (ED.), Humana Press, Inc., 24 p. (1996)
	C257	Kirschenolohr, H.L., et al., "Proliferation of Human Aortic Vascular Smooth Muscle Cells in Culture is Modulated by Active TGF-Beta", Cardiovascular Research, 29, 848-855, (1995)
	C258	Klebe et al., "Regulation of cell motility, morphology, and growth by sulfated glycosaminoglycans", Cell Motil. Cytoskel., 6:273-281 (1986)
	(259	Klein, H.O. et al., "Experimental Investigations on a Sequential Combination Chemotherapy Protocol" J. Cancer Res. Clin. Oncol vol 96 no.2 Jan, 1980 p 65-78
	C260	Kleinman, N.S., et al., "Prinzmetal's Angina during 5-Fluorourach Chemotherapy". The American Journal of Medicine, 82, 566-568, (1987)
	·C261	Knabbe, C., et al., "Induction of Transforming Grown Factor-B by the Antiestrogens Droloxifene, Tamaoxifen, and Toremifene in MCF-7 Cells", Am. J. Clin. Oncol. 14, S15-S20, (1981)
	C262	Kopp, A., et al., "Transforming Growth Factor Beta2 (TGF-Beta2) Levels in Plasma of Patients with Metastatic Breast Cancer Treated with Tamoxifen", Cancer Research, 55, 4512-4515, (Qct. 15, 1995)
	C263	Kost, J. Langer R. "Controlled Release of Bioactive Agents." Trends in Biotechnology, Vol. 2, No. 2, 1984, pp. 47-51
	C264	Kotoulas, I.G., et al., "Tamoxifen Treatment in Male Infertility. I. Effect on Spermatozoa", Fertility and Sterility. 61, 911-914, (May 1994)
	; ;	Koyama, N., et al., "Regulation of Smooth Muscle Cells Migration by a New Autocrine Tigration Factor and TGF-beta", Circulation, 84, Abstract No. 1829, II-459, (1991)
		Kremer, J.M., et al., "Fish-Oil Fatty Acid Supplementation in Active Rheumatoid Arthritis", Annals of Internal Medicine, 106, 497-502, (1987)
		Kunert, et al., "Paclitaxel Inhibits Developpment of Restenosis Following Experimental Balloon Angioplasty in the Rabbit Carotid Artery: European Heart Journal, 17, Abstract No. P1998, p. 368 (1996) Kunz et al., "Defining Corpners Rastenosis Names" (Finingle Artery) (1998) (1996)
		Kunz et al., "Defining Coronary Restenosis Newer Clinical and Angiographic Paradigms", Circulation 88 1310-1323 (September 1993) Kunz et al., "Suggestined Dilution and Inhibition of Paramidian Para
	C269	Kunz et al., "Sustained Dilation and Inhibition of Restenosis in a Pig Femoral Atery Injury Model", Circulation, 90, p 1-297, Abstract NO, 1598 (October 1994)

		of Application No. 09 910,388
	(270	Kunz et al., "Inhibition of Microfilament Reorganization Following Balloon Angioplasty Decreases Extent of
`		Geometric Remodeling in Restenosis, "J. of Amer. Coll. of Cardiology. A Merican College of Geometric
		Cardiology 44 th Annual Scientific Session, Abstract No. 122292, (March 19-22, 1995)
	(271	Kunz, L.L., et al., "Efficacy of Cytochalasin B in Inhibiting Coronary Restenosis Caused by Chronic Remodeling After Balloon Trauma in Swine", Journal of the American College of Cardiology, Supplement A., Abstract No. 984-23, p. 302, (Mar. 1995)
	(272	Kuramochi, H., "Conformational Studies and Electronic Structures of Tamoxifen and Toremifene and Their Allylic Carbocations Proposed as Reactive Intermediates Leading to DNA Adduct Formation", J. Med. Chem., 39, 2877-2886. (1996)
	C273	Kuzana, S., et al., "Effects of Some Anti-Rheumatic Agents on Copper-Catalyzed Thermal Aggregation of Gamma Globulin", Agents and Actions, 9 375-380, (1979)
	274	L.C., Palmaz et. al., Expandable Intraluminal Graft: A Preliminary Study, Radiology 1985;1:73-77.
	(27)	Labhsetwar et al., "Nanoparticles for site specific delivery of U-86983 in restenosis on pig coronary arteries," Proc. Intern. Symp. Control. Rel. Bioact. Mater. 22, 182-183 (1995).
	C276	Naird, J., et al., "Inhibition of Neointimal Proliferation with Low-dose Irradiation from a Beta-particle-emitting Stort", Circulation, 93, 529-536, (1996)
	C277	Langbein, W., "Too Many Drugs, Too Little Value in CV Conditions", In Vivo, 14-20, (June, 1995)
	C278	Lange, R.A., et al., "Cocaine-Induced Coronary-Artery Vasoconstriction", The New England Journal of Medicine, 321, 155 (1562, (1989))
	C279	Lange, R.L. et al., "Nonatheromatous Ischemic Heart Disease following Withdrawal from Chronic Industrial Nitroglycerin Exposure", Circulation, 46, 666-678, (1972)
	C280	Langer, R. et al., Polymeric Delivery Systems for Macromoleculus-Approaches for Studying In Vivo Release Kinetics and Designing Constant Rate Systems", in: <u>Biological Activities of Polymers</u> . Carraher, Jr. and Gebelein (eds), American Chemical Society Symposium Series 186 (pp. 95-105 (1982)
	C.581	Langer, R. et al., "Polymers for the Sustained Release of Proteins and Other Macromolecules", Nature 263:797-799 (1976)
·············	* C282	Langer, R., "New Methods of Drug Delivery", Science, Vol. 249, 28.09 1990, pp. 1527-1533
	C283	Langer, R., "Polymeric Delivery Systems for controlled Drug Release", Chem. Eng. Communi. 6:1-48 (1980)
	C284	Law et al., "Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer ells", Mol., Cell. Biol., 22:8184-8198 (2002)
	C285	Lawn, R.M., et al., "Feedback Mechanism of Focal Vascular Lesion Formation in Transgenic Apolipoprotein(a) Mice", The Journal of Biological Chemistry 271, 31367-31371, (1996)
	C286	Lazier, C.B., et al., "Comparison of the Effects of Tamoxifen and of a Tamoxifen Analogue that Does Not Bind the Estrogen Receptor on Serum Lipid Profiles in the Cockerel", Biochem. Cell Biol., 68, 210-217, (1990)
	C'287	L.C. Palmaz et al., Expandable Intraluminal Vascular Graft: A Feasibility Study, Surgery 1986 Feb; 199(2): 199-205.
	C288	Lehmann, K. et al., "Effect of cilazapril on the proliferative response after vascular damage", J. of Cardiovascular Pharmacology, 22 (Suppl. 4), S19-24, (1993)
•	C289	Lehmann-Bruinsma, et al., "Transforming Growth Factor B2 (TGF-B) Suppression of Smooth Muscle Cell (SMC) Proliferation After Balloon Angioplasty of Rat Carotid Arteries", Clin. Res. 42. Abstract No. 4A, (February 9-12, 1994)
	C290	Leroux, J.C., et al., "Internalization of poly(d L-lactic acid) nanaparticles by isolated human leukocytes and analysis of plasma proteins absorbed onto the particles", J. Biomed. Mater. Res. 28, 471-481, (1994)
	C291	Leroux, et al., "New Approach for the Preparation of Nanoparticles by an Emulsification-Diffusion Method", Eur. J. Pharm. Biopharm, 41, 14-18, (1995)
	C292	Levy, et al., "Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants," Chemical Abstracts, 121, 580; Abstract No. 263625g (1994)
	C293	Levy, R.J., et al., "Strategies for Treating Arterial Restonosis Using Polymeric Controlled Release Implants", In: Biotechnology and Bioactive Polymers, Proceedings of an American Chemical Society Symposium, Gebelein, C.G., (ed.), Plenum Press, New York, 259-268, (1994)
	(*294	Liau and Chan, "Regulation of extracellular matrix RNA levels in cultured smooth muscle cells: relationship to cellular quiescence", J. Cell Biol., 264:10315-10320 (1989)
	C295	Lichtlen et al., "Retardation of angiographic progression of coronary artery disease by difedipine", Lancet, 335:1109-1113 (1990)
	C296	Lincoff et al., "Local Drug Delivery for the Prevention of Restenosis" Circulation, 90 2070 2084 (October 1994)
	C297	Lindkaer-Jensen, S., et al., "Inhibition of Salicylate and Lithium Absorption in the Human Intestine by Copper Sulfate", Arch. Toxicol., 35, 175-179, (1976)
	C298	Lindner, "Vascular repair processes mediated by transforming growth factor-beta, Z Kardiol", 90 Suppl 3:17-22 (2001)
	* C299	Lipold, B.C., "Retardarzneiformen" in E. Numberg, Hagers Handbuch der pharmazeutischen Praxis, Vol. 2, Springer-Verlag Berlin Heidelberg New York, 5 th edition, 1991 pp. 832-840
	C300	Lippman and Mathews, "Heparins: varying effects on cell proliferation in vitro and lack of correlation with anticoagulant activity", Fed. Proc., 36:55-59 (1977)
A 11 11 A 144 2		

AND CONTROL OF THE STATE OF THE

			of Application No. 09 910,388
		C301	Liu et al., "Trapidil in preventing restenosis after balloon angioplasty in the atheroselerotic rabbit", Circulation, 81(3): 1089-1093 (1990)
		C302	Lopez-Anaya, A., et al., "Pharmacokinetics and Pharmacodynamics in Copper Deficiency I", Biological Trace Element Research, 40, 161-176, (1994)
	1	C303	Lopez-Casillas, et al., "Beta-gly can Presents Ligand to the TGFBeta Signaling Receptor", Cell. 73, 1435-1444, (July 2, 1993)
		C304	Loser, R., et al., "In Vivo and in Vitro Antiestrogenic Action of 3-Hydroxytamoxifen, Tamoxifen and 4- Hydroxytamoxifen", Eur. J. Cancer Clin. Oncol., 21, 985-990, (1985)
		C305	Lowe, et al., "Coronary In-Stent Restenosis: Current Status and Future Strategies". Journal of the American College of Cardiology, 1992, Vol. 39 No. 2, pp. 183-193.
		C\$06	Luan et al., "Rapamycin is an effective inhibitor of human renal cancer metastasis", Kidney Int., 63:917-926 (2003)
		C307	Lucas, C., et al., "The Authorrine Production of Transforming Growth Factor-B1 During Lymphocyte Activation", The Journal of Immunology, 145(5), 1415-1422, (1990)
		C308	Ludwig K. von Segesser, MD., "Heparin-Bonded Surfaces in Extracorporeal Membrane Oxygenation for Cardiae Supports, The Society of Thoracic Surgeons, (1996)
		C309	Luo, H. et al., "Chronic Vessel Constriction is an Important Mechanism of Restenosis After Balloon Angioplasty:
		C310	An Intravascular Ultrasound Analysis", Circulation, 90, 67 Scientific Sessions, Abstract No. 0318, p. 1-61, (1994) Luostarinen, R., et al., "Effect of Dietary Fish Oil Supplemented with Different Doses of Vitamin E on Neutrophil
		C311	Chemotaxis in Nealthy Volunteers", Nutrition Research, 12, 1419-1430, (1992) Lutgens et al., "Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression", Arterioscler, Thromb. Vasc. Biol., 22:975-982 (2002)
		C312	Lyons et al., "Mechanism of activation of latent recombinant transforming growth factor beta1 by plasmin", J. Cell. Biol., 110:1361-1367 (1990)
		C313	Macander et al., "Balloon Angioplasty for Treatment of In-Stent Restenosis: Feasibility, Safety, and Efficacy", Catheterization and Cardiovascular Diagnosis, 32 125-131 (1994)
		C314	Madri et al., "Endothelial cell behavior after denudation injury is modulated by transforming growth factor-betal and fibronectin", Lab. Invest., 60;755-764 (1989)
		C315	Magarian, "The Medicinal Chemistry of Nonsteroidal Antiestrogens: A Review," Current Medicinal Chemistry, 1, 61-104, (1994)
		C316	Majack, "Beta-type transforming growth factor specifies organizational behavior in vascular smooth muscle cell cultures". J. Cell Biol., 105:465-471 (1987)
		C317	Majack, R.A., et al., "Role of PDGF-A Expression in the Control of Vascular Smooth Muscle Cell Growth by Transforming Growth Factor-B", The Journal of Cell Biology 111, 239-247 (1990)
		C318	Majesky, M.W., et al., "Production of Transforming Growth Pagor betal During Repair of Arterial Injury", J. Clin. Invest., 88, 904-910, (1991)
		C319	Mambetisaeva, E.T., et al. "Effect of New Synthetic Cholesterol Derivatives on Cholesterol Metabolism in Cultured Rabbit Hepatocytes", Biokhimiya (Russia), 58, Translation, Plenum Publishing Corporation, 1126-1132, (1993)
		C320	Amiji, M., et al., "Surface Modification of Polymeric Materials with Poly (ethylene oxide), Albumin, and Heparin For Reduced Thrombogenicity," J. Biomater, Sci. Plymer Edn., Vol. 4, No. 3, pp. 217-234 (1993)
		C321	Manucci, P.M., et al., "Effect of Tamoxifen on Measurements of Hemostatis in Healthy Women", Arch. Intern. Med., 156, 1806-1810. (1996)
		C322	Marx and Marks, "Bench to Bedside: The development of rapamycin and its application to stent restenosis", Circulation 104:852-55 (2001)
		C323	Marx, "CMV-p.53 Interaction May Help Explain Clogged Arteries", Science, 265, 320, (Jul 1994)
		C324	Marzocchi, A., et al., "Restenosis after Coronary Angioplasty: It's Pathogenesis and Prevention," Cardiologia, 36, 309-320 (December, 1991) English Abstract only, reported in Medline, Accession, No. 93046311
		C325	Massague and Wotton, "Transcriptional control by the TGF-beta/Smad signaling system", EMBO J., 19(8):1745-54 (2000)
		C326	Massague et al., "Type beta transforming growth factor is an inhibitor" of myogenic differentiation", Proc., Natl. Acad. Sci., 83:8206-8210 (1986)
		C327	Massague, "Subunit structure of a high-affinity receptor for type beta-transforming growth factor; evidence for a disulfide-linked glycosylated receptor complex", J. Biol. Chem., 260(11):7059-7066 (1985)
~~~~~		C328	McAuslan, B.R., et al., "Cellular and Molecular Mechanisms in Angiogenesis", Trans. Ophthal. Soc. U.K., 100, 354-358, (1980)
		C329	VicCaffrey et al. "Genomic instability in the type II TGF-b1 receptor gene in atherosclerotic and restevotic vascular cells." J Clin Invest. 100:2182-2188 (1997)
		C330	McCaffrey et al., "Aging and arteriosclerosis: the increased proliferation of arterial smooth muscle cells isolated from old rats is associated with increased platelet-derived growth factor-like activity," J. Exp. Med., 467:163-174 (1988)
		C331	McCaffrey et al., "Decreased type II type ITGF-beta receptor ratio in cells derived from human atheroselerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1", J. Clin, Invest., 96:2667-2635
	للل		(1995)

CANDER TO SERVICE STATE OF THE SERVICE STATE OF THE

		<del></del>	of Application No. 09/910/388
	^	C332	McCaffrey, "TGF-betas and TGF-beta receptors in atherosclerosis," Cytokine and Growth Factor Rev., 11:103-114 (2000)
		C333	McCaffrey, T.A., et al., "Fucoidan is a Non-Anticoagulant Inhibitor of Intimal Hyperplasia", Biochemical and Biophysical Research Communications, 184, 773-781, (1992)
		C334	McCague, R., et al., "An Efficient, Large Scale Synthesis of Idoxifene (E)-1(4-12-(N-pyrrolidina) ethoxyly, L.
		C335	(4-iodophenyl) -2-phenyl-1-hutene)", Organic Preparations and Proc. Int., 26, 343-346, (1994)  McCague, R., et al., "Synthesis of 4-Stannylated Tamoxifen Analogues: Useful Precursors to Radiolabelled
	$\downarrow \downarrow$		[ Idoxifene and Axiridinyl 4-lodotamoxifen.", J. Labelled Compounds and Pharmaceuticals 34, 297-302, (1994)
	$\lambda$	C336	137 (1987), 132-137, (1987)
		C337	in a randomised trial", BMJ, 311, 977-980, (October 14, 1995)
		/338	estrogens", Molecular Endocrinology, 9, 65-669, (June 1995)
		C3.60	McLaughlin, C.S., et al., "Inhibition of Protein Synthesis by Trichothecenes", In: Mycotoxins in Human and Animal Health, Pathotox Publishers, Inc., 263-273, (1977)
		C340	McMurray et at., "A standardised method of culturing aortic explants, suitable for the study of factors affecting the phenotypic modulation, migration and proliferation of aortic smooth muscle cells," Atherosclerosis, 86:227-437 (1991)
		C341	12% (1991)
		C342	<u></u>
	<u>·                                       </u>	C343	<u></u>
		C344	Merrilees and Scott, "Antisense S-oligonucleotide against transforming growth factor-beta 1 inhibits proteoglycan synthesis in orderial wall." L Vase, Res. 31:322-329 (1994)
		C345	Merrilees et al., "Effect of TGF-beta(1) antisense S-oligonucleotide on synthesis and accumulation of matrix proteoglycans in balloon catheter-injured neointima of rabbit carotid arteries. 3". Vasc. Res. 37:50-60 (2000)
		C346	Netcaire et al., "Calcium and cell profiferation," Br. Med., Bull., 42(4):405-412 (1986)
		C347	Metcalfe, et al., "Protein Markers of Lesion Development in the Vessels of Transgratio Apo(a) Mice" Inflammation, Growth Regulatory Molecules & Atherosclerosis, J. Cellular Biechem., Supplement 18A, p 208, Abstract No. E212 (1994)
		C348	Metcalfe, et al., "Transforming Growth Factor-beta and the Protection From Cardiovascular Injury Hypothesis".
		C349	Meyer, S.C., "Functionalized Cytochalasins for Potential Biolechhology Transfer", Ph. D. Thesis (Selected Pages), Syracuse University, New York, 13 p., (May, 1994)
		C350	Michael N. Helmus, "Materials Selection, Chapter 2: Entercopedic Handbook of Biomaterials and Bioengineering, Part A: Materials Vol. 1 (1995)
		C351	Michael N. Helmus, "Materials Selection, Chapter 6, Gardiovsc. Pathol. 2(3)(Suppl.):53s-71s (July-Sept. 1993)
		C352	Michael N. Helmus, "Materials Selector for Medical Devices," Spectrum, 1-21, (July 30, 1993)
		C353	Michael N. Helmus, "Medical Device DesignA Systems Approach: Central Venous Catheters", (1990)
		C354	Michael N. Helmus, "Opportunities for Biomaterials," DH Reports, (February 1995)
		C355	Michael N. Helmus, "Technological Advances in Thromboresistant Materials," Spectrum, 1-13 (June 19, 1990)
		C356	Michael N. Helmus, "Thromboresistant Biomaterials: Technical Developments and Applications," Spectrum, (Sept. 12, 1990)
······································		C357	Middlebrook, J.L., et al., "Binding of T-2 Toxin to Aukaryotic Cell Ribosomes", Biochemical Pharmacology, 38 33110, (1989)
		C358	Milner, M.R., et al., "Usefulness of Fish Oil Supplements in Preventing Clinical Evidence of Restenosis After Percutaneous Transluminal Coronary Angioplasty", Am. J. Cardiol., 64, 294-299 (1989)
78 - N L		C359	Mintz, G.S., et al., "Chronic Compensatory Arterial Dilation Following Coronary Angioplasty: An Intravascular L Itrasound Study", JACC, Abstract No. 875-97, p. 138A, (1eb., 1994)
		C360	Mintz, G.S., et al., "Geometric Remodeling is the Predominant Mechanism of Clinical Restenosis After Coronary Angioplasty", JACC, Abstract No. 875-42, p. 138A, (Feb., 1998)
		C361	Mintz, G.S., et al., "Mechanisms of Late Arterial Response to Transcatheter Therapy: A Serial Quantitative Angiographic and Intravascular Ultrasound Study", Circulation, 90, Abstract No. 117, p. 1-24, (Oct., 1994)
		C362	Mirjalili, N. et al., "Methyl Jasmonate Induced Production of Taxol in Suspension Cultures of Taxus Cuspidata: Ethylene Interaction and Induction Models", Biotechnol. Prog., 12, 110-N8, (1996)
***************************************		C363	Mirjalili, N., et al., "Gas Phase Composition Effects on Suspension Cultures of Taxus cuspidata", Biotechnology and Bioengineering, 48, 123-132, (1995)
***		C364	Mitchell, L.L., et al., "Copper Deficiency Depresses Rat Aortae Superoxide Disputase Activity and Prostacyclin Synthesis", Prostaglandins, 35, 977-986, (1988)
		C365	Molling, K., "Naked DNA for Vaccine or Therapy", J. Mol. Med., 75, 242-246, (1977)

		of Application No. 09/910,388
	C366	Moorthy, B., et al., "Tamoxifen Metabolic Activation: Comparison of DNA Abducts Formed by Microsomal and
		Chemical Activation of Tamoxifen and 4-Hydroxytamoxifen with DNA Abducts Formed in Vivo". Cancer
		Research, 56, 53-57, (Jan. 1, 1996)
	C367	More, R.S., et al., "A targeted antithrombotic conjugate with antiplatelet and fibrinolytic properties which reduce in vivo thrombus formation", Chemical Abstracts, Vol. 120, No. 22, (May 30, 1994)
	C368	Morris et al., "Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses
		narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growt factor action on immune and nonimmune cells." Transplant Proc. 27:430-31 (1995)
	369	Morris, R.E., "Rapamycins: Antifungal, Antitumor, Antiproliferative, and Immunosuppressive Macrolides".
		Transplantation Reviews, 6, 39-87, (1992)
	C370	Morris, R.E., et al., "Immunosuppressive Effects of the Morpholinoethyl Ester of Mycophenolic Acid (RS-61443) in Rat and Nonhuman Primate Recipients of Heart Allografts", Transplantation Proceedings, 23, 19-25, (1991)
	C371	Nosedale and Grainger, "An antibody present in normal human serum inhibits the binding of cytokines to their receptors in an in vitro system," Biochem J., 343:125-133 (1999)
	C372	Nosadale, D.E. University of Cambridge Ph.D. Thesis, Differentiated state of smooth muscle and its relationship to TGP-β in vivo, DJG 005652-005910 (1998) and all references therein
	C373	Mosedale, D.E., et al., "Transforming Growth Factor-beta is Correlated with Smooth Muscle Cell Differentiation in Vivo", Circulation, 90, 67th Scientific Session, Abstract No. 1590, p. 1-296, (Oct., 1994)
	C374	Mueller, B.M., et al., "Antibody Conjugates with Morpholinodoxorubicin and Acid-Cleavable Linkers", Bioconjugate Chem. 1, 325-330, (1990)
	C375	Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen", J. Stero Biochem, 34, 1-6 (1989)
	C376	Murphy, C.S., et al., Structure-Activity Relationships of Nonisomerizable Derivatives of Tamoxifen: Important
	(376	of Hydroxyl Group and Side Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 421-428. (1991)
	C377	Murphy, L.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell
	(377	Proliferation in Vitro", Endockinology, 116, 1071-1078, (1985)
	C378	Myer, R.O. et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canola Oil an Added Copper to Alter the Unsaturated:Saturated Ration of Pork Fat", J. Anim. Sci., 10, 147-1423, (1992)
	C379	Nabel, E.G., et al., "Direct Transfer of Transforming Growth Factor Befa Group Into Arteries Stimulates Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10(6), 1093)
	C380	Nagakawa, Y., et al., "Effect of Eicosapentaenoic And on the Platelet Uggregation and Composition of Fatty Ac in Man", Atherosclerosis, 47, 71-75, (1983)
	C381	Nakagawa, et al., "A Case of Acute Myocardinal Infaration Intracoronary Arteries Due To Hormone Therapy.", Angiology, 45, 333-338. (May 1994)
	C382	Nakano, "Glucocorticoid Inhibits Thromin-Induced Expression of Platelet-Derived Growth Factor A-chain and Heparin-Binding Epidermal Growth Factor-Live Growth Factor in Human Aortic Smooth Muscle Cells:, The
		Journal of Biological Ch emistry, 268, 22941-23947 (1993)
	C383	Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Securities,
	(383	Equity Research Medical Technology, 10 p., (May. 3, 1995)
	C384	Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14(3), 1018-1026, (1996)
	C385	Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vascular
1	(	restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 (1994)
	C386	O'Leary, V.J., et al., "The Resistance of Low Density Lipolarotein to Oxidation Promoted by Copper and Its Use as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996)
	C387	Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 265, 781-784, (August 5, 1994)
	C388	Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-Inflammatory Agents: Analgesic Activity and Possible Opoid Receptor Activation", Agents and Actions, 21, 130 144, (1987)
	C389	Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989)
	C390	Orloy, S.N., et al., "Aftered beta-Adrenergic Regulation of Na-K-CLC dransport in Cultured Smooth Muscle Cel Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1995)
	C391	Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguant sine Adduct Formed in the Liver DN: of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996)
	C392	Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertrophy in Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 731-780, (1988)
	C393	Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis", Biochem Mol, Biol, Intern, 35, 117-124, (1995)
	C394	Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertension," A JI 1986 Dec: 147:1251-54.
	C395	Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Oog," 145 Am. J. Roentgenol, 1985;145;821-825.
		Palmaz et al., "Expandable Intraluminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov:

			of Application No. 09 910,388
		C397	Palmaz et al., "Normal and Stenotic Renal Arteries: Experimental Balloon-expandable Intraluminal Stenting," Radiology 1987 Sept; 164(3):705-708.
<del></del>		C398	Palmaz et al., "Removable Biliary Endoprosthesis," Am. J. Roentgenol, 1983;140(4):812-4.
		C399	Palmaz, et al., "Atherosclerotic Rabbit Aortas: Expandable Intraluminal Grafting," Radiology 1986 Sept; 160:723-
	$\forall$	C400	726.   Palmaz, et al., "Expandable Intrahepatic Portocaval Shunt Stents in Dogs with Chronic Portal Hypertension,"
			American Roentgen Ray Soc'y 1986 Annual Meeting, Washington, D.C., (BT 000079) (April 13-18, 1986).
		5,01	Palmaz, et al., "Intravascular Stents: Basic Physical and Biological Properties, Endoluminal Treatment: The Different Techniques,", Editors Michel Henry, Max Arnor, Edward B. Diethrich and Barry Katzen, Published by Springer Verlag; 4:149-158 (1997).
	$\top$	C402	Palmaz, J.C. "Balloon-Expandable Intravascular Stent," A JR 1988 June; 150:1263-1269.
		C403	Palmaz, J.C. "Expandable Intraluminal Graft: A Preliminary Study." Radiology 1984 Nov;153(P):329 Abs. 993.
		C404	Pandey, B.D. et al., "A Study of the Effects of Tamrabhasma, an Indigenous Preparation of Copper on Experimental Oustric Ulcers and Secretion", Indian Journal of Experimental Biology, 21, 258-264, (1983)
		C405	Pardoll, D., et al., Exposing the Immunology of Naked DNA Vaccines", Immunity, 3, 165-169, (1995)
		C106	Parthasatathy, S., et al. "A Role for Endothelial Cell Lipoxygenase in the Oxidative Modification of Low Density Lipoprotein", Proc. Nat. Acad. Sci., USA, 86, 1046-1050, (1989)
		C407	Pedron, N. et al., "The Effect of Acetylsalicyclic Acid on Menstrual Blood Loss in Women with ICDs", Contraception, 36, 295-303, N987)
		C408	Peng et al., "The immunosuppressant rapamycin mimics a starvation like signal distinct from amino acid and glucose deprivation," Mol. Cell., Biol., 22:5575-84 (2002)
	Ļ	C409	Pennisi, E., "Drug's Link to Genes Reveals Estrogen's Many Sides", Science 273, 1171. (Aug. 30, 1996)
		C410	Peress, N.S., et al., "Differential Expression of TGF-B1-2 and 3 Isolopus in Alzheimer's Disease: A Comparative Immunohistochemical Study with Cerebral Infarction, Agent Fluntan and Mouse Control Brains", Journal of Neuropathology and Experimental Neurology, \$4, 802-511. Notember 1995)
		C411	Peress, N.S., et al., "Glial Transforming Growth Factor (TGF) -B Isotypes in Multiple Sclerosis: Differential Glial Expression of TGF-B1, 2, and 3 Isotypes in Multiple Sclerosis", Journal of Neuroimmunology, 71, 115-123, (1996)
· · · · · · · · · · · · · · · · · · ·		C412	Perez, J.R., et al., "Regulation of Adhesion and Growth of Fibrosarcoma Cells by NF - kb RcIA Involves Transforming Growth Factor Beta", Molecular and Cellular Biology, 14, 5326-5332, (1994)
		C413	Pfister, W.R. et al., "Silicone Based Sustained and Controlled Release Drug Delivery Systems", 1985, 30 th National SAMPE Symposium and Exhibition, Anaheim, CA, March 19-21, 1985, pp. 490-498 (1985)
		C414	Pinto, H.C., et al., "Tamoxifen-associated Steatohepatitis C Report of Three Cases", Journal of Hepatology, 23, 95-97, (1995)
		C415	Polysciences Inc., TDMAC-Heparin Coatings, Nov. 1988, Data Sheet 4172
		C416	Post et alk., "The Relative Importance of Arterial Remodeling Compared With Intimal Hyerplasia in Lumen Renarrowing After Balloon Angioplasty" Circulation 89, 2816-2821 (June 1904)
		C417	Potter et al., "A mechanism hypothesis for DNA adduct formation following hexatic oxidative metabolism," Carcinogenesis, 15, 439-442 (1994)
		C418	Science, 245:186-188 (1989)
		C419	Presentation at The Society of CV & Interventional Radiology's Twelfth Annual Course On "Diagnostic Angiography and Interventional Radiology." Includes: "The Current Status of Vascular Prescheses" by Julio Palmaz at 118-120 (March 23 - 26 1987).
		C420	Program and abstracts of the Seventh International Conference on the Adjuvant Therapy of Cancer, held in Tuscon, Arizona on March 10-13, 1993
		C421	Pupita, G., et al., "Myocardial Ischemia Caused by Distal Coronary-Artery Constriction in Stable Angina Pectoris", The New England Journal of Medicine, 323, 514-520, (1990)
		C422	Rainsford, K.D., et al., "Concerning the Merits of Copper Aspirin as a Potential Anti-Inflammatory Drug", J. Pharmac., 28, 83-86, (1976)
		C423	Rainsford, K.D., et al., "Gastric Mucus Effusion Elicited by Oral Copper Compounds: Potential Anti-Ulec-Activity", Experientia, 32, 1172-1173, (1976)
		C424	Raisz, L.G., "Estrogen and Bone: New Pieces to the Puzzle", Nature Medicine, 2, 1077-1078, (1996)
		(1425	Raloff, "Tamoxifen Puts Cancer on Starvation Diet", Science News, 146, 292, (November 5, 1994)
		C426	Ray, P., et al., "Repression of interleukin-6 gene expression by 17beta-estradiol: Inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-6B by the estrogen receptor", FEBS Letters, 409, 79-85, (1997)
		C427	Razavi, M., "Unusual Forms of Coronary Artery Disease", Cleveland Clinic Consultations, 7, 25-46, (1975)
		C428	Recchia, F., et al., "Interferon-beta, Retinoids, and Tamoxifen in the Treatment of Metastatic Breast Cancer: A Phase II Study", Journal of Interferon and Cytokine Research, 15, 605-610, (1995)
		C429	Reckless, J., et al., "Tamoxifen Decreases Cholesterol Sevenfold and Abolishes Lipid Lesion Development in
	<b></b>	<b></b>	

		of Application No. 09 910,388
		Apolipoprotein E Knockout Mice", Circulation, 95, 1542-1548, (1997)
	C430	Reilly et al., "Antiproliferative effects of heparin on vascular smooth muscle cells are reversed by epidermal growth factor," J. Cell Physiol., 131 :(49-157 (1987)
	C431	Reilly, C.F., "Rat Vascular Smooth Muscle Cells Immortalized with SV40 Large T Antigen Possess Defined Smooth Muscle Cell Characteristics Including Growth Inhibition by Heparin", Journal of Cellular Physiology, 142, 342-351, (1990)
	C432	Reis, G.J., et al., "Randomized Trial of Fish Oil for Prevention of Restenosis After Coronary Angioplasty", The Lancet, 177-181, (1989)
	C433	Ribeiro, G., et al., "Adjuvant Tamoxifen for Male Breast Cancer (MBC)", Br. J. Cancer, 65, 252-254, (1992)
	C434	Rieckmann, P., et al., "Tumor Necrosis Factor-a Messenger RNA Expression in Patients with Relapsing-Remitting Multiple Sclerosis is Associated with Disease Activity", Ann. Neurol. 27, 82-88, (1996)
	0435	Riessen et al., "Prospects for Site-Specific Delivery of Pharmacologic and Molecular Therapies", J. Amer. Collago of Cardiol., 23, 1234-1244 (Apr. 1994)
	C436	Riessen et al., "Regional Differences in the Distribution of the Proteoglycans Biglycan and Decorin in the Extracellular Matrix of Atherosclerotic and Restenotic Human Coronary Ateries", Amer. J. Path 144, 962-974 (189-1994)
	C437	Roberts et al., "Type beta transforming growth factor: a bifunctional regulator of cellular growth," Proc. Natl. Acad Sci., 82:119-123 (1985)
	C438	Robinson, J.R. (ed), "Sustained and Controlled Release Drug Delivery Systems," New York, Marcel Dekker (1978). Chapters 1-2, 4, and 7-9.
	C439	Roche Lexikon Medizin, Urban und Schwarzenberg, 1984, page 69 "Antibiotika", and page 515 "Fibrin"
	C440	Rompp Chemie Lexikon, 9th ed., 1989-1990, pp. 206-208, & pp. 1350 and 1351
	C441	Rompp, Chemie-Lecikon, 8th ed., 1987, page 2633 "Mitosehemmer"
	C442	Roubin, "Intracoronary Stenting of Canine Coronary Arteries After Percutageous Coronary Angioplasty (PTCA)," Circulation 1986 Oct;74(Supp. II-458):1825 Abstract.
	C443	Rowinsky et al., "Taxol: Twenty years Later, the Story Unfolds," Journal of the National Cancer Institute, 1991, Vol 83 No. 24 pp 1778-1781
	C144	Rutqvist, L.E., et al., "Cardiac and Thromboembolic Morbidity Among Postmenopausal Women with Early-Stage Breast Cancer in a Randomized Trial of Adjuvant Tamoxifen", Journal of the National Cancer Institute, 85, 1398-1406, (1993)
	C445	Rutsch, et al., "Benestent-II Pilot Study: 6 months Follow Up of Phase I" Abstract, Society of Cardiology, (1995)
	C446	Ruygrok and Serruys, "From Bench to Bedside, Intracologiary Stenting, From Concept to Custom," Circulation 1996: 94:882-890
	C447	Ryan et al., "Transforming growth factor-beta-dependent events in vascular remodeling following arterial injury," J., Vase, Res., 40:37-46 (2003)
	C448	Saarto, T., et al., "Antiatherogenic Effects of Adjuvant Antiestrogens: A Randomized Trial Comparing the Effects of Tamoxifen and Toremifene on Plasma Lipid Levels in Postmenopausal Women with Node-Positive Breast Cancer", Journal of Clinical Oncology, 14, 429-433, (February 1996)
	C449	Sabatini et al., "RAFT1; a mammalian protein that einds to FK.BP12 in a rapamycin-dependent fashion and is homologous to yeast TORs", Cell, 78:35-43 (1994)
	C450	Saito, H., et al., "Influence of Maternal Drug Metabolism on the Fetal Toxicity Induced by Acetylsalicylic Acid", The Journal of Toxicological Sciences, 7, 177-184, (1988)
	C451	Sanchez, et al., "Control of Contact activation on end-point immobilized heparin, The role of antithrombin and the specific antithrombin-binding sequence," <i>J. Of Biomedical Materials Research</i> , pp. 655-661 (1995)
	C452	Sanderson et al., "Antibody-Coated Microspheres for Drug Delivery to Prevent Restenosis", Circulation, 90, 1–508, Abstract No. 2734 (October 1994)
	C453	Sargent, L.M., et al., "Induction of Hepatic Aneuploidy in Vivo by Tamoxifen, Toremifene and Idoxifene in Female Sprague-Dawley Rats", Carcinogenesis, 17, 1051-1056, (1996)
	C454	Schatz et al., "Balloon Expandable Intravascular Stents in Diseased Fluman Cadaver Coronary Arteries," Circulation 1987 Oet;70(4): Abstract 0102.
	C455	Schatz et al., "Balloon-expandable Intra-coronary Stents In The Adult Dog." Circulation 1987 Aug; 76(2):450-457.
	C456	Schatz, et al., "Balloon Expandable Intracoronary Stents In Dogs," Circulation 1986 Oct;74(Supp. II-458): 1824 Abstract,
	C457	Schatz, et al., "Clinical Experience with the Palmaz-Schatz Stent: Initial Results of Multicenter Study," Circulation 1991 Jan:83(1): 148-161.
	C458	Schatz, R.A. Introduction to Intravascular Stents, Cardiology Clinics 1988 Aug;6(3):35 72.
	C459	Schlaak, J.F., et al., "Different Cytokine Profiles in the Synovial Fluid of Patients with Ostoarthritis, Rheumatoid Arthritis and Seronegative Spondylarthropathies", Clinical and Experimental Rheumatology 14, 155-162, (1996)
-	C460	Schmidt, E.B., et al., "Long-Term Supplementation with n-3 Fatty Acids. II: Effect on Neutrophil and Monocyte Chemotaxis", Scand. J. Clin. Lab. Invest., 52, 229-236, (1992)
	C461	Schoenemanne, et al., "The Differential Diagnoses of Spontaneous Pneumothrax and Pulmonary Lymphangioleimyomatosis Clinical Picture Diagnoses and Theory,", Chiraq, 61, 301-303 (1990); reported in

		of Application No. 69 910,388
		Biosis, 90, 432367 (1990), English abstract only
	C462	Schulick et al., "Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia," PNAS 95:6983-6988 (1998)
/	C463	Schwartz, C.J., et al., "The Pathogenesis of Atherosclerosis: An Overview", Clin. Cardiol., 14, 1-1-4-16, (1991)
	C.404	Schwartz, G.G., et al., "Pathophysiology of Chronic Stable Angina", In: Atherosclerosis and Coronary Artery Disease, V. Fuster, et al., (eds.), Lippencott-Rayen Publishers, Philadelphia, pp. 1386-1400, (1996)
	C465	Sedlacek, S. "Estrogenic Properties of Tamoxifen on Serum Lipids in Postmenopausal Women with Breast Cancer (BCA)", Breast Cancer Research and Treatment, 14, Abstract No. 82, 153, (1989)
	C460	Sehgal et al., "Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization," J. Antibiot., 28:727-32 (1975)
	C467	Sobgal, "Sirolimus: its discovery, biological properties, and mechanism of action," Transplant, Proc., 35(3 Suppl):7S-148 (2003)
	C468	Serruys et al., "The new angiotensin converting enzyme inhibitor cilazapril does not prevent restenosis after coronary angioplasty; the results of the MERCATOR trial," JACC 19:258A, Abstract 783-2 (1992)
	C469	Serruys, et al., "A Comparison of Balloon-Expendable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease". The New England Journal of Medicine, 331, 489-495 (August, 1994)
	C470	Serruys, P.W., et al., "Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries Early Outcome of the Benestent-II Pilot Study", Circulation, 93, 412-422, (Feb. 1996)
	C471	Shanahan and Weissberg, "Smooth muscle cell heterogeneity: patterns of gene expression in vascular smooth muscle cells in vitro and in vivo," Arterioscler, Thromb. Vase, Biol., 18(2):333-338 (1998)
	C472	Shanahan, C.M., et al., 'High Expression of Genes for Calcification-regulating Proteins in Human Atherosclerotic Plagues', Journal of Clinical Investigation, 93, 2393-2402, (June, 1994)
	C473	Shapiro, L.M., "Echocardographic Features of Impaired Ventricular Function in Diabetes Mellitus", British Heart Journal, 47, 439-444, (1982)
	C474	Shemon, et al., "Tamoxifen Decreases Lipoprotein(a) in Patient With Breast Cancer,", Metabolism, 43, 531-532, (May 1994)
	C475	Shewmon, et al., "Tamoxifen and Estrogen Lower Circulating Lipaprotein(a) Concentration in Healthy Postmenopausal Women", Arterioscletosis and Turomposis, 14, 1589-1593, (1994)
	C476	Shimaoka, I., et al., "Purification of a Copper Binding Peptide from the Mushroom Grifola Frondosa and Its Effection Copper Absorption", J. Nutr. Biochem. 4, 33-38, (1993)
	C477	Shou et al., "Cardiac defects and altered ryanodine receptor function in mice lacking FK-BP 12," Nature, 391 (6666):489-92 (1998)
	C478	Siebenlist, U., et al., "Structure, Regulation and Function of NF-kB", Annu. Rev. Cell. Biol., 10, 405-455, (1994)
	C479	Sigwart, et al., "Intravascular Stents to Prevent Ocalusion and Restenosis After Transluminal Angioplasty," N. Engl. J. Med., Mar. 19, 1987, Vol. 316, No. 12, pp.701-06
	C;480	Sigwart, U., Frank, G.L. "Bioabsorbable, Drug-Eluting Intracoronary Stents: Design and Future Applications," Coroinary Stents. Springer-Verlag (1992)
	C481	Sigwart, Ulrich, "The Self Expanding Mesh Stent" Textbook of Interventional Cardiology, (Eric J. Topol, ed) 1990, Chapter 29, pp 605-622
	C482	Silber, S. "Drug-eluting stents: aktueller Stand", internet article on sigmund-silber.com/deutsch/varia/var-2003/03-09-5-Silber-Chemnitz.pdf of August 6, 2003
	C483	Sismondi, et al., "Metabolic Effects of Tamoxifen in Postmenopause.", Anticancer Res., 14, 2237-2244, (1994)
	C484	Soderberg, L.S., et al., "Copper (II) (3.5-Diisopropylsalicylate) sub2 Accelerates Recovery of B and T Cell Reactivity Following Irradiation", Scand J. Immunol., 26, 495-502, (1987)
	C485	Soderberg, L.S., et al., "Copper (II) sub2(3, 5-diisopropylsalicylate) sub4 Stimulates Hemopoiesis in Normal and Irradiated Mice", Exp. Hematol., 18, 577-580, (1988)
	C486	Soderberg, L.S., et al., "Postirradiation Treatment with Copper (II) sub2 (3.5-diisopropylsalicylate) sub4 Enhances Radiation Recovery and Hemopoietic Regeneration", Exp. Hematol., 18, 80 (x805, (1990))
	C487	Soderberg, L.S., et al., "Radiation Recovery Agents", DN & P. 3, 600-605, (1900)
	C488	Sollott, S.J., et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat", The Journal of Clinical Investigation, 95, 1869-1876, (Apr., 1995)
	C489	Song "Dexamethasone-nanoparticles for intra-arterial localization in restenosis in rats," Preced. Intern. Symp. Control. Rel. Mater., 22, 444-445 (1995)
	C490	Song, J., et al., "Tamoxifen (Estrogen Antagonist) Inhibits Voltage-Gated Calcium Current and Contractility in Vascular Smooth Muscle from Rats", The Journal of Pharmacology and Experimental Therapeutics, 227, 1444-1453, (1996)
	C491	Sorenson, J.R., "Copper Complexes Offer a Physiological Approach to Treatment of Chronic Disease", Progress in Medicinal Chemistry, 26, 437-568, (1989)
	('492	Sorenson, J.R., "Essential Metalloelement Metabolism and Radiation Protection and Recovery", Radiation Research, 132, 19-29, (1992)
	C493	Sorenson, J.R., "Pharmacological Activities of Copper Compounds", In: Handbook of Metal-Ligand Interactions in Biological Fluids Bioinorganic Medicince, vol. 2, Berton, G., (ed.), Marcel Dekker, Inc., New York, 128-1139, (1995)

of Application No. 09/910/388

		of Application No. 09/910/388
	C494	Sorenson, J.R., "Radiation Protection and Radiation Recovery with Essential Metalloclement Chelate", P.S.E.B.M., 210, 191-204, (1995)
	C495	Sorenson, J.R., "The Ulcerogenic Potential of Copper Aspirinate Seems to be More Imaginary than Real", Journal
<u> </u>	C496	of Pharmaceutical Sciences, 73, Open Forum, 1875-1878, (1984)  Sorenson, J.R., et al., "Antieoplastic Activities of Some Copper Salicylates", In: Trace Substances in
	164%	Environmental Health, vol. XVI, Hemphill, D.D., (ed.), University of Missouri, Columbia, 362-369, (1982)
	\$197	Sorenson, J.R., et al., "Bis (3, 5-diisopropylsaticylato) copper (II), a Potent Radioprotectant with Superoxide Dismutase Mimetic Activity", J. Med. Chem., 27, 1747-1749, (1984)
	C196	
	C499	
	C500	Solysa et al "Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic
	C501	and intravascular ultrasound follow-up." Circulation, 104:2007-i 1 (2001) (CVP228071-228075)  Sousa et al., "Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-
	C502	eluting Sents in human coronary arteries," Circulation, 107(3):381-3 (2003) (BSX 024170-024172)  Sousa, J.Exet al., "New Frontiers in Cardiology Drug-Eluting Stens: Part I", Circulation, 2003, 107:2274-2279,
	C503	Southgate and Newby, "Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state
	C504	is inhibited by 8-Br-cAMP but not 8-Br-cGMP," Atherosclerosis, 82:113-123 (1990)  Srivastava, K.C. Effects of Dietary Fatty Acids, Prostaglandins and Related Compounds on the Role of Platelets
		in Thrombosis", Bjochem, Exp. Biol., 16, 317-338, (1980)
	C505	Standley, P.R., et al. "Tamoxifen (an Antiestrogen) Reduces K Positive- and Agonist-Induced Vascular Contractility in Rat Resistance Vessels", Abstract No. 159
	C506	Stevenson, F., et al., "Idiotypic DNA Vaccines against B-cell Lymphoma", Immunological Reviews, 145, 221-228, (1995)
	C507	Stork, G., et al., "Total Synthesis of Cytochalasin B", Journal of the American Chemical Society, 100, 7775-7777. (1978)
	C508	Stouffer, et al., "TGF beta Has a Biphasic, Concentration Dependant Effect on EFF and PDGR-BB Induced Smooth Muscle Cell Proliferation, Inflammation, Growth Regulatory Molecules and Atherosclerosis.", J. Cellular
		Biochem, Supplement 18A, Abstract No. A321, 288, (1994)
	C509	Strepetti, A.V., et al., "Formation of Ayointimal Hyperplasia and Cytokin Poduction in Experimental Vein Grafts", Surgery, 123(4), 461-469, (1998)
	C510	Suckling, "Atherosclerosis Patents: Clues to the Next Drug Generation," Bio/Tech, 12 1379-1380 (December 1994)
	C511	Sudo, K., et al., "Antiestrogen-Binding Sites Distinct from the Astroget Receptor: Subcellular Localization, Ligand Specificity, and Distribution in Tissues of the Rail Endocrinology, 112, 425-434, (1983)
	C512	Swain, "Blazing new paths for product introductions," Madiral Device & Diagnostic Industry, Sept. 2003, p. 68-81
	C513	Szekanecz, Z., et al., "Increased Synovial Expression of Transforming Growth Factor (TGF) -B Receptor Endoglin and TGF- B1 in Rheumatoid Arthritis: Possible Interaction in the Pathogenesis of the Disease", Clinical Immunology and Immunopathology, 76, 187-194. (August 1995)
	C514	Tabas et al., "the Actin Cytoskeleton in Important for the Stimulation of Cholesterol Esterification by Atherogenic Lipoprotiens in Macrophages" J. Biol. Chem., 269, 22547-2556 (Sept. 9 1994)
	C515	Takashima, K. et al., "The Hypocholesterolemic Action of TA-7552 and its Effects on Cholesterol Metabolism in the Rat", Atherosclerosis, 107, 247-257, (1994)
	Ċ516	Tanaka et al., "lalpha 25 (OH) 303 Exerts Cytostatic effects on Murine Osteosarcoma Cells and Enhance Cytocidal Effects on Anticancer Drugs" Clinical Orthopaedics and related Research no. 247 1989 pgs. 290-296
	C517	Tanaka et al., "Prominent Inhibitory Effects of Tranilast on Migration and Proliferation of and Collagen Synthesis by Vascular Smooth Muscle Cells" Atherosclerosis, 107, 179-185 (1994)
	C518	Tanenbaum, S.W., "Microbiological, Preparative and Analytical Aspect of Cytochalasin Production", In: Cytochalasins Biochemical and Cell Biological Aspects, Tanenbaum, S.W., (ed.), Elsevier North-Holland
	C519	Biomedical Press. 2-14, (1978)  Tang et al., "Regression of collagen-induced arthritis with taxol, a microtubule stabilizer". Arthritis and
	* C520	Rheumatism, 36 (9) Suppl.:S45, 1993 Tawashi, R., "The dissolution rates of crystalline drugs", J. Mond. Pharm, 4.11, 968, pp 371-379
	C521	Teirstein (ed.), "Coronary Stents: pros and cons," Coronary Artery Disease, 5:561-000 (1994).
	C522	Tessari et al.: "Antiproliferative activity of unfractioned heparin on a human smooth muscle cell line. Pharmacol." Res., 21:145-6 (1989)
	C523	Testart, J., et al., "The Action of Anti-Inflammatory Drugs to the Fertility of Female Rats with Intrauterine Contraceptive Devices", J. Reprod. Fert., 63, 257-261, (1981)
	C524	Thompson, J. F., et al., "Comparison of Recombinant Transforming Growth Factor-beta -2 and Placebo as an adjunctive Agent for Macular Hole Surgery", Ophthalmology, 15(4), 700-706, (1998)
	C525	Thompson, N.L., et al., "Expression of Transforming Growth Factor-B1 in Specific Cells and Tixsue of Adult and Neonatal Mice", Journal of Cell Biology, 108, 661-669, (1989)

			of Application No. 69 910,388
7		C526	Tong et al., "Non-Thrombogenic Hemofiltration System for Acute renal failure Treatment: ASAIO Trans. 38: N1702-N1706 (1992)
		C527	Toomasian et al., "Evaluation of Duraflo II Herparin Coating in Prolonged Extracorporeal Membrane Oxygenation", ASAIO Trans 34: 410-14 (1988)
<b>—</b>	$\angle  $	C528	Topol, E. et al., "Frontiers in Interventional Cardiology" Circulation, 1998, 98:1802-1820,
	$\forall$	C529	Treasure, C.B., et al., "Hypertension and Left Ventricular Hypertrophy Are Associated With Impaired
	$\bot \setminus$	<u> </u>	Endothelium-Mediated Relaxation in Human Coronary Resistance Vessels", Circulation, 87, 86-93, (1993)
	\	C530	Treiber, A., et al., "Chemical and Biological Oxidation of Thiophene: Preparation and Complete Characterization of Tiophene S-Oxide Dimers and Evidence for Thiophene S-Oxide as an Intermediate in Thiophene Metabolism in vivo and In Vitro", J. Am. Chem. Soc., 119, 1565-1571, (1997)
		C5.\(\)	Tucker et al., "Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor," Science, 226:705-707 (1984)
		C532	Ulman, et al., "Drug Permeability of Modified Silicone Polymers," Journal of Controlled Release 1989; 10:276- 281
		C533	Ulman, K.L. et al., "Drug Permeability of Modified Silicone Polymers", J. Controlled Release, 10:251-260 (1989)
		C534	Van Der Giessen, et al., "Coronary Stenting With Polymer-Coated And Uncoated Self-Expanding Endoprosthesis In Pigs" Coron, Art. Disease 1992; 3:631-40
		C535	Van Der Glessen, et al., "Self-expandable Mesh Stents: an Experimental Study Comparing Polymer Coated and Uncoated Wallstent Stents in the Coronary Circulation of Pigs" "Circulation 82:III-542 (1990)
		C536	Van Sickle, WA., et al., "An Alternative Mechanism for the Inhibition of Cholesterol Biosyntesis in HepG2 Cells by N- [(1,5,9) -Trimethyldecyl] -4alpha, 10-dimethyl 8-aza-trans-decal-3beta-ol (MDL 28, 815)", The Journal of Pharmacology and Experimental Therapeutics, 267, 243-1249, (1993)
		C537	Vawter, M.P., et al. "TGF B1 and TGF B2 Concentrations are Elevated in Parkinson's Disease in Ventricular Cerebrospinal Fluid" (Experimental Neurology, 141, 313-332, (1996)
		C538	Vidensek N., et al., "Taxol Content in Bark, Wood, Root, Leaf, Twig, and Seedling from Several Taxus Species", Journal of Natural Products, 53, 1609-1610, (Nov./Dec., 1990)
	*	C539	Voigt, R., Lehbuch der pharmazeutischen Technologie, 5 th . edition VEB Verlag Voltzung Gesundheit Berlin, 1984, p 689
		C540	Von Schacky, C., et al., "Long-Term Effects of Dietary Marine omega-, Fatty Cods upon Plasma and Cellular Lipids, Platelet Function, and Eicasanoid Formation in Humans", J. Glin (n) etc., 76, 1626-1631, (1985)
		C541	Waksman, R., et al., "Intracoronary Radiation Before Stent Implantation Inhibits Neointima Formation in Stented Porcine Coronary Arteries", Circulation, 92, 1383-1886, (1995)
		C542	Wallace, et al., "Tracheobronchial Tree: Expandable Netal in Experimental and Clinical Applications," RADIOLOGY 1986 Feb; 188(2):309-12.
		C543	Wallace, J.M., et al., "Dietary Fish Oil Supplementation Alter Leukocyte Function and Cytokine Production in Healthy Women", Arteriosclerosis, Thrombosis and Vascular Biology, 15, 185-189, (1995)
		C544	Waller et al., "Crackers, Breakers, Stretchers, Dillers, Scrappers, Shavers, Burners, Welders and Melters: The Future Treatment of Atherosclerotic Coronary Artery Disease?" A Clinical-Morphologic Assessment," JACC 13:969-87 (1989)
		C545	Waller et al., "Differential effects of modem immunoshppressive agents on the development of intimal hyperplasia," Transpl. Int. 17:9-14 (2004)
		C546	Waller et al., "Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration." Transplant Proc. 37(1): 164-6 (2005).
		C547	Waller, B.F. X.L., et al., "Atherosclerotic and Nonatherosclerotic Coronary Artery Factors in Acute Myocardial Infarction", In: Acute Myocardial Infarction, Pepine, C.J., (ed.), F.A. Davis Company, Philadelphia, 29-104 (1989)
		C548	Walternberger, "Modulation of growth factor action: implications for the treatment of cardiovascular diseases," Circulation, 96:4083-4094 (1997)
		C549	Wang, X.L., et al., "Circulating Transforming Growth Factor Betal and Coronary Artery Disease", Cardiovascular Research, 34, 404-410 (1997)
		C550	Ward et al., "Inhibitory effects of translast on expression of transforming growth factor-beta isoforms and receptors in injured arteries," Atherosclerosis, 137:267-275 (1998)
_		C551	Ward et al., "Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting," Arterioscler, Thromb. Vasc. Biol. 22:940-948 (2002)
		C552	Watson, et al., "TGF-B1 and 25-Hydroxcholesterol Stimulate Osteoblast-Like Vascular Cells to Calcify", J. Clin. Invest., 93, 2106-2113 (May 1994)
		C553	Wei, C.M. et al., "Binding of Trichodermin to Mammalian Ribosomes and Its Inhibition by Other 12, 13- Epoxytrichotheces", Molecular & Cellular Biochemistry, 3, 215-219 (May 30, 1974)
		C554	Weissberg, P.L., et al., "Is Vascular Smooth Muscle Cell Proliferation Beneficial?", Lancet, N7, 305-307 (Feb. 3 1996)
		C555	West, G.B., "Comments on The Ulcerogenic Potential of Copper Aspirinate Seems to be More Imaginary than Real", Journal of Pharmaceutical Sciences, 74, Open Forum, 700 (1985)

of Application No. 09 910 388

\	C556	West, G.B., "Testing for Drugs Inhibiting the Formation of Gastric Cleers", Journal of Pharmacological Methods, 8, 33-37 (1982)
	C557	
	C558	192 L. C. L. D. A. J. O'T C. M. C College of Continued Continued from A December 188 of Taxable 1
	C559	1 William Land Control of the Land of the Market of Dalling the Affirm and the Affirm and Dalling the
	2560	1971 1 51 1 1 1 0 2 0 1 1 1 1 D. 1 D. 1 D. 1 D. 1 D. 1 D. 1
	C561	Williams, J.K., et al., "The Estrogen Receptor Agonist Antagonist Tamoxifen Inhibits Progression of Coronary Artery Atherosclerosis in Monkeys", Circulation, 92, November 1995, AHA Meeting (October 15, 1995)
	C562	Ligand. Provides Insights into the Role of Estrogen Receptor in Bone". Endocrinology, 138(9) (September 1997)
	C563	Winokly et al., "Expression of transforming growth factors \(\beta\) 1, 2, and 3 following vascular injury," J. Cell Biochem. Suppl. 15C:G414 (Abstr.) (1991)
	C564	Winslow, R., "Going for the Flow", The Wall Street Journal (Oct. 23,1995)
	C565	Winternitz, (N. et al., "Development of a Polymetric Surgical Paste Formulation for Taxol", Pharmaceutical Research, 13 308-375 (1996)
	C566	Wiseman, H., "Tamoxifen as an Antioxidant and Cardioprotectant", Biochem. Soc. Symp., 61, 209-219 (1995)
	C567	Wiseman, L.R., et al., "Toremifene A Review of its Pharmacological Properties and Clinical Efficacy in the Management of Advanced Breast Cancer", Drugs, 54, 141-160 (July 1997)
	C568	Witherup, K.M., et al., Taxus Spp. Needles Contain Amounts of Taxol Comparable to the Bark of Taxus brevifolia: Analysis and solation", Journal of Natural Products 23 (12-19-1255 (Sep./Oct., 1990)
	C569	Wolf, Y.G., et al., "Antibodies Against Transforming Growth Factor Betal Suppress Intimal Hyperplasia in a Rat Model", J. Clin. Invest., 93, N72-1178 (Mar. 1994)
	C570	Wrana, et al., "Mechanism of Activation of the TGF-B Receptor", Nature, 370 341-347 (August 4, 1994)
	C571	Wright et al., "Cytoclasin Inhibition of Slow Tension Indicase in Rat Aortic Rings", Am. J. Physion., 267 H1437-H1446 (1994)
	C572	Wright et al., "Percutaneous Endovascular Sterns: An Experimental Study," Radiology 1984 Nov;153(P):206 Abs 593.
	C573	Wright et al., "Percutaneous Endovascular Stents: An Experimental Evaluation," Radiology 1985;1:69-72.
	C574	Wu et al., "Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cylokine production and lymphoproliferation." Transplant. Porc., 23:238-240 (1991)
	C575	Wu et al., "The inhibitory mechanism of YC-1\a benzyl indazole, on smooth muscel cell proliferation: an in vitro and in vivo study," J. Pharmacol. Sci. 94:252-60(2004)
	C576	Wu, et al., "Silicone-covered Seft-expanding Metallic Stents for the Palliation of Malignant Esophageal Obstruction and Esophagorespiratory Fistulas: Experience in 32 Patients and a Review of the Literature," Gastrointest. Endosc. 1994; 40:22-33
	C577	Yamamoto et al., "Ribozyme oligonucleotides against transforming growth facotr-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease." Circulation, 102(11):1308-14 (2000)
	C578	Yang, N., et al., "Developing Particle-mediated Gene-transfet Technology for Research Into Gene Therapy of Cancer", Molecular Medicine Today, 476-481, (1996)
	C579	Yang, N.N., et al., "Estrogen Receptor: One Transcription Factor, Two Genomic Pathways", Calcified Tissue Intl., 54, 342, (1994)
	C580	Yang, N.N., et al., "Identification of an Estrogen Response Element Activated by Metabolites of 17Beta-Estradiol and Raloxifene", Science, 273, 1222-1225, (Oct. 30, 1996)
	C581	Young H., et al., "Pharmacokinetics and Biodistribution of Radiolabelled Idoxifene: Prospects for the Use of PET in the Evaluation of a Novel Antioestrogen for Cancer Therapy", Nucl. Ned. Biol., 22, 405-411, (May 1995)
	C582	Zhang, L. et al., "MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized and tamoxifen-treated nude mice". Oncogen, 15, 2093-2108, 1997)
	C583	Ziegler, J. "Raloxifene, Retinoids, and Lavender: AMe Too a Tamoxifen Alternatives Under Study", Journal of the National Cancer Institute, 88, 1100-1102, (1996)
······································	C584	Zohlnhofer et al., "Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties," Mol. Pharmacol, 65:880-889 (2004)
	C585	Answering Memorandum In Opposition To Plaintiffs' Motion For A Preliminary Injunction, Civil Action No. 03-283 Dated 4 3 03, U.S. District Court for the District of Delaware
	C586	Appendix To Answering Memorandum In Opposition To Plaintiffs' Motion For A Prefiminary Injunction, Volume 1. Civil Action No.03-283 Dated 4 3 03, U.S. District Court for the District of Delaware

	of Application No. 09 910,388
C587	Appendix To Answering Memorandum In Opposition To Plaintiffs' Motion For A Preliminary Injunction, Volume 2, Civil Action No.03-283 Dated 4/3/03, U.S. District Court for the District of Delaware
C588	BSC's Answering Brief in Opposition to Cordis' Motion for Summary Judgment Barring BSC from Asserting Equivalents for Certain Limitations of the '536 Patent, Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
C589	BSC's Reply Brief in Further Support of its Motion for Summary Judgment that Claims 6 and 8 of the '536 Patent are Not Anticipated by the Asserted Prior Art. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
C530	BSC's Reply Brief in Further Support of its Motion for Summary Judgment that the Cypher Stent Infringes Claims 6 and 8 of U.S. Patent No. 6.120.536. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
C591	Complaint , Civil Action No. 03-283, Filed 3-13-03, U.S. District Court for the District of Delaware
C592	CoNis' Answering Brief in Opposition to BSC's Motion for Summary Judgment that Claims 6 and 8 of the Ding '536 Patentare Not Anticipated by the Asserted Prior Art. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
 C593	Cordis' Answering Brief in Opposition to BSC's Motion for Summary Judgment that the Cypher Stent Infringes Claims 6 and 8 of U.S. Patent No. 6,120,536. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
C594	Cordis' Answering Markman Brief on the Construction of Terms in the Ding '536 Patent, Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
C595	Declaration Of Brian G. Firth, Civil Action No. 03-283 SLR, Dated 3/31 03, U.S. District Court for the District of Delaware
C596	Declaration Of Dr. Jeffrey W. Moses, M.D., Civil Action No. 03-283 SLR, Dated 3/31/03, U.S. District Court for the District of Delaware
C597	Declaration Of Dr. Martin B. Leon, M.D., Civil Action No. 03-283 SLR, Dated 3/31/67, U.S. District Court for the District of Delaware
C598	Declaration Of Dr. Paul S. Teirstein, M.D., F.A.C.C., Civil Action 30, 03-383 9LR, Dated 3/28/03, U.S. District Court for the District of Delaware
C599	Declaration Of Dr. Peter Fitzgerald, M.D., Ph.D., Civil Action No. 03-283 SLR, Dated 3/31/03, U.S. District Court for the District of Delaware
· C600	Declaration Of Dr. Richard E. Kuntz, M.D. 1.Sc., Exil Action 10. 8. 283 SLR, Dated 3/21/03, U.S. District Court for the District of Delaware
C601	Declaration Of Eric Simso, Civil Action No. 03-283, Dated 1/20/03, U.S. District Court for the District of Delaware
C'602	Declaration Of Jermone Segal, M.D., Civil Action No. 03-283 Dated 3/20/03, U.S. District Court for the District of Delaware
C603	Declaration Of Kinam Park, Ph.D., Civil Action No. 03-283 Dated 3/20/03, U.S. District Court for the District of, Delaware
C'604	Defendants' Answer, Counterclaim And Demand For Jury Trial, Civil Action No. 03-283, Filed 4/7/03, U.S. District Court for the District of Delaware
C605	Opening Expert Report Of Robson F. Storey, Ph.D., Civil Action No. 03-283 SLR, Dated 5/23 03, U.S. District Court for the District of Delaware
	Opening Expert Report Of Stephen R. Hanson, Ph.D., Civil Action No. 03-283 SLR, Dated 5:23-03, U.S. District Court for the District of Delaware
	Plaintiffs Boston Scientific Scimed, Inc. and Boston Scientific Corporation's Opening Claim Construction Brief, Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
C608	Plaintiffs Boston Scientific Scimed, Inc. and Boston Scientific Corporation's Reputtal Claim Construction Brief, Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
	Plaintiffs BSC's Memorandum in Support of its Motion for Summary Judgment that Claims 6 and 8 of the 1536 Patent are Not Anticipated by the Asserted Prior Art. Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
	Plaintiffs BSC's Memorandum in Support of its Motion for Summary Judgment that the Cypher Stent Infringes Claims 6 and 8 of U.S. Patent No. 6,120,536 Patent, Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
C611	Plaintiffs' Opening Brief In Support Of Their Motion For Preliminary Injunction, Civil Action No. 03-283 Filed 3 20 03, U.S. District Court for the District of Delaware
C612	Plaintiffs' Reply Brief In Support Of their Motion For Preliminary Injunction, Civil Action No. 03-283 SLR, Dated 4-10-03, U.S. District Court for the District of Delaware
 C613	Plaintiffs' Reply To Defendant's Counterclaim, Civil Action No. 03-283 Filed 4 21 03, U.S. District Count for the

SANGEROUS CONTROL OF THE CONTROL OF

<i>N</i>	of Application No. 09 910,388
	District of Delaware
C 614	Preliminary Injunction Hearing Transcript, Volume A. Civil Action No. 03-27 (SLR), Dated 7-21-03, U.S. District Court for the District of Delaware
C615	Preliminary Injunction Hearing Transcript, Volume B. Civil Action No. 03-27 (SLR), Dated 7-22-03, U.S. District Court for the District of Delaware
(.01)	Preliminary Injunction Hearing Transcript, Volume C. Civil Action No. 03-27 (SLR), Dated 7-23-03, U.S. District Court for the District of Delaware
C617	Rebuttal Expert Report Of Kiman Park, Ph.D., Civil Action No.03-283 SLR, Dated 6 2 03, U.S. District Court for the District of Delaware
C618	Reducted Public Version: Cordis' Opening Markman Brief of the Constitution of Terms in the Ding '536 Patent, Civil Action No. 03-283 SLR U.S. District Court for the Dispring of Delaware
C619	Redacted Public Vision: Opening Brief in Support of Co'dif Motion for Summary Judgment Barring BSC from Asserting Equivalents for Certain Limitations of the Discontinual Civil Action No. 03-283 SLR U.S. District Court for the District of Delaware
C620	Reply Brief in Support of Credis' Motion for Junimary Judgment Barring BSC from Asserting Equivalents for Certain Limitations of the Ding Patent, Civil Action 50, 03-283 SLR U.S. District Court for the District of Delaware
C621	Second Declaration Of Jerome Segal, M.D., Civil Action No. 03-283 SLR, Dated 4/10-03, U.S. District Court for the District of Delaware
C622	Second Declaration Of Kinam Park, Ph.D., Civil Action No. 03-283 SLR, Dated 4/10/03, U.S. District Court for the District of Delaware
C623	Goodnight, S.H., "The Effects of n-3 Fatty Acids on Atherosclerosis and the Vascular Response to Injury", Arch. Pathol. Lab. Med., 117, 102-106. (January, 1993)

EXAMINER SOL	Son son DA	ATE CONSIDERED 11 10 70 7	
*IEXAMINER: Initial if reference considered, whether considered. Include copy of this form with next comm	r or not citation is in conformance wi nunication to applicant.	oth MPEP 609; Draw line through citation if not in co	aformance and no
·			